UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~February 28,~~November 30, 2023

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-38594

TILRAY BRANDS, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware	82-4310622
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
265 Talbot Street West, Leamington, ON	N8H 5L4
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (844) 845-7291

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

TLRY

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐

Non-accelerated filer	☐	Smaller reporting company	☐

Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☒ No ☐

As of ~~April 3, 2023,~~January 5, 2024, the registrant had ~~618,007,938~~742,725,148 shares of Common Stock, $0.0001 par value per share issued and outstanding.

This Quarterly Report on Form 10-Q for the quarter ended ~~February 28,~~November 30, 2023 (the “Form 10-Q”) contains forward-looking statements under Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the "safe harbor" created by those sections and other applicable laws. Such statements involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward-looking statements under the Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be subject to the “safe harbor” created by those sections and other applicable laws. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “project,” “will,” ~~“would”,~~“would,” “seek,” or “should,” or the negative or plural of these words or similar expressions or variations are intended to identify such forward-looking statements. Forward-looking statements include, among other things, our beliefs or expectations relating to our future performance, results of operations and financial condition; our intentions or expectations regarding our cost savings initiatives; our strategic initiatives, business strategy, supply chain, brand portfolio, product performance and expansion efforts; current or future macroeconomic trends; and our expectations regarding regulatory developments; future corporate acquisitions and strategic transactions; and our synergies, cash savings and efficiencies anticipated from the integration of our completed acquisitions and strategic transactions.

Risks and uncertainties that may cause actual results to differ materially from forward-looking statements include, but are not limited to, those identified in this Form 10-Q and other risks and matters described in our most recent Annual Report on Form 10-K for the fiscal year ended May 31, ~~2022~~2023 as well as our other filings made from time to time with the U.S. Securities and Exchange Commission and in our Canadian securities filings.

Forward looking statements are based on information available to us as of the date of this Form 10-Q and, while we believe that information provides a reasonable basis for these statements, these statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. You should not rely upon forward-looking statements or forward-looking information as predictions of future events.

We undertake no obligation to update forward-looking statements to reflect actual results or changes in assumptions or circumstances, except as required by applicable law.

	*February 28,*			*May 31,*			*November 30,*			*May 31,*
	*2023*			*2022*			*2023*			*2023*
Assets
Current assets
Cash and cash equivalents	$	164,997		$	415,909		$	143,373		$	206,632
Marketable Securities		243,286			—
Restricted cash								1,576			—
Marketable securities								116,418			241,897
Accounts receivable, net		78,342			95,279			90,596			86,227
Inventory		202,800			245,529			252,702			200,551
Prepaids and other current assets		69,087			46,786			36,626			37,722
Assets held for sale								736			—
Total current assets		758,512			803,503			642,027			773,029
Capital assets		425,263			587,499			615,087			429,667
Right-of-use assets		6,492			12,996
Operating lease, right-of-use assets								13,551			5,941
Intangible assets		994,325			1,277,875			953,419			973,785
Goodwill		2,005,701			2,641,305			2,009,714			2,008,843
Interest in equity investees		4,638			4,952			4,638			4,576
Long-term investments		7,620			10,050			8,034			7,795
Convertible notes receivable		168,356			111,200			74,681			103,401
Other assets		4,993			314			9,406			222
Total assets	$	4,375,900		$	5,449,694		$	4,330,557		$	4,307,259
Liabilities
Current liabilities
Bank indebtedness	$	18,125		$	18,123		$	20,181		$	23,381
Accounts payable and accrued liabilities		163,422			157,431			216,898			190,682
Contingent consideration		16,219			16,007			7,704			16,218
Warrant liability		7,414			14,255			3,768			1,817
Current portion of lease liabilities		2,528			6,703			5,043			2,423
Current portion of long-term debt		77,892			67,823			12,993			24,080
Current portion of convertible debentures payable		184,082			—			128,399			174,378
Total current liabilities		469,682			280,342			394,986			432,979
Long - term liabilities
Contingent consideration		10,596			—			13,000			10,889
Lease liabilities		8,598			11,329			69,974			7,936
Long-term debt		89,419			117,879			169,099			136,889
Convertible debentures payable		223,087			401,949			123,691			221,044
Deferred tax liabilities		164,412			196,638			166,454			167,364
Other liabilities		3,335			191			—			215
Total liabilities		969,129			1,008,328			937,204			977,316
Commitments and contingencies (refer to Note 17)
Commitments and contingencies (refer to Note 19)
Stockholders' equity
Common stock ($0.0001 par value; 980,000,000 shares authorized; 617,857,031 and 532,674,887 shares issued and outstanding, respectively)		62			53
Series A Preferred Stock ($0.0001 par value; 10,000,000 shares authorized; 120,000 and nil shares issued and outstanding, respectively)		—			—
Common stock ($0.0001 par value; 1,198,000,000 common shares authorized; 732,907,552 and 656,655,455 common shares issued and outstanding, respectively)								73			66
Preferred shares ($0.0001 par value; 10,000,000 preferred shares authorized; nil and nil preferred shares issued and outstanding, respectively)								—			—
Additional paid-in capital		5,723,342			5,382,367			5,942,671			5,777,743
Accumulated other comprehensive loss		(42,948	)		(20,764	)		(38,367	)		(46,610	)
Accumulated Deficit		(2,276,794	)		(962,851	)		(2,536,040	)		(2,415,507	)
Total Tilray Brands, Inc. stockholders' equity		3,403,662			4,398,805			3,368,337			3,315,692
Non-controlling interests		3,109			42,561			25,016			14,251
Total stockholders' equity		3,406,771			4,441,366			3,393,353			3,329,943
Total liabilities and stockholders' equity	$	4,375,900		$	5,449,694		$	4,330,557		$	4,307,259

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

(in thousands of United States dollars, except for share and per share data, unaudited)

	*Three months ended*						*Nine months ended*						*Three months ended*						*Six months ended*
	*February 28,*						*February 28,*						*November 30,*						*November 30,*
	*2023*			*2022*			*2023*			*2022*			*2023*			*2022*			*2023*			*2022*
Net revenue	$	145,589		$	151,871		$	442,936		$	475,047		$	193,771		$	144,136		$	370,720		$	297,347
Cost of goods sold		157,288			112,042			363,139			351,497			146,362			101,254			279,115			205,851
Gross profit (loss)		(11,699	)		39,829			79,797			123,550
Gross profit														47,409			42,882			91,605			91,496
Operating expenses:
General and administrative		38,999			38,445			117,385			121,401			43,313			37,878			83,829			78,386
Selling		6,452			8,641			25,792			25,283			7,583			9,669			14,442			19,340
Amortization		23,518			24,590			71,872			84,345			21,917			23,995			44,142			48,354
Marketing and promotion		7,354			7,578			23,137			20,163			9,208			8,535			17,743			15,783
Research and development		171			164			502			1,464			56			165			135			331
Change in fair value of contingent consideration		352			(30,747	)		563			(29,065	)		300			—			(10,807	)		211
Impairments		1,115,376			—			1,115,376			—
Litigation (recovery) costs		(5,230	)		4,215			(1,970	)		6,489
Litigation costs, net of recoveries														3,042			2,815			5,076			3,260
Restructuring costs		2,663			—			10,727			795			2,655			8,064			3,570			8,064
Transaction (income) costs		5,382			5,023			(3,882	)		35,653			1,094			3,552			9,596			(9,264	)
Total operating expenses		1,195,037			57,909			1,359,502			266,528			89,168			94,673			167,726			164,465
Operating loss		(1,206,736	)		(18,080	)		(1,279,705	)		(142,978	)		(41,759	)		(51,791	)		(76,121	)		(72,969	)
Interest expense, net		(1,040	)		(2,312	)		(8,560	)		(22,422	)		(8,625	)		(3,107	)		(18,460	)		(7,520	)
Non-operating income (expense), net		1,213			71,037			(50,229	)		186,329			821			(18,450	)		(3,581	)		(51,442	)
(Loss) income before income taxes		(1,206,563	)		50,645			(1,338,494	)		20,929
Income taxes (benefit) expense		(10,811	)		(1,830	)		(15,313	)		(2,739	)
Net (loss) income	$	(1,195,752	)	$	52,475		$	(1,323,181	)	$	23,668
Loss before income taxes														(49,563	)		(73,348	)		(98,162	)		(131,931	)
Income tax (recovery) expense														(3,380	)		(11,713	)		3,884			(4,502	)
Net loss													$	(46,183	)	$	(61,635	)	$	(102,046	)	$	(127,429	)
Total net income (loss) attributable to:
Stockholders of Tilray Brands, Inc.		(1,170,998	)		43,190			(1,313,943	)		1,340			(49,008	)		(69,463	)		(120,533	)		(142,945	)
Non-controlling interests		(24,754	)		9,285			(9,238	)		22,328			2,825			7,828			18,487			15,516
Other comprehensive gain (loss), net of tax
Foreign currency translation gain (loss)		6,390			18,498			(78,499	)		(114,641	)		5,203			(24,597	)		8,412			(84,889	)
Unrealized gain (loss) on convertible notes receivable		95,345			(39,296	)		75,177			(56,250	)		—			(17,643	)		—			(20,168	)
Total other comprehensive gain (loss), net of tax		101,735			(20,798	)		(3,322	)		(170,891	)
Comprehensive (loss) income	$	(1,094,017	)	$	31,677		$	(1,326,503	)	$	(147,223	)
Total other comprehensive loss, net of tax														5,203			(42,240	)		8,412			(105,057	)
Comprehensive loss													$	(40,980	)	$	(103,875	)	$	(93,634	)	$	(232,486	)
Total comprehensive income (loss) attributable to:
Stockholders of Tilray Brands, Inc.		(1,092,491	)		34,605			(1,336,127	)		(150,318	)		(43,814	)		(111,186	)		(112,290	)		(243,636	)
Non-controlling interests		(1,526	)		(2,928	)		9,624			3,095			2,834			7,311			18,656			11,150
Weighted average number of common shares - basic		615,534,670			485,668,750			597,829,714			470,303,170			730,769,132			611,711,377			710,877,859			589,112,358
Weighted average number of common shares - diluted		615,534,670			488,546,790			597,829,714			478,050,130			730,769,132			611,711,377			710,877,859			589,112,358
Net (loss) income per share - basic	$	(1.90	)	$	0.09		$	(2.20	)	$	0.00
Net (loss) income per share - diluted	$	(1.90	)	$	0.09		$	(2.20	)	$	0.00
Net loss per share - basic													$	(0.07	)	$	(0.11	)	$	(0.17	)	$	(0.24	)
Net loss per share - diluted													$	(0.07	)	$	(0.11	)	$	(0.17	)	$	(0.24	)

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

									*Accumulated*																			*Accumulated*
	*Number of*					*Additional*			*other*						*Non-*						*Number of*				*Additional*			*other*						*Non-*
	*common*		*Common*			*paid-in*			*comprehensive*			*Accumulated*			*controlling*						*common*		*Common*		*paid-in*			*comprehensive*			*Accumulated*			*controlling*
	*shares*		*stock*			*capital*			*income (loss)*			*Deficit*			*interests*			*Total*
Balance at May 31, 2021		446,440,641	$	46		$	4,792,406		$	152,668		$	(486,050	)	$	6,243		$	4,465,313
Third party contribution to Superhero Acquisition LP		—		—			—			—			—			52,995			52,995
Share issuance - options exercised		417,489		—			—			—			—			—			—
Share issuance - RSUs exercised		3,665,337		—			—			—			—			—			—
Shares effectively repurchased for employee withholding tax		—		—			(5,944	)		—			—			—			(5,944	)
Stock-based compensation		—		—			9,417			—			—			—			9,417
Comprehensive income (loss) for the period		—		—	��		—			(101,421	)		(41,649	)		7,045			(136,025	)
Balance at August 31, 2021		450,523,467	$	46		$	4,795,879		$	51,247		$	(527,699	)	$	66,283		$	4,385,756
Share issuance - Superhero Acquisition LP		9,817,061		—			117,804			—			—			—			117,804
Share issuance - Double Diamond Holdings note		2,677,596		—			28,560			—			—			(28,560	)		—
Share issuance - options exercised		98,044		—			—			—			—			—			—
Share issuance - RSUs exercised		470,324		—			—			—			—			—			—
Shares effectively repurchased for employee withholding tax		—		—			(2,742	)											(2,742	)
Share issuance - legal settlement		215,901		—			2,170												2,170
Stock-based compensation		—		—			12,876			—			—			—			12,876
Comprehensive income (loss) for the period		—		—			—			(41,652	)		(201	)		(1,022	)		(42,875	)
Balance at November 30, 2021		463,802,393	$	46		$	4,954,547		$	9,595		$	(527,900	)	$	36,701		$	4,472,989
Share issuance - Breckenridge Acquisition		12,540,479	$	2		$	114,066			—			—			—			114,068
Share issuance - legal settlement		2,743,485		—			20,000			—			—			—			20,000
Share issuance - options exercised		190,620		—			778			—			—			—			778
Share issuance - RSUs exercised		170,928		—			—			—			—			—			—
Share issuance - purchase of capital and intangible assets		1,289,628		—			12,146			—			—			—			12,146
Stock-based compensation		—		—			9,355			—			—			—			9,355
Comprehensive income (loss) for the period		—		—			—			(8,585	)		43,190			(2,928	)		31,677
Balance at February 28, 2022		480,737,533	$	48		$	5,110,892		$	1,010		$	(484,710	)	$	33,773		$	4,661,013
																					*shares*		*stock*		*capital*			*loss*			*Deficit*			*interests*			*Total*
Balance at May 31, 2022		532,674,887	$	53		$	5,382,367		$	(20,764	)	$	(962,851	)	$	42,561		$	4,441,366			532,674,887	$	53	$	5,382,367		$	(20,764	)	$	(962,851	)	$	42,561		$	4,441,366
Share issuance - equity financing		32,481,149		3			129,590			—			—			—			129,593			32,481,149		3		129,590			—			—			—			129,593
Shares issued to purchase HEXO convertible note receivable		33,314,412		3			107,269			—			—			—			107,272			33,314,412		3		107,269			—			—			—			107,272
HTI Convertible Note - conversion feature		—		—			9,055			—			—			—			9,055			—		—		9,055			—			—			—			9,055
Share issuance - Double Diamond Holdings note		1,529,821		1			5,063			—			—			—			5,064
Share issuance - Double Diamond Holdings dividend settlement																						1,529,821		1		5,063			—			—			—			5,064
Share issuance - options exercised		3,777		—			—			—			—			—			—			3,777		—		—			—			—			—			—
Share issuance - RSUs exercised		950,893		—			—			—			—			—			—			950,893		—		—			—			—			—			—
Shares effectively repurchased for employee withholding tax		—		—			(1,189	)		—			—			—			(1,189	)		—		—		(1,189	)		—			—			—			(1,189	)
Stock-based compensation		—		—			9,193			—			—			—			9,193			—		—		9,193			—			—			—			9,193
Dividends declared to non-controlling interests		—		—			—			—			—			(8,561	)		(8,561	)		—		—		—			—			—			(8,561	)		(8,561	)
Comprehensive income (loss) for the period		—		—			—			(58,968	)		(73,482	)		3,839			(128,611	)		—		—		—			(58,968	)		(73,482	)		3,839			(128,611	)
Balance at August 31, 2022		600,954,939	$	60		$	5,641,348		$	(79,732	)	$	(1,036,333	)	$	37,839		$	4,563,182			600,954,939		60		5,641,348			(79,732	)		(1,036,333	)		37,839			4,563,182
Shares issued to purchase Montauk		1,708,521		—			6,422			—			—			—			6,422			1,708,521		—		6,422			—			—			—			6,422
Share issuance - options exercised		4,183		—			—			—			—			—			—			4,183		—		—			—			—			—			—
Share issuance - RSUs exercised		237,611		—			—			—			—			—			—			237,611		—		—			—			—			—			—
Stock-based compensation		—		—			10,943			—			—			—			10,943					—		10,943			—			—			—			10,943
Share issuance - Double Diamond Holdings note		10,276,305		1			38,753			—			—			(32,280	)		6,474			10,276,305		1		38,753			—			—			(32,280	)		6,474
Comprehensive income (loss) for the period		—		—			—			(41,723	)		(69,463	)		7,311			(103,875	)				—		—			(41,723	)		(69,463	)		7,311			(103,875	)
Balance at November 30, 2022		613,181,559	$	61		$	5,697,466		$	(121,455	)	$	(1,105,796	)	$	12,870		$	4,483,146			613,181,559	$	61	$	5,697,466		$	(121,455	)	$	(1,105,796	)	$	12,870		$	4,483,146

Balance at May 31, 2023																						656,655,455	$	66	$	5,777,743		$	(46,610	)	$	(2,415,507	)	$	14,251		$	3,329,943
Share issuance - HEXO acquisition																						39,705,962		4		65,158			—			—			—			65,162
Share issuance - settlement of contractual change of control severance incurred from HEXO acquisition																						865,426		—		1,500			—			—			—			1,500
Share issuance - Double Diamond Holdings dividend settlement																						5,004,735		—		8,146			—			—			—			8,146
Share issuance - HTI convertible note																						17,148,541		2		49,998												50,000
Share issuance - RSUs exercised																						3,912,481		—		—			—			—			—			—
Shares effectively repurchased for employee withholding tax																						—		—		(4,860	)		—			—			—			(4,860	)
Equity component related to issuance of convertible debt, net of issuance costs																						—		—		3,953			—			—			—			3,953
Stock-based compensation																						—		—		8,257			—			—			—			8,257
Dividends declared to non-controlling interests																								—		—			—			—			(7,891	)		(7,891	)
Comprehensive income (loss) for the period																						—		—		—			3,049			(71,525	)		15,822			(52,654	)
Balance at August 31, 2023																						723,292,600	$	72	$	5,909,895		$	(43,561	)	$	(2,487,032	)	$	22,182		$	3,401,556


Share issuance - HTI convertible note																						1,032,616		—		2,313			—			—			—			2,313
Share issuance - Settlement of litigation claims from MediPharm Labs Inc																						1,573,152		—		3,477			—			—			—			3,477
Share issuance - Repurchase of TLRY 23 convertible note																						7,000,000		1		20,457			—			—			—			20,458
Share issuance - Settlement of equity component of TLRY 23 convertible note																						—		—		(1,672	)		—			—			—			(1,672	)
Share issuance - RSUs exercised		487,192		—			—			—			—			—			—			9,184		—		—			—			—			—			—
Stock-based compensation		—		—			9,630			—			—			—			9,630			—		—		8,201			—			—			—			8,201
Share issuance - Double Diamond Holdings note		4,188,280		1			15,912			—			—			(8,235	)		7,678
Preferred share issuance		120,000		—			334			—			—			—			334
Comprehensive income (loss) for the period		—		—			—			78,507			(1,170,998	)		(1,526	)		(1,094,017	)		—		—		—			5,194			(49,008	)		2,834			(40,980	)
Balance at February 28, 2023		617,977,031	$	62		$	5,723,342		$	(42,948	)	$	(2,276,794	)	$	3,109		$	3,406,771
Balance at November 30, 2023																						732,907,552	$	73	$	5,942,671		$	(38,367	)	$	(2,536,040	)	$	25,016		$	3,393,353

~~Included in common stock is 120,000 of Series A preferred stock with par value of $0 as described in Note 13 (Stockholders’ equity).~~ The accompanying notes are an integral part of these condensed interim consolidated financial statements.

	*For the nine months*						*For the six months*
	*ended February 28,*						*ended November 30,*
	*2023*			*2022*			*2023*			*2022*
Cash used in operating activities:
Net (loss) income	$	(1,323,181	)	$	23,668
Net loss							$	(102,046	)	$	(127,429	)
Adjustments for:
Deferred income tax recovery		(29,537	)		(17,296	)		(4,042	)		(12,941	)
Unrealized foreign exchange loss		13,711			1,699
Unrealized foreign exchange (gain) loss								(5,604	)		2,261
Amortization		101,156			113,824			62,341			67,387
Loss (gain) on sale of capital assets		(2	)		(631	)
Inventory valuation write down		55,000			12,000
Impairments		1,115,376			—
(Gain) loss on sale of capital assets								(20	)		13
Other non-cash items		12,933			962			(2,623	)		10,372
Stock-based compensation		29,766			27,025			16,458			20,136
Loss (gain) on long-term investments & equity investments		2,843			(2,401	)
Loss (gain) on derivative instruments		13,534			(210,653	)
(Gain) loss on long-term investments & equity investments								(412	)		1,918
Loss on derivative instruments								7,992			18,997
Change in fair value of contingent consideration		563			(29,065	)		(10,807	)		211
Change in non-cash working capital:
Accounts receivable		18,053			(458	)		4,524			6,690
Prepaids and other current assets		(32,680	)		(953	)		3,764			(7,780	)
Inventory		(11,808	)		(16,512	)		8,669			5,046
Accounts payable and accrued liabilities		(1,419	)		(57,947	)		(24,445	)		(1,941	)
Net cash used in operating activities		(35,692	)		(156,738	)		(46,251	)		(17,060	)
Cash used in investing activities:
Investment in capital and intangible assets		(8,394	)		(28,470	)
Cash provided by (used in) investing activities:
Investment in capital and intangible assets, net								(10,011	)		(7,537	)
Proceeds from disposal of capital and intangible assets		2,175			11,526			365			2,160
Purchase of marketable securities, net		(243,186	)		—
Net cash paid for business acquisition		(28,122	)		326
Net cash used in investing activities		(277,527	)		(16,618	)
Disposal (purchase) of marketable securities, net								125,479			(243,186	)
Business acquisitions, net of cash acquired								(60,626	)		(24,372	)
Net cash provided by (used in) investing activities								55,207			(272,935	)
Cash provided by (used in) financing activities:
Share capital issued, net of cash issuance costs		129,593			—			—			129,593
Shares effectively repurchased for employee withholding tax		(1,189	)		(3,149	)		—			(1,189	)
Proceeds from long-term debt		1,288			—			32,621			1,288
Repayment of long-term debt and convertible debt		(64,658	)		(34,570	)
Repayment of long-term debt								(14,901	)		(10,420	)
Proceeds from convertible debt								21,553			—
Repayment of convertible debt								(107,330	)		(48,975	)
Repayment of lease liabilities		(1,114	)		(4,672	)		(91	)		(1,114	)
Net increase in bank indebtedness		2			8,779
Net decrease in bank indebtedness								(3,200	)		(2,819	)
Net cash provided by (used in) financing activities		63,922			(33,612	)		(71,348	)		66,364
Effect of foreign exchange on cash and cash equivalents		(1,615	)		(2,284	)		709			(2,060	)
Net decrease in cash and cash equivalents		(250,912	)		(209,252	)		(61,683	)		(225,691	)
Cash and cash equivalents, beginning of period		415,909			488,466			206,632			415,909
Cash and cash equivalents, end of period	$	164,997		$	279,214		$	144,949		$	190,218

Included in the statement of cash flows cash and cash equivalents is $1,576 of restricted cash as of November 30, 2023, $nil as of May 31, 2023.

The accompanying notes are an integral part of these condensed interim consolidated financial statements.

Note 1. Basis of presentation and summary of significant accounting policies

The accompanying unaudited condensed interim consolidated financial statements (the “financial statements”) reflect the accounts of the Company for the quarterly period ended ~~February 28, 2023.~~ November 30, 2023. The financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and notes required by U.S. GAAP and should be read in conjunction with the audited consolidated financial statements (the “Annual Financial Statements”) included in the Company’s Annual Report on Form 10-K for the fiscal year ended May 31, ~~2022~~2023 (the “Annual Report”). These unaudited condensed interim consolidated financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

These condensed interim consolidated financial statements have been prepared on the going concern basis which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company’s accounting policies.

All amounts in the unaudited condensed interim consolidated financial statements, notes and tables have been rounded to the nearest thousand, except par values and per share amounts, unless otherwise indicated.

Certain items of the comparative figures have been changed to conform to the presentation adopted in the current period.

Subsidiaries are entities controlled by the Company. Control exists when the Company either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in the condensed interim consolidated financial statements from the date that control commences until the date that control ceases. A complete list of our subsidiaries that existed prior to our most recent year end is included in the Annual ~~Report.~~

OnReport, except for the entities acquired within Note ~~February 10,~~7 (Business acquisitions), during the period ended November 30, 2023~~the Company divested its ownership interest in ASG Pharma Ltd., a wholly-owned subsidiary incorporated in Malta, and, therefore, it is~~ no ~~longer consolidated in the Company's results. The Company recognized a gain of $312 in other non-operating (losses) gains, net as a result of the disposal.~~

We classify term deposits and other investments that have maturities of greater than three months but less than one year as marketable securities. The fair value of marketable securities is based on quoted market prices for publicly traded securities. Marketable securities are carried at fair value with changes in fair value recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense)”.

We classify cash that is legally or contractually restricted as to withdrawal or usage, as restricted cash. As of November 30, 2023, the Company reported $1,576 restricted cash related to letters of credit and collateral from the acquisition of HEXO Corp. as described in Note 7 (Business acquisitions).

We classify capital assets that are available and which are probable for immediate sale in their present condition, which the Company has approved the action or plan to sell, as assets held for sale. As of November 30, 2023, the Company reported $736 assets held for sale related to Kirkland lake property from the acquisition of HEXO Corp. as described in Note 7 (Business acquisitions). Assets held for sale are to be measured at the lower of carrying amount and the fair value less costs to sell. Disposition of assets held for sale are recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense)”.

When there are changes in circumstances that were previously considered unlikely to occur, and it is decided not to proceed with a sale, an asset that was previously classified as assets held for sale is reclassified as held and used. The asset is then remeasured at the lower of its carrying amount before being classified as held for sale less the amortization that would have occurred and the fair value on the date the decision not to proceed with a sale was made. Changes in the carrying amount are recorded in the statement of net loss and comprehensive loss.

Investments in equity securities of entities over which the Company does not have a controlling financial interest or significant influence are classified as an equity investment and accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the “measurement alternative”). In applying the measurement alternative, the Company performs a qualitative assessment on a quarterly basis and recognizes an impairment if there are sufficient indicators that the fair value of the equity investments is less than carrying values. Changes in value are recorded in the statement of net loss and comprehensive loss, within the line, “Non-operating income (expense)”.

Investments in entities over which the Company does not have a controlling financial interest but has significant influence, are accounted for using the equity method, with the Company’s share of earnings or losses reported in earnings or losses from equity method investments on the statements of net loss and comprehensive loss. Equity method investments are recorded at cost, ~~plus~~adjusted for the Company’s share of undistributed earnings or losses, and impairment, if any, within “Interest in equity investees” on the balance sheets. The Company assesses investments in equity method investments when events or circumstances indicate that the carrying amount of the investment may be impaired. If it is determined that the current fair value of an equity method investment is less than the carrying value of the investment, the Company will assess if the shortfall is other than temporary (OTTI). Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the equity investee to sustain an earnings capacity that would justify the carrying amount of the investment. Once a determination is made that an OTTI exists, the investment is written down to its fair value in accordance with ASC 820 at the reporting date, which establishes a new cost basis.

Convertible notes receivable include various investments in which the Company has the right, or potential right to convert the indenture into common stock of the investee and are classified as available-for-sale and are recorded at fair value. Unrealized gains and losses during the year, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and the cumulative effect is reported as a separate component of shareholders' equity until realized. We use judgement to assess convertible notes receivables for impairment at each measurement date. Convertible notes receivables are impaired when a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded in the statements of loss and comprehensive loss and a new cost basis for the investment is established. We also evaluate whether there is a plan to sell the security, or it is more likely than not that we will be required to sell the security before recovery. If neither of the conditions exist, then only the portion of the impairment loss attributable to credit loss is recorded in the statements of net loss and the remaining amount is recorded in other comprehensive income (loss).

Basic earnings (loss) per share is computed by dividing reported net income (loss) by the weighted average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed by dividing reported net income (loss) by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants and RSUs and the incremental shares issuable upon conversion of the convertible debentures payable and similar instruments.

~~In computing diluted earnings (loss) per share, common share equivalents are~~ ~~not~~ ~~considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the~~ ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~February 28, 2023,~~ the dilutive potential common share equivalents outstanding consist of the following: 16,431,876 common shares from RSUs, 4,660,046 common shares from share options, 6,209,000 common shares from warrants and 36,388,651 common shares from convertible debentures payable.

On ~~July 12, 2022,~~ ~~the Company and HEXO entered into various commercial transaction agreements, as described in Note~~ 23 (Segment reporting), which includes an advisory services arrangement. Revenue is recognized as the advisory services are provided to HEXO. Payments received for the services in advance of performance are recognized as a contract liability.

Revenue is recognized when the control of the promised goods or services, through performance obligation, is transferred/provided to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for the performance obligations.

Excise taxes remitted to tax authorities are government-imposed excise taxes on cannabis and beer. Excise taxes are recorded as a reduction of sales in net revenue in the consolidated statements of operations and recognized as a current liability within accounts payable and ~~other current~~accrued liabilities on the consolidated balance sheets, with the liability subsequently reduced when the taxes are remitted to the tax authority.

In addition, amounts disclosed as net revenue are net of excise taxes, sales tax, duty tax, allowances, discounts and rebates.

In determining the transaction price for the sale of goods or ~~service,~~services, the Company considers the effects of variable consideration and the existence of significant financing components, if any.

~~Some~~We may enter into certain contracts for the sale of goods or services, ~~may~~ which provide customers with ~~a right~~rights of return, volume ~~discount,~~discounts, bonuses for volume/quality achievement, and/or sales ~~allowance.~~allowances. In addition, the Company may provide in certain circumstances, a retrospective price reduction to a customer based primarily on inventory movement. ~~These~~The inclusion of these items may give rise to variable consideration. The Company uses the expected value method to estimate the variable consideration because this method ~~best predicts~~provides the most accurate estimation of the amount of variable consideration to which the Company will be entitled. The Company uses historical evidence, current information and forecasts to estimate the variable consideration. The Company reduces revenue and recognizes a contract liability equal to the amount expected to be refunded to the customer in the form of a future rebate or credit for a retrospective price reduction, representing its obligation to return the customer’s consideration. The estimate is updated at each reporting period date.

On July 12, 2022, the Company and HEXO Corp. ("HEXO") entered into various commercial transaction agreements, as described in Note 26 (Segment reporting), which included an advisory services arrangement. The fees associated with the advisory services arrangement were recognized as revenue when such services were provided to HEXO. Any payments that were received for such services in advance of performance were recognized as a contract liability. On June 22, 2023, the Company completed the acquisition of HEXO, as described in Note 7 (Business acquisitions), simultaneously terminating the advisory services arrangement and other commercial transactions.

The Company expenses costs net of any gains directly attributable to business acquisitions and classifies these items as transaction (income) costs. These items include among other things, legal fees to complete the acquisition, financial advisor and due diligence costs, and transaction related compensation. These items are recognized as incurred.

Basic earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the weighted average number of common shares outstanding during the year. Diluted earnings (loss) per share is computed by dividing reported net income (loss) attributable to stockholders of Tilray Brands, Inc. by the sum of the weighted average number of common shares and the number of dilutive potential common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options, warrants, and RSUs and the incremental shares issuable upon conversion of the convertible debentures and similar instruments. Shares of common stock outstanding under the share lending arrangement entered into in conjunction with the TLRY 27 Notes, see Note 13 (Convertible debentures payable) are excluded from the calculation of basic and diluted earnings per share because the borrower of the shares is required under the share lending arrangement to refund any dividends paid on the shares lent.

In computing diluted earnings (loss) per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. For the three months ended November 30, 2023 and November 30, 2022, the dilutive potential common share equivalents outstanding consisted of the following: 20,939,082 and 16,884,493 common shares from RSUs, 6,280,065 and 4,674,512 common shares from share options, 6,209,000 and 6,209,000 common shares for warrants and 77,181,260 and 23,981,704 common shares for convertible debentures, respectively.

In August 2023, the FASB issued ASU 2023-05,Business Combination - Joint Venture Formations (Subtopic 805-60) Recognition and Initial Measurement (“ASU 2023-05”), which is intended to address the accounting for contributions made to a joint venture. ASU 2023-05 is effective for the Company beginning June 1, 2026. This update will be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.

In October 2023, the FASB issued ASU 2023-06,Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative, which amends the disclosure or presentation requirements related to various subtopics in the FASB Accounting Standards Codification (the “Codification”). The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective for any entity. The Company is currently evaluating the effect of adopting this ASU.

In November 2023, the FASB issued ASU 2023-07,Segment Reporting (Topic 280) Improvements to Reportable Segment Disclosures, which requires public entities to disclose information about their reportable segments’ significant expenses on an interim and annual basis. ASU 2023-07 is effective for the Company beginning the year ended May 31, 2025. The Company is currently evaluating the effect of adopting this ASU.

In December 2023, the FASB issued ASU 2023-09,Income Taxes (Topic 740) Improvements to Income Tax Disclosures, which requires public entities to disclose specific categories in the rate reconciliation and provide additional information for reconciling items that meet a quantitative threshold on an annual basis. ASU 2023-09 is effective for the Company beginning the year ended June 01, 2024. The Company is currently evaluating the effect of adopting this ASU.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Subtopic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. The Company adopted the ASU 2021-08 ~~is effective for the Company~~ beginning June 1, ~~2023.~~2023, ~~This update will be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.~~

In ~~August 2020,~~ ~~the FASB issued ASU~~ ~~2020~~-~~06,~~~~Debt~~—~~Debt with Conversion and Other Options (Subtopic~~ ~~470~~-20~~) and Derivatives and Hedging~~—~~Contracts in Entity~~’~~s Own Equity (Subtopic~~ ~~815~~-40~~): Accounting for Convertible Instruments and Contracts in an Entity~~’~~s Own Equity~~ ~~(“ASU~~ ~~2020~~-~~06”~~), which amends and simplifies existing guidance in an effort to reduce the complexity of accounting for convertible instruments and to provide financial statement users with more meaningful information. The Company adopted ASU ~~2020~~-06 ~~beginning~~ ~~June 1, 2022~~ ~~and the adoption~~however, it did not have ~~material retrospective impacts on our condensed interim consolidated financial statements~~.

In ~~May 2021,~~ ~~the FASB issued ASU~~ ~~2021~~-~~04,~~~~Modifications and Extinguishments (Subtopic~~ ~~470~~-50~~), Compensation~~—~~Stock Compensation (Topic~~ ~~718~~~~), and Derivatives and Hedging~~—~~Contracts in Entity~~’~~s Own Equity (Subtopic~~ ~~815~~-40) ~~(“ASU~~ ~~2021~~-~~04”~~~~), which amends existing guidance for earnings per share (EPS) in accordance with Topic~~ ~~260.~~ ~~The Company adopted the ASU beginning~~ ~~June 1, 2022~~ ~~and the adoption of ASU~~ ~~2021~~-04 ~~did~~ ~~not~~ ~~have an~~any impact on ~~our condensed interim consolidated financial statements.~~

In ~~November 2021,~~ ~~the FASB issued ASU~~ ~~2021~~-~~10,~~~~Government Assistance (Topic~~ ~~832~~~~), Disclosures by Business Entities about Government Assistance,~~ ~~which is intended to increase the transparency of government assistance including the disclosure of (~~1~~) the types of assistance, (~~2~~) an entity’s accounting for the assistance, and (~~3~~) the effect of the assistance on an entity’s financial statements. The Company adopted the ASU beginning~~ ~~June 1, 2022~~ ~~and the adoption of ASU~~ ~~2021~~-04 ~~did~~ ~~not~~ ~~have an impact on the disclosure in~~ our condensed interim consolidated financial statements.

	*February 28,*		*May 31,*		*November 30,*		*May 31,*
	*2023*		*2022*		*2023*		*2023*
Plants	$	13,566	$	14,521	$	14,908	$	10,884
Dried cannabis		84,066		116,739		107,805		89,801
Cannabis trim		591		592		-		322
Cannabis derivatives		8,557		24,685		4,814		9,229
Cannabis vapes		2,631		542		7,076		1,173
Packaging and other inventory items		17,621		21,691		17,924		19,997
Wellness inventory		12,797		13,275		11,395		11,164
Beverage alcohol inventory		30,100		27,840		52,371		27,837
Distribution inventory		32,871		25,644		36,409		30,144
Total	$	202,800	$	245,529	$	252,702	$	200,551

~~During the~~ ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~February 28, 2023~~~~, the Company recorded charges of $55,000 for an inventory valuation adjustment as a component of cannabis cost of good sold, compared to~~ ~~$nil~~ ~~and $12,000 for the~~ ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~February 28, 2022.~~ ~~This charge was driven by the decision of management to repurpose a portion of our existing supply of dried cannabis inventory.~~

~~The Company recorded non-cash impairments of $81,500 on its production facility in Canada and $22,500 on its equipment for the~~ ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~February 28, 2023,~~ which the Company has temporarily made idle in order to reduce cultivation costs and right-size the Company's production to align with current and projected demand. The impairment was calculated based on the excess of carrying value over fair value which was determined using a market approach. A reasonably possible change in any of the inputs within the determination of fair value would ~~not~~ ~~result in a material change to the impairment recorded.~~

The table below presents the lease-related assets and liabilities recorded on the balance sheet.

The following table presents the future undiscounted payment associated with lease liabilities as of November 30, 2023:

	*February 28,*			*May 31,*			*November 30,*			*May 31,*
	*2023*			*2022*			*2023*			*2023*
Customer relationships & distribution channel	$	613,461		$	617,437		$	620,876		$	614,062
Licenses, permits & applications		367,649			377,897			370,753			366,793
Non-compete agreements		13,644			12,512			12,441			12,394
Intellectual property, trademarks, knowhow & brands		585,777			634,997			594,948			583,468
		1,580,531		$	1,642,843			1,599,018		$	1,576,717
Less: accumulated amortization		(170,362	)	$	(154,124	)		(229,755	)		(187,088	)
Less: impairments		(415,844	)		(210,844	)		(415,844	)		(415,844	)
Total	$	994,325		$	1,277,875		$	953,419		$	973,785

The Company recorded non-cash impairments of $110,000 of its customer relationships & distribution channel, $55,000 of its licenses, permits & applications and $40,000 of its intellectual property, trademarks, knowhow & brands for the ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~February 28, 2023,~~ ~~as a result of the decline in market share in its Canadian cannabis with certain product lines and customers. As of~~ ~~February 28, 2023~~~~, included~~Included in licenses, permits & applications ~~is $182,009 of indefinite-lived intangible assets. As of~~ ~~May 31, 2022~~~~, there~~ was ~~$248,411~~$184,858 of indefinite-lived intangible assets ~~included in Licenses, permits & applications.~~

~~In calculating the impairment amount, using an income approach, the Company used a discount rate~~as of ~~13.50%~~November 30, 2023, ~~increased from 11.21% used in the~~compared to $181,093 as of May 31, ~~2022~~ 2023~~annual assessment, a terminal growth rate of 2%-5% consistent with the rate used in the~~ ~~May 31, 2022~~ annual assessment, and an average revenue growth rate of 0%-40% over 5 years to correlate with the cash flows anticipated with the individual intangible assets that were assessed, while these assets have ~~not~~ ~~been assessed individually in the past the associated cash flows were included in the~~ ~~May 31, 2022~~ ~~goodwill annual assessment which used an average growth rate of 46%~~. ~~A reasonably possible change in any of the inputs within the determination of fair value would~~ ~~not~~ ~~result in a material change to the impairment recorded.~~

Expected future amortization expense for intangible assets as of ~~February 28,~~November 30, 2023 are as follows:

	*Amortization*		*Amortization*
2023 (remaining three months)	$	19,443
2024		75,720
2024 (remaining six months)			$	36,861
2025		72,616		73,722
2026		72,616		73,722
2027		72,616		73,722
2028				73,722
Thereafter		499,305		436,812
Total	$	812,316	$	768,561

Based upon a combination of factors including a sustained decline in the Company’s market capitalization below the Company’s carrying value, coupled with challenging macro-economic conditions, most particularly the rising interest rate environment and slower than anticipated progress in global cannabis legalization, the Company concluded that it is more likely than ~~not,~~ ~~that the fair value of our reporting units was less than their carrying amounts as at~~ ~~February 28, 2023.~~ Accordingly, the Company valued the fair value of each reporting segment by using the income approach, which estimates the fair value of each reporting unit based on the future discounted cash flows. Upon updating the Company’s forecasted cash flows there were no impairments identified from changes in management’s forecasts, however, due to the increased borrowing rates and the decline of the company’s market capitalization, the Company was led to adjust the Company specific risk premium which resulted in the non-cash impairment charges of ~~$603,500~~ ~~of cannabis goodwill and~~ ~~$15,000~~ ~~of wellness goodwill for the~~ ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~February 28, 2023.~~ ~~The non-cash charge has~~ no ~~impact on the Company’s compliance with debt covenants, its cash flows or available liquidity.~~

~~In the Company's cannabis goodwill assessment the Company used a discount rate of 13.50%, increased from 11.21% used in the~~ ~~May 31, 2022~~ ~~annual assessment, a terminal growth rate of 5% consistent with the rate used in the~~ ~~May 31, 2022~~ ~~annual assessment, and an average revenue growth rate of 40% over~~ 5 ~~years as a result of anticipated federal legalization in various countries, decreased from 46% used in the~~ ~~May 31, 2022~~ ~~annual assessment. A~~ 1% ~~increase in the discount rate would result in an additional $300,000 in impairment, a~~ 1% ~~decrease in the terminal growth rate would result in an additional $250,000 in impairment and a~~ 5% ~~decrease in the average growth rate would result in an additional $200,000 in impairment.~~

~~In the Company's wellness goodwill assessment the Company used a discount rate of 11.80%, increased from 10% used in the~~ ~~May 31, 2022~~ ~~annual assessment, a terminal growth rate of 3% consistent with the rate used in the~~ ~~May 31, 2022~~ ~~annual assessment, and an average revenue growth rate of 10% over~~ 5 ~~years, consistent with the rate used in the~~ ~~May 31, 2022~~ ~~annual assessment. A~~ 1% ~~increase in the discount rate would result in an additional $14,000 in impairment, a~~ 1% ~~decrease in the terminal growth rate would result in an additional $10,000 in impairment and a~~ 5% ~~decrease in the average growth rate would result in an additional $5,000 in impairment.~~

Acquisition of ~~Double Diamond Distillery LLC (d/b/a Breckenridge Distillery)~~Montauk Brewing Company, Inc.

On ~~December~~November 7, ~~2021,~~2022, ~~the~~Tilray acquired Montauk Brewing Company, ~~through its wholly-owned subsidiary Four Twenty Corporation, acquired all the membership interests of Double Diamond Distillery LLC (d/b/a Breckenridge Distillery)~~Inc. (“Montauk”), a ~~Colorado limited liability company and~~leading craft brewer based in Montauk, New York, which expanded our distribution network with a ~~leading distilled spirits~~strong brand ~~located~~ in ~~Breckenridge, Colorado (the “Breckenridge Acquisition”).~~the tri-state region of the U.S. In consideration for the ~~Breckenridge Acquisition,~~acquisition of Montauk, and after giving effect to post-closing adjustments, the Company paid an aggregate ~~amount~~purchase price equal to ~~$114,068~~$35,123, which was comprised of $ 28,701 in cash and the remainder through the issuance of ~~12,540,479~~1,708,521 shares of ~~Tilray’s Class~~Tilray's common stock (having a value of $6,422 at closing). In the event that Montauk achieves certain volume and/or EBITDA targets on or before 2December 31, 2025, the stockholders of Montauk shall be eligible to receive additional contingent cash consideration of up to $18,000. The Company determined that the closing date fair value of this contingent consideration was $10,245 based on the inputs disclosed in Note 25 ~~common shares.~~(Fair value measurements).

The table below summarizes ~~the~~ fair value of the assets acquired and the liabilities assumed at the effective acquisition date.

	*Amount*		*Amount*
Consideration
Cash			$	28,701
Shares	$	114,068		6,422
Contingent consideration				10,245
Net assets acquired
Current assets
Cash and cash equivalents		326		1,983
Accounts receivable		2,128		1,116
Prepaids and other current assets		367		467
Inventory		20,351		1,570
Long-term assets
Capital assets		11,179		420
Customer relationships (15 years)		9,800		18,540
Intellectual property, trademarks & brands (15 years)		69,950		13,650
Goodwill		2,797		17,803
Total Assets		116,898
Total assets				55,549
Current liabilities
Accounts payable and accrued liabilities		2,228		1,580
Long-term liabilities
Deferred tax liability		602		4,851
Other liabilities				3,750
Total liabilities		2,830		10,181
Total net assets acquired	$	114,068	$	45,368

~~The goodwill of $2,797 is primarily related to factors such as synergies and market opportunities and is reported under~~In the ~~Company’s Beverage alcohol segment. Revenue for~~ event that the Montauk acquisition had occurred on June 1, 2022, the Company would have ~~been higher by~~had additional net revenue of approximately ~~$6,000~~$3,100 and ~~$12,000~~$9,000 for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2022 ~~2022,~~ ~~if the acquisition had taken place on~~ ~~June 1, 2021.~~ ~~Net~~and net loss and comprehensive net loss would have increased by approximately ~~$1,500~~$600 and ~~$3,000~~$500 for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2022,~~if the acquisition had taken place on~~ ~~June 1, 2021,~~ primarily as a result of amortization of the intangible assets acquired. This unaudited pro forma financial information does not reflect the realization of any expected ongoing synergies relating to the integration of ~~Breckenridge.~~Montauk.

On ~~November 7, 2022,~~June 22, 2023, Tilray acquired ~~Montauk Brewing Company, Inc. ("Montauk"),~~HEXO, a ~~leading craft brewer~~cannabis company in ~~Metro New York located in Montauk, New York~~Canada (the ~~“Montauk~~“HEXO Acquisition”). for the purpose of expanding the Company’s revenue base, production capabilities around certain form factors and growth opportunities with the Redecan brand. In consideration for the ~~Montauk~~HEXO Acquisition, the Company paid ~~an initial~~a total purchase price equivalent of ~~$35,110,~~$93,882, which consisted of ~~cash consideration of $28,688 and~~ stock consideration of ~~$6,422 through~~$63,927, settlement of convertible notes receivable of $28,720, the ~~issuance~~fair value of ~~1,708,521 shares~~HEXO stock-based compensation of ~~Tilray's Class~~ 2$1,188 and the assumption of warrants of $47. In connection with the HEXO Acquisition, each outstanding HEXO common share was exchanged for 0.4352 of a share of Tilray common stock and each outstanding HEXO preferred share was exchanged for 0.7805 of a share of Tilray common stock. In ~~addition,~~ the ~~stockholders~~aggregate, the Company issued 39,705,962 shares of ~~Montauk shall be eligible~~Tilray common stock, at a share price of $1.61 per share, in connection with the HEXO Acquisition. The Company intends to ~~receive additional contingent cash consideration~~sell HEXO's Kirkland lake property and has recorded the value of ~~up to $18,000~~the associated capital assets as an asset held for sale.

The Company is in the ~~event that Montauk achieves certain volume and/or EBITDA targets on or before~~ ~~December 31, 2025.~~ ~~The Company determined that~~process of assessing the ~~closing date~~ fair value of ~~this~~the net assets acquired and, as a result, the fair value may be subject to adjustments pending completion of final valuations and post-closing adjustments. The table below summarizes the preliminary estimated fair value of the assets acquired and the liabilities assumed for the HEXO Acquisition at the effective acquisition date as follows:

Included in accounts payable and accrued liabilities was $12,253 of litigation settlement accruals as of June 22, 2023.

In the event the HEXO Acquisition had occurred on June 1, 2022, the Company would have had, on an unaudited proforma basis, additional net revenue of approximately $nil and $7,000 for the three and six months period ended November 30, 2023 and $20,000 and $40,000 for the three and six months period ended November 30, 2022, respectively, and its net loss and comprehensive net loss would have increased by approximately $nil and $1,800 for the three and six months period ended November 30, 2023, and $30,000 and $60,000 for the three and six months period ended November 30, 2022, respectively. This unaudited pro forma financial information does not reflect the realization of any expected ongoing synergies relating to the integration of HEXO.

On August 3, 2023, Tilray acquired the remaining 57.5% equity interest in Truss Beverage Co. ("Truss"), a cannabis beverage company, from Molson Coors Canada ("Molson"). This purchase represents the equity portion of Truss that had not been previously acquired as part of the HEXO Acquisition. The consideration paid by Tilray consisted of $74 (CAD$100) in cash and contingent consideration fair valued at $4,181. Tilray initially planned to divest Truss' assets and recorded the value of the associated capital assets and lease obligations as an asset held for sale. Tilray has agreed to pay Molson as contingent consideration an amount equal to 57.5% of any proceeds from any divesture, net of any costs and expenses associated with the disposition. During the period ended November 30, 2023, due to a change in circumstance in the Company's ability to sell these assets, they were subsequently reclassified as capital assets as the Company has made alternative plans for their utilization. The asset was ~~$10,245.~~then remeasured at the lower of its carrying amount before being classified as held for sale less the amortization that would have occurred and the fair value on the date the decision not to proceed with a sale was made. Changes in the carrying amount were recorded in the statement of net loss and comprehensive loss as amortization in cost of goods sold.

The Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value of the net assets acquired may be subject to adjustments pending completion of final valuations and post-closing adjustments. The table below summarizes preliminary estimated fair value of the assets acquired and the liabilities assumed at the effective acquisition ~~date. During the~~ ~~three~~ ~~months ended~~ ~~February 28, 2023,~~ ~~the Company recorded measurement period adjustments to its initial allocation of purchase price~~date as ~~a result of ongoing valuation procedures on assets and liabilities assumed, included: (i) an increase in other liabilities of $3,750, related to identified unfavorable contracts with~~ ~~third~~ ~~party production companies; (ii) a decrease in deferred tax liability of~~ ~~$1,031;~~ ~~and (iii) an increase to goodwill of $2,719 due to the incremental period adjustments. The impact of measurement period adjustments to the results of operations was immaterial.~~follows:

	*Amount*		*Amount*
Consideration
Cash	$	28,688
Shares		6,422
Cash consideration			$	74
Investment in equity investees				3,145
Contingent consideration		10,245		4,181
Net assets acquired
Current assets
Cash and cash equivalents		1,983		6,739
Accounts receivable		1,116		1,038
Prepaids and other current assets		467		78
Inventory		1,570		2,573
Asset held for sale				2,960
Long-term assets
Capital assets		420
Customer relationships (15 years)		16,570
Intellectual property, trademarks & brands (15 years)		12,430
Non-compete agreements (5 years)		1,240
Goodwill		20,326
Total Assets		56,122
Intangible assets				296
Total assets				13,684
Current liabilities
Accounts payable and accrued liabilities		1,580		5,408
Long-term liabilities
Deferred tax liability		5,437
Other liabilities		3,750		876
Total liabilities		10,767		6,284
Total net assets acquired	$	45,355		7,400

~~Revenue for~~ In the event that the Truss acquisition had occurred on June 1, 2022 the Company would have ~~been higher by~~had, on an unaudited proforma basis, additional net revenue of approximately ~~$3,100~~$nil and ~~$12,000~~$3,000 for the three and ~~nine~~six months period ended ~~February 28,~~November 30, 2023~~, if~~and $3,300 and $6,300 for the ~~acquisition had taken place on~~ ~~June 1, 2022.~~ three~~Net~~ and six months period ended November 30, 2022, respectively, and its net loss and comprehensive net loss would have increased by approximately $~~600~~nil and ~~$1,100~~$700 for the three and ~~nine~~six months period ended ~~February 28,~~ November 30, 2023,~~, if~~ and $500 and $1,200 for the ~~acquisition had taken place on~~ ~~June 1,~~ three and six months period ended November 30, 2022,~~primarily as a result of amortization of the intangible assets acquired.~~ respectively. This unaudited pro forma financial information does not reflect the realization of any expected ongoing synergies relating to the integration of ~~Montauk.~~Truss.

The Company is in the process of assessing the fair value of the net assets acquired and, as a result, the fair value may be subject to adjustments pending completion of final valuations and post-closing adjustments. The table below summarizes the preliminary estimated fair value of the assets acquired and the liabilities assumed for the Craft Acquisition at the effective acquisition date as follows:

In the event that the Craft Acquisition had occurred on June 1, 2022, the Company would have had, on an unaudited proforma basis, additional revenue of approximately $14,000 and $55,000 for the three and six months period ended November 30, 2023 and $42,000 and $85,000 for the three and six months period ended November 30, 2022, respectively, and its net loss and comprehensive net loss would have increased by approximately $2,000 and $5,000 for the three and six months period ended November 30, 2023, and $1,400 and $900 for the three and six months period ended November 30, 2022, respectively. This unaudited pro forma financial information does not reflect the realization of any expected ongoing synergies relating to the integration of the Craft Acquisition.

	*February 28,*		*May 31,*		*November 30,*		*May 31,*
	*2023*		*2022*		*2023*		*2023*
HEXO Convertible Note	$	93,675	$	-	$	-	$	28,720
MedMen Convertible Note		74,681		111,200		74,681		74,681
Total convertible notes receivable		168,356		111,200		74,681		103,401
Deduct - current portion		-		-		-		-
Total convertible notes receivable, non current portion	$	168,356	$	111,200	$	74,681	$	103,401

On ~~July 12, 2022,~~June 22,2023,the Company ~~closed a strategic alliance with HEXO, pursuant to which the Company acquired~~completed the HEXO Convertible Note from HT Investments MA LLC (“HTI”). At the time of closing, the HEXO Convertible Note had a principal balance of $173,700, which is to be repaid and or redeemed at 110% of the outstanding principal balance. The purchase price paid to HTI for the HEXO Convertible Note was $157,272. The purchase price paid to HTI was satisfied by Tilray's issuance of (i) a newly-issued $50,000 convertible promissory note ("HTI Convertible Note"), see Note 11 ~~(Convertible debentures payable~~) ~~and (ii) the remaining balance was paid through the issuance of 33,314,412 shares of Tilray's Class~~ 2 ~~common stock, par value~~ ~~$0.0001~~ (collectively, the “HTI Share Consideration”). The HEXO Convertible Note bears interest at a rate of 5.0% per annum, calculated daily, which is payable to Tilray on a semi-annual basis. Interest payments made under the HEXO Convertible Note will be paid in cash until ~~July 12, 2023~~ ~~and, thereafter, such interest shall accrue but be added to the principal amount. The HEXO Convertible Note has a maturity date of~~ ~~May 1, 2026.~~ ~~Subject to certain limitations and adjustments, the HEXO Convertible Note is convertible into HEXO Common Shares at Tilray's option at any time prior to the~~ ~~second~~ ~~scheduled trading day prior to the maturity date, at a conversion price of~~ ~~CAD$5.60~~ per HEXO Common share as determined the day before exercise, including all capitalized interest. HEXO has the ability to force the conversion if the daily VWAP per common share is equal to or exceeds $42.00 per share for ~~twenty~~ ~~consecutive trading days. The conversion price was updated on~~ ~~December 19, 2022,~~ ~~from~~ ~~CAD$0.40~~ to ~~CAD$5.60~~ ~~to reflect HEXO's~~ ~~14:1~~ ~~reverse stock split. Under the HEXO Convertible Note, the Company holds a~~ ~~first~~-priority security interest on substantially all of HEXO’s assets. In the event of a default on the HEXO Convertible Note, the Company would be entitled to exercise its rights as a secured creditor, and the Note would become redeemable at 115% of the outstanding principal balance.

~~All~~ ~~third~~~~-party transaction costs associated with the acquisition of these notes were reimbursed by HEXO. During the~~ ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~February 28, 2023~~, in connection with the HEXO Convertible Note, the Company recognized interest income of $2,171 and $5,549 respectively, and an other-than-temporary change in fair value which led to a non-cash impairment to the carrying value of the HEXO Convertible Note, which resulted in a loss of $63,597 for the ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~February 28, 2023.~~ Due to changes in HEXO operations, which culminated in HEXO's assessment of a going concern issue regarding HEXO's ability to meet their minimum liquidity covenant, resulting in the Company increasing the forfeiture rate to 30% on the HEXO Convertible Note.

~~The HTI Share Consideration included a purchase price derivative, where the consideration paid is adjusted based on the sum of the VWAP of the Company's common stock for the~~ 44 trading days after the issuance of the shares. The purchase price derivative is settled through the issuance of additional shares of the Company if the share price declined, or a cash payment back to the Company if the share price increased over the applicable period. On issuance this was valued at ~~$nil.~~ The subsequent change in fair value resulted in a gain of $18,256 due to the share price increasing, which was recorded in Transaction (income) costs, and was collected in cash by the Company during the period ended ~~February 28, 2023~~.

~~The fair value of the HEXO Convertible Note was determined using the Black-Scholes model using the following assumptions: the risk-free rate of~~ ~~3.50%;~~ ~~expected life of the convertible note; volatility of 90% based on comparable companies; forfeiture rate of~~ ~~30%;~~ ~~dividend yield of~~ ~~nil~~ ~~and the exercise price of the respective conversion feature.~~

~~Concurrent with the aforementioned purchase of the HEXO Convertible Note, the Company and HEXO also entered into various commercial transaction agreements~~Acquisition as described in Note 237 ~~(Segment reporting)~~(Business acquisitions). Concurrently with the closing of the HEXO Acquisition, the HEXO convertible note was converted into shares of HEXO.

On August 31, 2021, the Company issued 9,817,061 shares valued at $117,804 to acquire 68% interest in Superhero Acquisition L.P. (“SH Acquisition”), which purchased a senior secured convertible note issued by MedMen (the "MedMen Convertible Note"), together with certain associated warrants to acquire Class B subordinate voting shares of MedMen, in the principal amount of $165,799. The MedMen Convertible Note bears interest at the Secured ~~overnight financing rate~~Overnight Financing Rate ("SOFR") plus 6%, with a SOFR floor of 2.5% ~~and,~~with any accrued interest isbeing added to the outstanding principal amount. The outstanding principal amount, ~~and~~together with accrued interest is to be paid aton August 17, 2028, the maturity date of the MedMen Convertible Note. SH Acquisition was also granted “top-up” rights enabling it (and its limited partners) to maintain its percentage ownership (on an “as-converted” basis) in the event that MedMen issues equity ~~securities upon conversion of convertible securities that~~ ~~may~~ ~~be issued by MedMen. The Company’s~~securities. SH Acquisition’s ability to convert the MedMen Convertible Note and exercise the Warrants is dependent upon U.S. federal legalization of cannabis ~~(a “Triggering Event”)~~ or Tilray’s waiver of such requirement as well as any additional regulatory approvals.

~~During~~was based upon the~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~February 28, 2023~~, in connection with the Medmen Convertible Note, the Company recognized an other-than-temporary change in fair value, which resulted in a non-cash impairment expense of $117,778 which includes the reversal of the fair value adjustments which were previously recorded in accumulated other comprehensive loss. As a result, of the deterioration of capital market conditions from increased interest rates and recent delays in US Federal cannabis legalization, the Company increased the forfeiture rate to 30% on the Medmen Convertible Note and recorded the aforementioned loss on the Medmen Convertible Notes through impairments.

~~The Company recognized interest income, which is included as part of the convertible debentures in the amount of $3,474 and $10,480 for the~~ ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~February 28, 2023.~~ ~~The Company also recognized unrealized gain (loss) on convertible notes receivable in other comprehensive income of $82,100 and $70,779 for the~~ ~~three~~ ~~and~~ ~~nine~~ ~~months ended~~ ~~February 28, 2023, $(~~~~39,296) and $(56,250) for the~~ ~~three~~ ~~months ended~~ ~~February 28, 2022.~~

~~The~~ fair value of the ~~MedMen Convertible Note was determined using~~collateral assets net of disposal costs. In the prior year, the Company used the Black-Scholes model using the following assumptions: the risk-free rate of 3.50%; expected life of the convertible note; volatility of 70% based on comparable companies; forfeiture rate of nil; dividend yield of nil; probability of legalization between 0% and 60%; and, the exercise price of the respective conversion feature.

The Company did not derive any revenue or cash from MedMen's operations, and fully complies with all limitations imposed by applicable U.S. law and regulations in connection with its ownership of the MedMen Convertible Note. In addition, the Company did not recognize any interest income on the MedMen Convertible Note for the three and six months ended November 30, 2023, which would have increased its value.

	*February 28,*		*May 31,*		*November 30,*		*May 31,*
	*2023*		*2022*		*2023*		*2023*
Equity investments measured at fair value	$	1,972	$	4,347	$	2,534	$	2,144
Equity investments under measurement alternative		5,648		5,703		5,500		5,651
Total	$	7,620	$	10,050	$	8,034	$	7,795

Aphria Inc., a subsidiary of the Company, has an operating line of credit in the amount of C$1,000, which bears interest at the lender’s prime rate plus 75 basis points. As of ~~February 28,~~November 30, 2023, the Company has not drawn on the line of credit. The operating line of credit is secured by a security interest on that certain real property located at 265 Talbot St. West, Leamington, Ontario.

CC Pharma GmbH, a subsidiary of the Company, has ~~three~~two operating lines of credit for €~~8,000,€3,500,~~7,000 and €500 each, which bear interest at Euro ~~Over Night Index Average~~Short-Term Rate ("ESTR") plus ~~1.79%~~2.50% and Euro Interbank Offered Rate ("EURIBOR") plus ~~3.682%~~4.00%, respectively. As of ~~February 28,~~November 30, 2023, a total of €~~7,663~~7,438 ($~~8,125)~~8,181) was drawn down from the available credit of €~~12,000.~~7,500. The operating ~~lines~~line of credit for €7,000 are secured by ~~a security~~an interest in the inventory of CC Pharma ~~GmbH.~~GmbH as well as the Densborn facility and underlying real property. The operating line of credit for €500 is unsecured.

Four Twenty Corporation (“420”), a subsidiary of the Company, has a revolving credit facility of $30,000, which bears interest at ~~EURIBOR~~SOFR plus an applicable margin. As of ~~February 28,~~November 30, 2023, the Company has drawn ~~$10,000~~$12,000 on the revolving line of credit. The revolving credit facility is secured by all of Montauk, the Craft Acquisition's assets and 420's assets and includes a corporate guarantee by a subsidiary of the Company.

The following table sets forth the net carrying amount of long-term debt instruments:

OnDuring the quarter ended ~~November 28, 2022,~~August 31, 2023, Four Twenty Corporation ("420"), a wholly-owned subsidiary of the Company, repaid its $100,000 term loan and entered  into a new secured credit agreement, which comprised of: (i) a $70,000 term loan facility, bearing interest at SOFR plus an ~~Amended~~applicable margin and ~~Restated~~having a maturity date of June 30, 2028 (the "420 Term Loan"), and (ii) a $20,000 delayed draw term loan facility, issued on the same terms as the $70,000 term loan facility (the "420 Delayed Draw Term Loan" and, together with the 420 Term Loan the "420 Secured Credit Agreement"). The 420 Term Loan was fully drawn on June 30, 2023. The 420 Delayed Draw Term Loan was fully drawn on September 29, 2023 to fund part of the purchase price for the Craft Acquisition as described in Note 7 (Business acquisitions). Under the terms of the 420 Secured Credit Agreement, ~~(the “Amended~~the Company pledged all of Sweetwater, Breckenridge, Montauk and ~~Restated Credit Agreement”) amending~~the Craft Acquisition's assets and ~~restating~~ the ~~existing credit facility in~~related equity interests, and Tilray Brands, Inc. provided a limited guarantee, as well as requiring the ~~aggregate principal amount of~~ ~~C$66,000.~~ ~~The Amended and Restated Credit Agreement extended the term of the existing credit facility~~lenders approval to ~~November 28, 2025.~~ ~~The principal amount of loans outstanding at the time of the amendment was~~ ~~C$66,000.~~transfer assets to Tilray Brands, Inc.

As of ~~February 28,~~November 30, 2023, ~~the Company~~420 wasnot in compliance with ~~all of its covenants~~the leverage ratio covenant under ~~its long-term debt agreements.~~ the 420 Secured Credit Agreement, but obtained a waiver from the lender on January 5, 2024.

The following table sets forth the net carrying amount of the convertible debentures payable:

	*February 28,*		*May 31,*		*November 30,*		*May 31,*
	*2023*		*2022*		*2023*		*2023*
5.20% Convertible Notes ("TLRY 27")					$	123,691	$	100,476
HTI Convertible Note	$	45,762	$	—		-		47,834
5.25% Convertible Notes ("APHA 24")		223,087		216,753		128,399		120,568
5.00% Convertible Notes ("TLRY 23")		138,320		185,196		-		126,544
Total		407,169		401,949		252,090		395,422
Deduct - current portion		184,082		-		128,399		174,378
Total convertible debentures payable, non current portion	$	223,087	$	401,949	$	123,691	$	221,044

The TLRY 27 convertible debentures were issued on May 30, 2023 and on June 9, 2023 by way of overallotment, in the principal amount of $172,500 (the “TLRY 27 Notes”). The TLRY 27 Notes bear interest at a rate of 5.20% per annum, payable semi-annually in arrears on June 15 and December 15 of each year, and mature on June 15, 2027, unless earlier converted. The TLRY 27 Notes are Tilray’s general unsecured obligations and rank senior in right of payment to all of Tilray’s indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment with any of Tilray’s unsecured indebtedness that is not so subordinated, including TLRY 23 and APHA 24, effectively junior in right of payment to any of Tilray’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of Tilray’s current or future subsidiaries. Noteholders will have the right to convert their TLRY 27 Notes into shares of Tilray’s common stock at their option, at any time, until the close of business on the second scheduled trading day immediately before June 15, 2027. The initial conversion rate is 376.6478 shares per $1,000 principal amount of TLRY 27 Notes, which represents a conversion price of approximately $2.66 per share. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events.

The TLRY 27 Notes will be redeemable, in whole and not in part, at Tilray’s option at any time on or after June 20, 2025 at a cash redemption price equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date, but only if the last reported sale price of Tilray’s common stock exceeds 130% of the conversion price for a specified period of time. If certain corporate events that constitute a fundamental change occur, then, subject to a limited exception, noteholders may require Tilray to repurchase their TLRY 27 Notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date. In connection with the Company’s offering of the TLRY 27 Notes, the Company entered into a share lending agreement with an affiliate of Jefferies LLC (the “Share Borrower”), pursuant to which it lent to the Share Borrower 38,500,000 shares of the Company’s common stock (the "Borrowed Shares"). The Borrowed Shares were newly-issued shares, will be held as treasury shares until the expiration or early termination of the share lending agreement and may be used by purchasers of the TLRY 27 Notes to sell up to 38,500,000 shares of the Company’s common stock. The fair value of the share lending agreement has been recorded as part of the unamortized discount on the debenture. The Company expects that the selling stockholders will use their position created by such sales to establish their initial hedge with respect to their investments in the TLRY 27 Notes. The Company did not receive any proceeds from the sale of the Borrowed Shares.

During the three and six months ended November 30, 2023, the Company recognized interest expense of $2,423 and $4,485 and accretion of amortized discount interest of $2,829 and $5,624. For the same periods in the prior year there was no interest or accretion of amortized discount.

	*February 28,*			*May 31,*		November 30,		May 31,
	*2023*			*2022*		2023		2023
4.00% Contractual debenture	$	50,000		$	—	$	—	$	50,000
Unamortized discount		(4,238	)		—		—		(2,166	)
Net carrying amount	$	45,762		$	—	$	—	$	47,834

On July 12, 2022, the Company issued a $50,000 convertible promissory note to HTI ("HTI Convertible Note"), bearing a 4% interest rate payable on a quarterly basis and having a maturity date of September 1, 2023. On August 31, 2023,. ~~The fair value of~~ the ~~conversion feature was determined to be $9,055. Refer to Note~~ 6 ~~(Convertible notes receivable~~) ~~for additional details on this transaction. HTI~~ ~~may~~ ~~convert~~Company settled in full the HTI Convertible Note through the issuance of shares as described in ~~whole or in part, at any time prior to the~~Note ~~second~~15 ~~trading day immediately preceding the maturity date, into shares of Common Stock at a conversion price equal to $4.03, which is calculated as~~ ~~125%~~ ~~of the closing sale price as of the closing date (~~ ~~July 12, 2022)~~(Stockholders' equity). In no ~~event will HTI be allowed to effect a conversion of the HTI Convertible Note if such conversion, along with all other shares of Common Stock beneficially owned by HTI and its affiliates, would exceed~~ ~~9.99%~~ ~~of the outstanding Common Stock (the "Beneficial Ownership Limitation"). If HTI does~~ ~~not~~ ~~elect or is unable to elect to convert under the Beneficial Ownership Limitation the Company will be responsible for repaying the HTI Convertible Note in cash.~~

	*February 28,*			*May 31,*			*November 30,*			*May 31,*
	*2023*			*2022*			*2023*			*2023*
5.25% Contractual debenture	$	350,000		$	350,000		$	350,000		$	350,000
Debt settlement		(90,760	)		(90,760	)		(213,260	)		(213,260	)
Fair value adjustment		(36,153	)		(42,487	)		(8,341	)		(16,172	)
Net carrying amount	$	223,087		$	216,753		$	128,399		$	120,568

The APHA 24 convertible debentures, were entered into in April 2019, in the principal amount of $350,000, bear interest at a rate of 5.25% per annum, payable semi-annually in arrears on June 1 and December 1 of each year, and mature on June 1, 2024, unless earlier converted (the APHA 24 Notes"). The APHA 24 Notes are Tilray’s general unsecured obligations and rank senior in right of payment to all of Tilray’s indebtedness that is expressly subordinated in right of payment to the notes; equal in right of payment with any of Tilray’s unsecured indebtedness that is not so subordinated, including TLRY 23 and TLRY 27, effectively junior in right of payment to any of Tilray’s secured indebtedness to the extent of the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of Tilray’s current or future subsidiaries.

Holders of the APHA 24 Notes may convert all or any portion of ~~their Notes,~~such note, in multiples of $1$1 principal amount, at their option at any time between December 1, 2023 to the maturity date of June 1, ~~2024~~.2024. The initial conversion which the Company may settle in cash, or common shares of Tilray, or a combination thereof, at Tilray's election, is equivalent to an initial conversion price of approximately $11.20 per common share, subject to adjustments in certain events. ~~In addition, holders of the APHA~~ 24~~may~~ ~~convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time preceding~~ ~~December 1, 2023,~~ ~~if:~~

The Company may redeem for cash all or part of the ~~Notes,~~APHA 24, at its option, if the last reported sale price of the Company’s common shares has been at least 130% of the conversion price then in effect for at least 20 trading days during any 30 consecutive trading day period ending on and including trading day immediately preceding the date on which the Company provides notice of redemption. The redemption of the APHA 24 will be equal to 100% of the principal amount ~~of $259,240~~ plus accrued and unpaid interest to, but excluding, the redemption date.

The Company elected the fair value option under ASC ~~TLRY~~ 23825Fair Value Measurements for the APHA 24. The APHA 24 was initially recognized at fair value on the balance sheet. All subsequent changes in fair value, excluding the impact of the change in fair value related to instrument-specific credit risk are recorded in non-operating income. The changes in fair value related to instrument-specific credit risk is recorded through other comprehensive income (loss).

The Company plans to purchase or exchange some or all of its APHA 24 Notes, in open market purchases, privately negotiated transactions or otherwise prior to their maturity in June 2024. Such purchases or exchanges, if any, will depend on prevailing market conditions, contractual restrictions and other factors. See Note 27 (Subsequent Events) for additional details.

The overall change in fair value of APHA 24 during the six months ended November 30, 2023 decreased by $7,831 ( November 30, 2022 – $6,542 of fair value changes), this was comprised of $6,041 of fair value changes and a foreign exchange loss of $1,790.

There was $136,740 principal outstanding as at November 30, 2023 and May 31, 2023.

During the ~~nine~~three and six months ended ~~February 28,~~November 30, 2023,the Company ~~repurchased outstanding~~ recognized total interest expense of $1,795 and $3,589, respectively and total interest expense of $3,393 and $6,786, respectively for the same period in the prior year.

TLRY 23 notes in the principal amount of $50,000, in exchange for a purchase price of $48,975. As a result of this transaction, the unamortized discount was reduced by $918 and a gain of $191 was recorded in non-operating income (expense), net.Notes

The TLRY 23 ~~bears~~Notes bore interest at a rate of 5.00% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. ~~Additional interest~~On ~~may~~September 12, 2023, ~~accrue on~~ the Company repurchased $20,000 of its TLRY 23 ~~in specified circumstances. The TLRY~~ 23 ~~will mature on~~ ~~October 1, 2023,~~ ~~unless earlier repurchased, redeemed or converted. There are~~ noNotes for cancellation by issuing 7,000,000 shares and paying $610 of cash to settle both principal ~~payments required over the~~ ~~five-year term~~and accrued interest. Upon repurchase of the TLRY 23 ~~except~~Notes, a portion of the settlement consideration was allocated to the equity component of the instrument and was recognized as a $1,672 reduction of additional paid-in capital in the ~~case~~Consolidated Statements of ~~redemption or events~~Changes in Equity. Additionally, this repurchase resulted in a loss of ~~default.~~$1,062 which was recorded in other non-operating (losses) gains, net as shown in Note 24 (Non-operating income (expense)).

~~The TLRY~~ 23 ~~is an unsecured obligation and ranks senior in right of payment to all of~~After cancellation, the ~~Company's indebtedness that is expressly subordinated in right of payment to the TLRY~~ ~~23;~~ ~~equal in right of payment with any of the Company's unsecured indebtedness that is~~ ~~not~~ so subordinated; effectively junior in right of payment to any of the Company's secured indebtedness to the extent the value of the assets securing such indebtedness; and structurally junior to all indebtedness and other liabilities (including trade payables but excluding intercompany obligations) of the Company's current or future subsidiaries.

~~Upon conversion, the Company will pay or deliver, as the case~~ ~~may~~ be, cash, shares of our common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election (the “cash conversion option”). The initial conversion rate for the convertible notes is 5.9735 shares of common stock per ~~one thousand~~ ~~dollar~~outstanding principal amount of notes, which is equivalent to an initial conversion price of approximately $167.41 per share of common stock, which represents approximately 835,275 shares of common stock, based on the $139,830 aggregate principal amount of convertible notes outstanding as of ~~February 28, 2023~~~~. Throughout the term~~balance of the TLRY 23 Notes was $107,330. On October 2, 2023, the ~~conversion rate~~ ~~may~~ ~~be adjusted upon~~Company repaid the ~~occurrence~~remaining principal of ~~certain events.~~

~~Prior to the close of business on the business day immediately preceding~~ ~~April 1, 2023~~, the TLRY 23 ~~will be convertible only under the specified circumstances. On or after~~ ~~April 1, 2023~~ ~~until the close of business on the business day immediately preceding the maturity date,~~ ~~September 30, 2023~~, ~~holders~~ ~~may~~ ~~convert all or any portion of their TLRY~~ ~~23,~~Notes in ~~multiples of $1 principal amount, at the option of the holder regardless of the aforementioned circumstances.~~cash upon maturity.

~~As of~~ ~~February 28, 2023~~~~, the Company was in compliance with all the covenants set forth under the TLRY~~ ~~23.~~ ~~The effective interest rate on the debt is 6.9%, the Company recognized interest expense of $1,748 and $6,077 and amortized discount interest of $630 and $2,169 for~~During the three and ~~nine~~six months ended ~~February 28, 2023.~~November 30, 2023, the Company recognized total interest expense of $1,592 and $2,122, respectively and total interest expense of $2,373 and $3,746, respectively for the same period in the prior year.

As of ~~February 28,~~November 30, 2023 and May 31, ~~2022,~~2023, there were 6,209,000 warrants outstanding, with an original exercise price of $5.95 per warrant, expiring March 17, 2025. Each warrant is exercisable for one common share of the Company.

The warrants contain anti-dilution price protection features, which adjust the exercise price of the warrants if the Company subsequently issues common stock at a price lower than the exercise price of the warrants. In the event additional warrants or convertible debt are issued with a lower and/or variable exercise price, the exercise price of the warrants will be adjusted accordingly. During the ~~nine~~six months ended ~~February 28,~~November 30, 2023, the Company issued shares which triggered the anti-dilution price protection feature lowering the exercise price to ~~$3.15.~~$1.61. These warrants are classified as liabilities as they are to be settled in registered shares, and the registration statement is required to be active, unless such shares may be subject to an applicable exemption from registration requirements. The holders, at their sole discretion, may elect to affect a cashless exercise, and be issued exempt securities in accordance with Section 3(a)(9) of the 1933 Act. In the event the Company does not maintain an effective registration statement, the Company may be required to pay a daily cash penalty equal to 1% of the number of shares of common stock due to be issued multiplied by any trading price of the common stock between the exercise date and the share delivery date, as selected by the holder. Alternatively, the Company may deliver registered common stock purchased by the Company in the open market. The Company may also be required to pay cash if it does not have sufficient authorized shares to deliver to the holders upon exercise.

The Company estimated the fair value of ~~the warrant liability~~warrants outstanding at ~~February 28,~~November 30, 2023 at ~~$1.19~~$0.607 per warrant using the Black Scholes pricing model (Level 3) with the following assumptions: Risk-free interest rate of ~~3.94%~~4.4%, expected volatility of ~~70%~~50%, expected term of ~~2.55~~1.30 years, strike price of ~~$3.15~~$1.61 and fair value of common stock of ~~$2.83.~~$1.81.

Expected volatility is based on both historical and implied volatility of the Company’s common stock.

On ~~February 21, 2023,~~ in connection with the issuance of the Consideration Shares, Tilray filed a certificate of designation (the "Certificate of Designation") with the Secretary of State of the State of Delaware, effective as of the time of filing, designating the rights, preferences, privileges and restrictions of the shares of the Series A Preferred Stock.

~~General;~~ No ~~Transferability.~~ ~~Shares of Series A Preferred Stock will be uncertificated and represented in book-entry form.~~ No ~~shares of Series A Preferred stock~~ ~~may~~ ~~be transferred by the holder thereof.~~

~~Voting Rights.~~ ~~The Certificate of Designation provides that each share of Preferred Stock will have 1,000 votes and will vote together with the outstanding shares of Class~~ 2 common stock as a single class exclusively with respect to any proposal to adopt amendments to the Company’s amended and restated certificate of incorporation (as amended) (collectively, the “Charter Amendments”) by (a) eliminating provisions relating to the Company’s Class 1 ~~common stock, par value $0.0001 per share (the “Class~~ 1 ~~Common Stock”), in connection with the previous automatic conversion of all issued and outstanding shares of Class~~ 1 ~~Common Stock into shares of Class~~ 2 ~~Common Stock, (b) reclassifying the authorized shares of Class~~ 1 ~~Common Stock as Class~~ 2 ~~Common Stock, and (c) adding a provision to automatically reclassify each issued and outstanding share of Class~~ 2 ~~Common Stock as~~ ~~one~~ ~~share of common stock, par value $0.0001, of the Company (“Common Stock”), the cumulative result being the Company having only~~ ~~two~~ ~~classes of stock authorized for issuance — common stock and preferred stock.~~

~~The Series A Preferred Stock will be voted, without action by the holder, on any such proposal in the same proportion as shares of Class~~ 2 ~~Common Stock are voted. The Series A Preferred Stock otherwise has~~ no ~~voting rights except as otherwise required by the General Corporation Law of the State of Delaware.~~

~~Dividends.~~ ~~Holders of Series A Preferred Stock are entitled to receive dividends on shares of Series A Preferred Stock equal (on an as-if-converted-to-Class-~~2~~-Common-Stock basis, disregarding for such purpose any conversion limitations hereunder) to and in the same form as dividends actually paid on shares of the Class~~ 2 ~~Common Stock when, as and if such dividends are paid on shares of the Class~~ 2 ~~Common Stock.~~ No ~~other dividends shall be paid on shares of Series A Preferred Stock.~~

~~Rank Liquidation.~~ ~~The Series A Preferred Stock ranks~~ ~~pari passu~~ ~~with the Class~~ 2 ~~Common Stock as to any distribution of assets upon liquidation, dissolution or winding up of the Company, whether voluntarily or involuntarily.~~

~~Automatic Conversion.~~ Upon the closing of the polls at any meeting of the Company’s stockholders held for the purpose of voting on the Charter Amendments (taking into account any adjournment or postponement thereof), each issued and outstanding share of Series A Preferred Stock will, without any further action on the part of the holder thereof or the Company, automatically be converted (the “Automatic Conversion”) into a number of fully paid and nonassessable shares of Common Stock as determined by dividing the Stated Value (as defined by the Certificate of Designation) by the Conversion Price then in effect. The conversion price per share upon an Automatic Conversion for the Series A Preferred Stock shall be the Stated Value of such share, subject to adjustment in the event that the Conversion Price then in effect is equal to or less than the Minimum Price, as defined in Nasdaq Listing Rule ~~5635~~~~(d)(~~1~~)(A) (the “Conversion Price”) see Note~~ 24 ~~(Subsequent events).~~

As of ~~February 28,~~November 30, 2023, the Company had ~~990,000,000~~1,198,000,000 common shares and 10,000,000 preferred shares authorized to be issued, ~~of which 243,333,333 are Class~~ 1with 732,907,552 common shares ~~with~~and nil ~~shares issued and outstanding, 736,666,667 are Class~~ 2 ~~shares, with 613,181,559 shares issued and outstanding and 10,000,000 are Series A Preferred Stock with 120,000~~preferred shares issued and outstanding. Historically, the Company has issued shares of its common stock as consideration for business acquisitions, including the settlement of convertible notes, the settlement of litigation claims, in connection with public offerings and as payment of dividends to non-controlling interests for profit distributions.

During the ~~nine~~six months ended ~~February 28,~~November 30, 2023, the Company issued the following ~~Class~~ 2common shares:

~~During the~~ ~~nine~~ ~~months ended~~ ~~February 28, 2023~~~~, the Company issued the following Series A preferred stock shares:~~

The Company maintains stock-based compensation plans as disclosed in our Annual Financial Statements. For the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, the total stock-based compensation was $ ~~9,630~~8,201 and $ ~~29,766, whereas for~~16,458. For the three and ~~nine~~six months ended ~~February 28,~~November 30, 2022,, total stock based compensation was ~~$9,355~~$ 10,943 and ~~$27,025~~$ 20,136 respectively.

During the ~~three~~ ~~and~~ ~~nine~~six months ended ~~February 28,~~November 30, 2023, the Company granted ~~nil~~11,559,549 time-based RSUs, and 7,566,146 performance-based RSUs ( November 30, 2022 - 6,004,995 time-based RSUs and ~~nil~~ ~~and~~ 2,634,744 performance based ~~RSUs (~~ ~~February 28, 2022~~ - ~~nil~~ ~~and 69,508 time-based RSUs and~~ ~~nil~~ ~~and 1,414,666~~RSUs). The 7,566,146 performance based ~~RSUs).~~RSUs issued during the quarter had performance conditions not yet finalized. The Company's total stock-based compensation expense recognized is as follows:

	*For the three months*				*For the nine months*				*For the three months*				*For the six months*
	*ended February 28,*				*ended February 28,*				*ended November 30,*				*ended November 30,*
	*2023*		*2022*		*2023*		*2022*		*2023*		*2022*		*2023*		*2022*
Stock options	$	20	$	273	$	644	$	4,968	$	—	$	20	$	—	$	624
RSUs		9,610		9,082		29,122		22,057		8,201		10,923		16,458		19,512
Total	$	9,630	$	9,355	$	29,766	$	27,025	$	8,201	$	10,943	$	16,458	$	20,136

				*Unrealized*									*Unrealized*
	*Foreign*			*loss on*						*Foreign*			*loss on*
	*currency*			*convertible*						*currency*			*convertible*
	*translation*			*notes*						*translation*			*notes*
	*gain (loss)*			*receivables*			*Total*			*gain (loss)*			*receivables*			*Total*
Balance May 31, 2022	$	54,413		$	(75,177	)	$	(20,764	)	$	54,413		$	(75,177	)		(20,764	)
Other comprehensive loss		(56,443	)		(2,525	)		(58,968	)		(56,443	)		(2,525	)		(58,968	)
Balance August 31, 2022	$	(2,030	)	$	(77,702	)	$	(79,732	)	$	(2,030	)	$	(77,702	)	$	(79,732	)
Other comprehensive loss		(24,080	)		(17,643	)		(41,723	)		(24,080	)		(17,643	)		(41,723	)
Balance November 30, 2022	$	(26,110	)	$	(95,345	)	$	(121,455	)
Other comprehensive (loss) reversal		(16,838	)		95,345			78,507
Balance February 28, 2023	$	(42,948	)	$	—		$	(42,948	)
Balance at November 30, 2022										$	(26,110	)	$	(95,345	)	$	(121,455	)

Balance May 31, 2023										$	(46,610	)	$	—		$	(46,610	)
Other comprehensive loss											3,049			—			3,049
Balance August 31, 2023										$	(43,561	)	$	—		$	(43,561	)
Other comprehensive loss											5,194			—			5,194
Balance November 30, 2023										$	(38,367	)	$	—		$	(38,367	)

The following tables summarize the information relating to the Company’s subsidiaries, SH Acquisition (68%), CC Pharma Nordic ApS (75%), Aphria Diamond (51%), and ColCanna S.A.S. (90%) before intercompany eliminations.

Summary of balance sheet information of the entities in which there is a non-controlling interest as of ~~February 28,~~November 30, 2023:

	SH		*CC Pharma*			*Aphria*			*ColCanna*			*February 28,*			SH		*CC Pharma*			*Aphria*			*ColCanna*			*November 30,*
	*Acquisition*		*Nordic ApS*			*Diamond*			*S.A.S.*			*2023*			*Acquisition*		*Nordic ApS*			*Diamond*			*S.A.S.*			*2023*
Current assets	$	—	$	163		$	94,103		$	157		$	94,423		$	—	$	73		$	131,023		$	196		$	131,292
Non-current assets		74,681		—			139,749			3,025			217,455			74,681		—			131,726			3,580			209,987
Current liabilities		—		(713	)		(13,468	)		(39	)		(14,220	)		—		(14	)		(129,105	)		(6,613	)		(135,732	)
Non-current liabilities		—		(405	)		(176,071	)		(6,455	)		(182,931	)		—		(1,195	)		(49,833	)		(1,460	)		(52,488	)
Net assets	$	74,681	$	(955	)	$	44,313		$	(3,312	)	$	114,727		$	74,681	$	(1,136	)	$	83,811		$	(4,297	)	$	153,059

Summary of balance sheet information of the entities there is a non-controlling interest as of May 31, ~~2022~~2023:

	SH		*CC Pharma*			*Aphria*			*ColCanna*			*May 31,*			SH		*CC Pharma*			*Aphria*			*ColCanna*			*May 31,*
	*Acquisition*		*Nordic ApS*			*Diamond*			*S.A.S.*			*2022*			*Acquisition*		*Nordic ApS*			*Diamond*			*S.A.S.*			*2023*
Current assets	$	—	$	485		$	20,546		$	193		$	21,224		$	—	$	114		$	127,689		$	224		$	128,027
Non-current assets		111,200		158			152,786			93,738			357,882			74,681		—			135,085			3,307			213,073
Current liabilities		—		(642	)		(63,196	)		(53	)		(63,891	)		—		(1,166	)		(142,554	)		(6,697	)		(150,417	)
Non-current liabilities		—		(410	)		(29,653	)		(6,537	)		(36,600	)		—		—			(53,197	)		(1,428	)		(54,625	)
Net assets	$	111,200	$	(409	)	$	80,483		$	87,341		$	278,615		$	74,681	$	(1,052	)	$	67,023		$	(4,594	)	$	136,058

Summary of income statement information of the entities in which there is a non-controlling interest for the ~~nine~~six months ended ~~February 28,~~November 30, 2023:

	SH			*CC Pharma*			*Aphria*			*ColCanna*			*February 28,*			SH			*CC Pharma*			*Aphria*			*ColCanna*			*November 30,*
	*Acquisition*			*Nordic ApS*			*Diamond*			*S.A.S.*			*2023*			*Acquisition*			*Nordic ApS*			*Diamond*			*S.A.S.*			*2023*
Revenue	$	—		$	126		$	98,960		$	—		$	99,086		$	—		$	—		$	57,078		$	—		$	57,078
Total expenses		107,297			659			54,285			91,026			253,267			—			54			32,803			(519	)		32,338
Net (loss) income		(107,297	)		(533	)		44,675			(91,026	)		(154,181	)		—			(54	)		24,275			519			24,740
Other comprehensive (loss) income		70,778			(13	)		(707	)		373			70,431			—			(30	)		404			(222	)		152
Net comprehensive (loss) income	$	(36,519	)	$	(546	)	$	43,968		$	(90,653	)	$	(83,750	)	$	—		$	(84	)	$	24,679		$	297		$	24,892
Non-controlling interest %		32	%		25	%		49	%		10	%	NA				32	%		25	%		49	%		10	%	NA
Comprehensive (loss) income attributable to NCI		(11,686	)		(137	)		21,544			(9,065	)		656			-			(21	)		12,093			30			12,102
Additional income attributable to NCI		—			—			8,968			—			8,968			—			—			6,554			—			6,554
Net comprehensive (loss) income attributable to NCI	$	(11,686	)	$	(137	)	$	30,512		$	(9,065	)	$	9,624		$	—		$	(21	)	$	18,647		$	30		$	18,656

Summary of income statement information of the entities in which there is a non-controlling interest for the ~~nine~~six months ended ~~February 28,~~November 30, 2022:

	SH			*CC Pharma*			*Aphria*			*ColCanna*			*February 28,*			SH			*CC Pharma*			*Aphria*			*ColCanna*			*November 30,*
	*Acquisition*			*Nordic ApS*			*Diamond*			*S.A.S.*			*2022*			*Acquisition*			*Nordic ApS*			*Diamond*			*S.A.S.*			*2022*
Revenue	$	—		$	354		$	88,470		$	—		$	88,824		$	—		$	108		$	65,437		$	—		$	65,545
Total expenses		(7,568	)		431			47,841			(192	)		40,512			(7,006	)		471			39,039			56,265			88,769
Net (loss) income		7,568			(77	)		40,629			192			48,312			7,006			(363	)		26,398			(56,265	)		(23,224	)
Other comprehensive (loss) income		(55,601	)		30			(2,509	)		(2,203	)		(60,283	)		(11,321	)		—			(1,590	)		363			(12,548	)
Net comprehensive (loss) income	$	(48,033	)	$	(47	)	$	38,120		$	(2,011	)	$	(11,971	)	$	(4,315	)	$	(363	)	$	24,808		$	(55,902	)	$	(35,772	)
Non-controlling interest %		32	%		25	%		49	%		10	%	NA				32	%		25	%		49	%		10	%	NA
Net comprehensive (loss) income	$	(15,371	)	$	(12	)	$	18,679		$	(201	)	$	3,095
Comprehensive (loss) income attributable to NCI																	(1,381	)		(91	)		12,156			(5,590	)		5,094
Additional income attributable to NCI																	—			—			6,056			—			6,056
Net comprehensive (loss) income attributable to NCI																$	(1,381	)	$	(91	)	$	18,212		$	(5,590	)	$	11,150

On January 5, 2024, Aphria Inc. (“Aphria”), a wholly-owned subsidiary of the Company, entered into an Amended and Restated Wholesale Cannabis Supply Agreement (the “Supply Agreement”) with 1974568 Ontario Limited (“Aphria Diamond”), Aphria’s joint venture with Double Diamond Holdings Ltd. The Supply Agreement amends and restates the existing supply agreement, effective as of September 1, 2023, and amends certain terms relating to pricing and product classes. Due to the terms stipulated in the Supply Agreement, the reduced transfer price will lead to a decrease in income attributable to non-controlling interest over the duration of the agreement. If this agreement had been effective June 1, 2023, the Company would have recognized approximately $15,000 in additional net income attributed to the Stockholders of Tilray Brands, Inc.

The determination of the Company’s overall effective tax rate requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws. The effective tax rate reflects the income earned and taxed in various United States federal, state, and foreign jurisdictions. Tax law changes, increases, and decreases in temporary and permanent differences between book and tax items, valuation allowances against the deferred tax assets, ~~stock-based~~stock compensation, ~~amortization of intangibles,~~ and the Company’s change in income in each jurisdiction all affect the overall effective tax rate. It is the Company’s practice to recognize interest and penalties related to uncertain tax positions in income tax expense.

The Company reported income tax ~~recovery~~(recovery) expense of ~~$(10,811)~~$(3,380) and ~~$(15,313)~~$3,884 for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, and income tax recovery of ~~$(1,830)~~$(11,713) and ~~$(2,739)~~$ (4,502) for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2022. The income tax ~~expense~~benefit in the current period varies from the US statutory income tax rate and prior period primarily due to the geographical mix of earnings and losses with no tax benefit resulting from valuation allowances in certain jurisdictions.

The Company has payments on long-term debt, refer to Note 1012 (Long-term debt), convertible notes, refer to Note 1113 (Convertible debentures payable), material purchase commitments and construction commitments as follows:

~~The following table presents the future undiscounted payment associated with lease liabilities as of~~ ~~February 28, 2023~~:

In the ordinary course of business, we are at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves may be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is not probable or the amount of loss is not estimable, we do not accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available and available insurance coverage, our management believes that it has established appropriate legal reserves. Any incremental liabilities arising from pending legal proceedings are not expected to have a material adverse effect on our consolidated financial position, consolidated results of operations, or consolidated cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable, may be material to our consolidated financial position, consolidated results of operations, or consolidated cash flows.

There have been no material changes from the legal proceedings since our Annual Report on Form 10-K for the fiscal ~~quarter~~year ended ~~November 30, 2022,~~ May 31, 2023, except with respect to certain aspects of the legal proceedings disclosed below:

~~Approved Settlement of Tilray Brands, Inc. Reorganization Litigation (Delaware, New York)~~ – ~~Special Litigation Committee~~

On ~~February 27, 2020,~~ ~~Tilray stockholders Deborah Braun and Nader Noorian filed a class action and derivative complaint in the Delaware Court of Chancery styled Braun v. Kennedy, C.A.~~ ~~No.~~~~2020~~-~~0137~~~~-KSJM. On~~ ~~March 2, 2020,~~ ~~Tilray stockholders Catherine Bouvier, James Hawkins, and Stephanie Hawkins filed a class action and derivative complaint in the Delaware Court of Chancery styled Bouvier v. Kennedy, C.A.~~ ~~No.~~~~2020~~-~~0154~~~~-KSJM.~~

On ~~March 4, 2020,~~ ~~the Delaware Court of Chancery entered an order consolidating the~~ ~~two~~ cases and designating the complaint in the Braun/Noorian action as the operative complaint. The operative complaint asserts claims for breach of fiduciary duty against Brendan Kennedy, Christian Groh, Michael Blue, and Privateer Evolution, LLC (the “Privateer Defendants”) for alleged breaches of fiduciary duty in their alleged capacities as Tilray’s controlling stockholders and against Kennedy, Maryscott Greenwood, and Michael Auerbach for alleged breaches of fiduciary duties in their capacities as directors and/or officers of Tilray in connection with the prior merger of Privateer Holdings, Inc. with and into a wholly owned subsidiary (the “Downstream Merger”). The complaint alleges that the Privateer Defendants breached their fiduciary duties by causing Tilray to enter into the Downstream Merger and Tilray’s Board to approve that Downstream Merger, and that Defendants Kennedy, Greenwood, and Auerbach breached their fiduciary duties as directors by approving the Downstream Merger. Plaintiffs allege that the Downstream Merger gave the Privateer Defendants hundreds of millions of dollars of tax savings without providing a corresponding benefit to Tilray and its minority stockholders and that the Downstream Merger unfairly transferred and extended Kennedy, Blue, and Groh’s control over Tilray.

In ~~August 2021,~~ the Company’s Board of Directors established a Special Litigation Committee (the “SLC”) of independent directors to re-assert director control and investigate the derivative claims in this litigation matter. The SLC has appointed the law firm Wilson Sonsini to assist the SLC with an ongoing investigation of the underlying claim and determine whether continued prosecution of such claims was in the best interests of the Company.

On ~~May 27, 2022,~~ ~~the SLC informed the Court that it had completed its investigation; determined~~ ~~not~~ to seek dismissal of the Action; and confirmed its determination that the Company had suffered significant damages and that the SLC would pursue claims to recover appropriate amounts for the Company's benefit. Thereafter, the SLC, all of the Defendants, and certain non-parties participated in ~~two~~ ~~mediation sessions before former Chancellor of the Delaware Court of Chancery Andre G. Bouchard.~~

On ~~July 15, 2022,~~ the SLC reached an agreement in principle with the Defendants and certain of the non-parties, and their respective insurers, to resolve the claims asserted in the Action in exchange for an aggregate amount of $26,900 to be paid to Tilray plus mutual releases. The SLC subsequently reached a further agreement with an additional non-party and plaintiffs to settle the entire Action. On ~~December 20, 2022,~~ the parties submitted to the Delaware Court of Chancery a Stipulation and Agreement of Compromise, Settlement, and Release ("SLC Settlement") which provided for, among other things, an aggregate cash amount of $39,900 to be paid to Tilray in exchange for mutual releases. Tilray stockholders will ~~not~~ ~~receive any direct payment from the SLC Settlement. The SLC Settlement was formally approved by the Delaware Court following a hearing on~~ ~~February 27, 2023,~~ ~~and Tilray received the settlement proceeds following such approval.~~

On May 4, 2020, Ganesh Kasilingam filed a lawsuit in the United States District Court for the Southern District of New York (“SDNY”), against Tilray Brands, Inc., Brendan Kennedy and Mark Castaneda, on behalf of himself and a putative class, seeking to recover damages for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Kasilingam litigation”). The complaint alleges that Tilray and the individual defendants overstated the anticipated advantages of the Company’s revenue sharing agreement with Authentic Brands Group (“ABG”), announced on January 15, 2019, and that the plaintiff suffered losses when Tilray’s stock price dropped after Tilray recognized an impairment with respect to the ABG deal on March 2, 2020. On August 6, 2020, SDNY entered an order appointing Saul Kassin as Lead Plaintiff and The Rosen Law Firm, P.A. as Lead Counsel. Lead Plaintiff filed an amended complaint on October 5, 2020, which asserts the same Sections 10(b) and 20(a) claims against the same defendants on largely the same theory, and includes new allegations that Tilray’s reported inventory, cost of sales, and gross margins in its financial reports during the class period were false and misleading because Tilray improperly recorded unsellable “trim” as inventory and understated the cost of sales for its products.

On September 27, 2021, the U.S. District Court entered an Opinion & Order granting the Defendants’ motion to dismiss the amended complaint in the Kasilingam ~~litigation.~~litigation without prejudice. On December 3, 2021, the lead plaintiff filed a second amended complaint alleging similar claims against Tilray and Brendan Kennedy. The defendants moved to dismiss thesecond amended complaint on February 2, 2022. On September 28, 2022, the Court granted in part and denied in part the defendants’ motion to dismiss the second amended complaint. On October 12, 2022, the Company filed a motion for reconsideration and/or interlocutory appeal of this Court decision. ~~The Company still believes~~

On August 21, 2023, the U.S. District Court granted Tilray’s motion for reconsideration and dismissed the second amended complaint with leave to amend one final time. On September 27, 2023, plaintiff filed a third amended complaint. Tilray continues to believe that all of the underlying claims in the amended complaint are without merit and ~~intends to defend vigorously against them, but there can~~should be no ~~assurances as to the outcome.~~

On ~~December 5, 2018,~~ a putative securities class action was commenced in SDNY against a number of defendants including Aphria and certain current and former officers and directors. The action claims that the defendants misrepresented the value of ~~three~~ ~~cannabis-producing properties Aphria acquired in Jamaica, Colombia, and Argentina (the “LATAM Assets”). On~~ ~~December 3, 2018,~~ ~~two~~ ~~notorious short-sellers issued a report about the acquisitions, claiming the LATAM Assets were non-functional or non-existent, which allegedly caused Aphria’s stock price to fall. On~~ ~~April 15, 2019,~~ Aphria took impairment charges on the LATAM Assets, which also allegedly caused Aphria’s stock price to decline. The putative class action claims that Aphria artificially inflated the price of its publicly-traded stock by making false statements about the LATAM Assets, and when the purported truth was revealed by a short-seller report and write-down, the stock price declined, harming investors.

On ~~September 30, 2020,~~ the Court denied the motion to dismiss the complaint as to Aphria, Vic Neufeld, and Carl Merton, and granted the motion as to Cole Cacciavillani, John Cervini, Andrew DeFrancesco, and SOL Global Investments. On ~~October 1, 2020,~~ ~~Plaintiffs moved for reconsideration of the order dismissing DeFrancesco and SOL or, in the alternative, to amend their complaint. On~~ ~~October 14, 2020,~~ ~~Aphria, Neufeld, and Merton moved for reconsideration of the order denying their motion to dismiss.~~dismissed with prejudice.

On ~~September 29, 2021,~~ ~~the U.S. District Court issued an Order that (i) permitted the plaintiffs~~Legal Proceedings Related to amend their lawsuit to revive the claims against Andy DeFrancecso; and (ii) declined to revisit his decision that claims could proceed against Aphria/Tilray, Vic Neufeld, and Carl Merton. Plaintiffs declined to amend their complaint, however, and so the action is proceeding solely against Aphria/Tilray, Neufeld, and Merton. On ~~December 5, 2022,~~ ~~the parties engaged in a mediation session with an independent mediator. However,~~ no ~~settlement agreement was reached.~~Contractual Obligations

On February 21, 2020, 420 Investments Ltd., as Plaintiff (“420 Investments”), filed a lawsuit against Tilray Brands, Inc. and High Park Shops Inc. as Defendants, in Calgary, Alberta in the Court of Queen’s Bench of Alberta. In August 2019, Tilray and High Park entered into an Arrangement Agreement with 420 Investments and others (the “Agreement”). Pursuant to ~~determine any potential damages from this proceeding. The Company~~the Agreement, High Park was to acquire the securities of 420 Investments. In February 2020, Tilray and High Park gave notice of termination of the ~~individual defendants believe~~Agreement. 420 Investments alleges that the ~~claims are~~termination was unlawful and without merit and ~~intend~~further alleges that the Defendants had no legal basis to terminate. 420 Investments alleges that the Defendants did not meet their contractual and good faith obligations under the Agreement. 420 Investment seeks damages in the stated amount of C$110,000, plus C$20,000 in aggravated damages. The Tilray and High Park Statement of Defense and counterclaim were both filed on March 20, 2020. 420 Investment’s Statement of Defense to our counterclaim was filed on April 20, 2020. Respectively, 420 Investments and Tilray / High Park served each other with their Affidavits of Records on August 25, 2020 and November 30, 2020. Tilray and High Park cross-examined the litigation representative of 420 Investments. The Company denies the Plaintiff’s allegations and intends to continue to vigorously defend ~~against the claims, but~~this litigation matter, although there can be no ~~assurances~~assurance as to ~~the~~its outcome.

~~LATAM~~In February 2023, Tilray and ~~Nuuvera Class Actions and Individual Actions (Canada)~~

OnHigh Park filed an Application for Summary Judgment to collect an unpaid C$7,000 bridge loan made to ~~January 29, 2018,~~ ~~Aphria announced the acquisition of Nuuvera Inc. On~~ ~~July 17, 2018,~~ ~~Aphria announced a planned expansion into Latin America and the Caribbean with the acquisition of LATAM Holdings Inc. The following class actions and~~ ~~four~~420 ~~individual proceedings have been commenced in Canada against Aphria and several current or former officers~~ Investments on August 28, 2019, relating to the ~~Nuuvera~~subject transaction. That debt was repayable in March 2020, but was never repaid. The application is pending and ~~LATAM transactions:~~

~~(i)~~ a ~~proposed class action (the "Vecchio Action") commenced~~decision from the Court is expected on Tilray’s Application for Summary Judgment in the ~~Ontario Superior Court in~~calendar year of ~~February 2019,~~ 2024.and amended thereafter, alleging statutory and common law misrepresentations and oppression relating to the Nuuvera and LATAM transactions. The Vecchio Action names Aphria, Merton, Neufeld, Cacciavillani and 5 ~~underwriters as defendants;~~

~~(ii)~~ ~~four~~ individual actions (the "Individual Actions") commenced by Wan, Bergerson, Landry, and Profinsys in the Ontario Superior Court alleging statutory and common law misrepresentations relating to the LATAM and Nuuvera transactions. The Individual Actions name Aphria, Merton, Neufeld, and Cacciavillani as defendants.

~~In the Vecchio Action a motion for certification and leave was heard. For Reasons for Decision released~~ ~~August 6, 2021,~~ and with the consent of Aphria and the individually named Defendants, the Court granted leave to proceed with the secondary market statutory cause of action, and certified the Action on behalf of a defined class of purchasers. Also, on consent, the Court dismissed the claims of oppression and common law misrepresentation against Aphria and the individual defendants, as well as all claims against Carl Merton. The Court granted certification of the primary market statutory cause of action against all remaining Defendants but made it conditional on a successful motion by the Plaintiff to have the Court appoint a ~~second~~ ~~Plaintiff for that aspect of the Claim. The defendant underwriters are appealing~~ ~~one~~ ~~term of that final aspect of the Court's decision. We continue to believe that these claims are without merit and plan to vigorously defend against this action.~~

On November 5, 2021 Docklight Brands, Inc. (“Docklight”) filed a complaint against the Company and its wholly-owned subsidiary, High Park Holdings, Ltd. ~~(“High Park”)~~ in Superior Court of the State of Washington, King County. Docklight claimed breach of contract against High Park arising from a 2018 license agreement pursuant to which Docklight licensed certain Bob Marley-related brands to High Park (as amended in 2020 and 2021, the “High Park License”). In addition, Docklight brought a negligent misrepresentation claim against Tilray, alleging that certain individuals at Tilray or Aphria had made false statements to Docklight in order to induce Docklight to waive Docklight’s alleged right to terminate the High Park License for change-of-control on the basis of the 2021 Tilray-Aphria Arrangement Agreement. Effective October 10, 2023, the parties entered into a settlement agreement pursuant to which the Company paid an aggregate amount equal to $3,000 to Docklight ~~seeks injunctive relief as well as unspecified damages. On~~ ~~December 17, 2021,~~ ~~Defendants removed~~in exchange for mutual releases and a dismissal of the ~~case to the United States District Court, Federal District of Washington. Defendants’ answer to the complaint was timely filed by~~ ~~January 21, 2022,~~ ~~and discovery in this~~pending Docklight litigation ~~matter is ongoing. Tilray and High Park continue to believe that the claims are without merit and we intend to continue to vigorously defend the Docklight suit.~~claims.

In July 2022, MediPharm Labs Inc. (“MediPharm) and Peter Hwang obtained a judgement for damages against HEXO Inc. in ~~Litigation (recovery)~~an amount equal to CAD $9,800, together with costs ~~is $33,000 relating~~and interest, in connection with HEXO’s alleged failure to pay for certain products. Subsequent to Tilray’s acquisition of HEXO, on October 2, 2023, MediPharm, HEXO and Tilray reached a settlement of the ~~SLC Settlement (net~~MediPharm judgment. Specifically, the terms of ~~costs)~~the settlement consisted of the following: (i) CAD $3,000 cash payment to MediPharm; (ii) issuance to MediPharm of a product supply credit for CAD $1,000 for the purchase of Tilray cannabis products at market pricing; (iii) Tilray acquired all of the outstanding shares of a MediPharm subsidiary in exchange for the issuance by Tilray of 1,573,152 Tilray common shares; (iv) payment of CAD $210 to Peter Hwang; and (v) dismissal of the MediPharm judgment and mutual releases of all claims.

As described in Note 11 (Accounts payable and accrued liabilities), the total litigation expense ~~accruals equaling $25,000~~accrual included in accrued liabilities as of November 30, 2023 was $25,338 to cover various ongoing litigation matters that are probable and estimable ~~for~~( May 31, 2023 - $25,000). During the ~~three~~ ~~and~~ ~~nine~~six months ended ~~February 28, 2023.~~November 30, 2023, the Company assumed $12,253 of litigation accruals from the acquisition of HEXO, several of which were settled in the period as described above. The Company did not assume any litigation accruals from the Craft Acquisition.

The Company reports its net revenue in four reporting segments: cannabis, distribution, beverage alcohol and wellness.

	*For the three months*				*For the nine months*				*For the three months*				*For the six months*
	*ended February 28,*				*ended February 28,*				*ended November 30,*				*ended November 30,*
	*2023*		*2022*		*2023*		*2022*		*2023*		*2022*		*2023*		*2022*
Cannabis costs	$	80,362	$	37,042	$	137,800	$	122,492	$	46,472	$	28,577	$	96,989	$	57,438
Beverage alcohol costs		10,663		8,091		32,932		20,674		30,513		11,420		41,779		22,269
Distribution costs		57,964		57,566		165,443		178,093		60,147		52,495		121,615		107,479
Wellness costs		8,299		9,343		26,964		30,238		9,230		8,762		18,732		18,665
Total	$	157,288	$	112,042	$	363,139	$	351,497	$	146,362	$	101,254	$	279,115	$	205,851

	*For the three months*						*For the nine months*						*For the three months*						*For the six months*
	*ended February 28,*						*ended February 28,*						*ended November 30,*						*ended November 30,*
	*2023*			*2022*			*2023*			*2022*			*2023*			*2022*			*2023*			*2022*
Executive compensation	$	2,754		$	4,238		$	9,359		$	9,565		$	3,324		$	3,050		$	6,985		$	6,605
Office and general		6,799			4,012			20,011			21,755			8,065			7,383			16,233			13,212
Salaries and wages		13,621			14,076			38,407			37,536			15,795			10,151			28,909			24,786
Stock-based compensation		9,630			9,355			29,766			27,025			8,201			10,943			16,458			20,136
Insurance		3,159			4,835			8,588			14,461			2,499			2,726			6,348			5,429
Professional fees		1,165			3,601			5,385			9,669			2,503			1,730			4,002			4,220
Gain on sale of capital assets		(15	)		(861	)		(2	)		(631	)
Insurance proceeds		-			(4,032	)		-			(4,032	)
(Gain) loss on sale of capital assets														(23	)		(64	)		(20	)		13
Travel and accommodation		1,104			1,102			3,484			2,876			1,374			1,219			2,481			2,380
Rent		782			2,119			2,387			3,177			1,575			740			2,433			1,605
Total	$	38,999		$	38,445		$	117,385		$	121,401		$	43,313		$	37,878		$	83,829		$	78,386

In connection with the execution of our acquisition strategy and strategic transactions, the Company has incurred restructuring and exit costs associated with the integration efforts of these non-recurring transactions. The Company recognized $2,655 and $3,570 of restructuring charges for the three and six months ended November 30, 2023, compared to $8,064 and $8,064 for prior year comparative periods. The Company approves detailed restructuring initiative plans at the executive level and recognizes these expenses in the period in which the plan has been committed to. All amounts incurred as of November 30 2023, have been paid.

Within the Cannabis reporting unit, three restructuring plans have been initiated as follows; HEXO acquisition related charges which is expected to take place 24 months from the acquisition date, Truss acquisition related charges which is expected to take place 18 months from the acquisition date and the Canadian business cost reduction plan, which concluded during the quarter. In the six month period ended November 30, 2023, the following expenses were recognized, $1,221 of employee termination benefits for the HEXO acquisition plan, $1,586 of restructuring charges related to the costs of exiting the facility until the new business has resumed for the Truss acquisition plan and $281 of employee termination benefits for the Canadian business cost reduction plan.

Within the Distribution reporting unit, the Company executed a cost optimization plan during the three months ended November 30, 2023. It is expected that this plan will be completed within the current fiscal year. In the six month period ended November 30, 2023, the Company recognized $482 related to employee termination benefits in association with executing this plan.

For the prior period three and six months ended November 30, 2022, the Company recognized $8,064 and $8,064 which was comprised of $1,599 of exit cost and $2,758 for inventory adjustments from the termination of our producer partnership in Uruguay due to a breach of the underlying contract in our International cannabis business. Additionally, amounts related to the Tilray-Aphria Arrangement Agreement for the closure of our Canadian cannabis facility in Enniskillen of $1,512 million were incurred. The Company also incurred $2,195 million of write-offs from the exit of our medical device reprocessing business in our distribution reporting segment. These exit costs were completed in the prior year quarter ended November 30, 2022, and did not have on going impacts in the six months ended November 30, 2023.

	*For the three months*						*For the nine months*						*For the three months*						*For the six months*
	*ended February 28,*						*ended February 28,*						*ended November 30,*						*ended November 30,*
	*2023*			*2022*			*2023*			*2022*			*2023*			*2022*			*2023*			*2022*
Change in fair value of convertible debenture payable	$	207		$	56,128		$	(20,375	)	$	151,851		$	(3,894	)	$	(12,698	)	$	(6,041	)	$	(20,582	)
Change in fair value of warrant liability		5,256			21,089			6,841			58,802			6,247			37			(1,951	)		1,585
Foreign exchange loss		(1,955	)		(2,548	)		(26,621	)		(18,452	)
Foreign exchange loss (gain)														(1,024	)		907			5,243			(24,666	)
Loss on long-term investments		(925	)		(3,326	)		(2,529	)		(6,834	)		459			(596	)		350			(1,604	)
Other non-operating (losses) gains, net		(1,370	)		(306	)		(7,545	)		962			(967	)		(6,100	)		(1,182	)		(6,175	)
Total	$	1,213		$	71,037		$	(50,229	)	$	186,329		$	821		$	(18,450	)	$	(3,581	)	$	(51,442	)

~~Other~~Included in other non-operating (losses) gains, net for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, ~~includes amounts~~are losses of $(967) and $(1,182) resulting from the downside protection share issuance relating to ~~settle outstanding notes with non-controlling interest shareholders.~~the HTI note, as described in Note 15 (Stockholders' equity) and the gain on the settlement of TLRY 23 Convertible Notes.

The Company has classified its financial instruments as described in Note 3 Significant accounting policies in our Annual Financial Statements.

The carrying values of accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to their short periods to maturity.

At ~~February 28,~~November 30, 2023 and May 31, 2023 the Company had long-term debt of ~~$nil~~ ( ~~May 31, 2022~~ ~~- $20,358)~~$4,472 and $3,280, respectively, and the principal portion of convertible debentures payable of $309,240 and $464,070, respectively, subject to fixed interest rates. The Company’s long-term debt is valued based on discounting the future cash outflows associated with the long-term debt. The discount rate is based on the incremental premium above market rates for the U.S. Department of the Treasury securities of similar duration. In each period thereafter, the incremental premium is held constant while the U.S. Department of the Treasury security is based on the then current market value to derive the discount rate.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of ~~February 28,~~November 30, 2023 and May 31, ~~2022~~2023 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

								*February 28,*										*November 30,*
	*Level 1*		*Level 2*		*Level 3*			*2023*			*Level 1*		*Level 2*		*Level 3*			*2023*
Financial assets
Cash and cash equivalents	$	164,997	$	—	$	—		$	164,997		$	143,373	$	—	$	—		$	143,373
Marketable Securities		243,286		—		—			243,286
Restricted cash												1,576							1,576
Marketable securities												116,418		—		—			116,418
Convertible notes receivable		—		—		168,356			168,356			—		—		74,681			74,681
Equity investments measured at fair value		376		1,596		5,648			7,620			—		—		5,500			5,500
Financial liabilities
Warrant liability		—		—		(7,414	)		(7,414	)		—		—		(3,768	)		(3,768	)
Contingent consideration		—		—		(26,815	)		(26,815	)		—		—		(20,704	)		(20,704	)
APHA 24 Convertible debenture		—		—		(223,087	)		(223,087	)		—		—		(128,399	)		(128,399	)
Total recurring fair value measurements	$	408,659	$	1,596	$	(83,312	)	$	326,943		$	261,367	$	—	$	(72,690	)	$	188,677

								*May 31,*										*May 31,*
	*Level 1*		*Level 2*		*Level 3*			*2022*			*Level 1*		*Level 2*		*Level 3*			*2023*
Financial assets
Cash and cash equivalents	$	415,909	$	—	$	—		$	415,909		$	206,632	$	—	$	—		$	206,632
Restricted cash												—		—		—			—
Marketable Securities												241,897		—		—			241,897
Convertible notes receivable		—		—		111,200			111,200			—		—		103,401			103,401
Equity investments measured at fair value		1,878		2,469		5,703			10,050			1,056		1,088		5,651			7,795
Financial liabilities
Warrant liability		—		—		(14,255	)		(14,255	)		—		—		(1,817	)		(1,817	)
Contingent consideration		—		—		(16,007	)		(16,007	)		—		—		(27,107	)		(27,107	)
APHA 24 Convertible debenture		—		—		(216,753	)		(216,753	)		—		—		(120,568	)		(120,568	)
Total recurring fair value measurements	$	417,787	$	2,469	$	(130,112	)	$	290,144		$	449,585	$	1,088	$	(40,440	)	$	410,233

The Company’s financial assets and liabilities required to be measured on a recurring basis are its convertible notes receivable, equity investments measured at fair value, ~~debt securities classified as available-for-sale,~~convertible debentures measured at fair value, acquisition-related contingent consideration, and warrant liability.

Convertible notes receivable and ~~equity~~long-term investments are recorded at fair value. The estimated fair value is determined using ~~quoted market prices, broker or dealer quotations or discounted cash flows~~the Black Scholes option pricing model, probability of legalization and is classified as Level 3.

~~Debt securities classified as available-for sale~~Convertible debentures payable are recorded at fair ~~value. The~~value when elected or required under US GAAP. Specifically, the APHA 24 instrument's estimated fair value is determined using the Black-Scholes option pricing model and is classified as Level 2.3.

Certain equity investments recorded at fair value have quoted prices in active markets for identical assets and are classified as Level ~~1.The~~1. The Company classified securities with observable inputs as Level 2 and without a quoted market price as Level 3.

The warrants associated with the warrant liability are classified as Level 3 derivatives. Consequently, the estimated fair value of the warrant liability is determined using the Black-Scholes pricing model. Until the warrants are exercised, expire, or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity, the warrant liability (which relates to warrants to purchase shares of common stock) is marked-to-market each reporting period with the change in fair value recorded in change in fair value of warrant liability. Any significant adjustments to the unobservable inputs disclosed in the table below would have a direct impact on the fair value of the warrant liability.

The contingent consideration from the acquisitions of SweetWater, Montauk, and ~~Montauk,~~Truss due in December 2023, ~~and~~ December 2025, and upon the triggering event if met, respectively and are payable in cash, is determined by discounting future expected cash outflows at a discount rate in the range of 5%~~, and~~ - 11.4%, ~~respectively~~ and probability of achievement of 25% and ~~80%~~90%. The unobservable inputs into the future expected cash outflows result in a fair value measurement classified as Level 3.

~~The APHA~~ 24six ~~Convertible debentures payable are recorded at fair value. The estimated~~months ended November 30, 2023, a decrease in fair value ~~is determined using~~of $10,584, inclusive of changes in foreign exchange, was recognized and was comprised of a decrease of fair value of $13,218 for the ~~Black-Scholes option pricing model~~contingent consideration from the Sweetwater acquisition as a result of a lower probability of achieving the incentive targets which was offset by an increase in fair value of $2,411 for the contingent consideration from the Montauk acquisition as a result of a higher probability of achieving the incentive targets. Lastly, the addition of $4,181 of contingent consideration liability was assumed as part of the Truss acquisition and ~~is classified~~an increase in fair value of $223 as ~~Level~~ 3.a result of foreign exchange.

The balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled, as follows:

The unrealized gain (loss) on fair value for the convertible debenture, the warrant liability, contingent consideration, and debt securities classified under available-for-sale method is recognized in the consolidated statements of loss and comprehensive loss using the following inputs:

The Company's prepaids and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable. There have been no changes to the Company’s capital management approach in the period. The Company considers its cash and cash equivalents and marketable securities as capital.

Information reported to the Chief Operating Decision Maker (“CODM”) for the purpose of resource allocation and assessment of segment performance focuses on the nature of the operations. The Company operates in four reportable segments: (1) cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis, (2) beverage alcohol operations, which encompasses the production, marketing and sale of beverage and beverage alcohol products, (3) distribution operations, which encompasses the purchase and resale of pharmaceuticals products to wholesale and pharmacy customers, and (4) wellness products, which encompasses hemp foods and hemp-based cannabidiol (“CBD”) consumer products. This structure is in line with how our Chief Operating Decision Maker (“CODM”) assesses our performance and allocates resources.

Operating segments have not been aggregated and no asset information is provided for the segments because the Company’s CODM does not receive asset information by segment on a regular basis.

	*For the three months*					*For the nine months*				*For the three months*				*For the six months*
	*ended February 28,*					*ended February 28,*				*ended November 30,*				*ended November 30,*
	*2023*			*2022*		*2023*		*2022*		*2023*		*2022*		*2023*		*2022*
Cannabis
Net cannabis revenue	$	47,549		$	55,045	$	156,017	$	184,269	$	67,114	$	49,898	$	137,447	$	108,468
Cannabis costs		80,362			37,042		137,800		122,492		46,472		28,577		96,989		57,438
Gross profit (loss)		(32,813	)		18,003		18,217		61,777
Gross profit											20,642		21,321		40,458		51,030
Distribution
Distribution revenue		65,385			62,532		186,158		198,587		67,223		60,188		136,380		120,773
Distribution costs		57,964			57,566		165,443		178,093		60,147		52,495		121,615		107,479
Gross profit		7,421			4,966		20,715		20,494		7,076		7,693		14,765		13,294
Beverage alcohol
Net beverage alcohol revenue		20,640			19,597		62,689		48,765		46,505		21,395		70,667		42,049
Beverage alcohol costs		10,663			8,091		32,932		20,674		30,513		11,420		41,779		22,269
Gross profit		9,977			11,506		29,757		28,091		15,992		9,975		28,888		19,780
Wellness
Wellness revenue		12,015			14,697		38,072		43,426		12,929		12,655		26,226		26,057
Wellness costs		8,299			9,343		26,964		30,238		9,230		8,762		18,732		18,665
Gross profit	$	3,716		$	5,354	$	11,108	$	13,188	$	3,699	$	3,893	$	7,494	$	7,392

On July 12, 2022, Tilray acquired the HEXO Convertible Note from HTI and also entered into a strategic alliance with HEXO Corp. (“HEXO”) as discussed in Note 68 (Convertible notes receivable) and Note 1113 (Convertible debentures payable). In addition, the Company and HEXO entered into various commercial transaction ~~agreements, including (i) an advisory services agreement regarding Tilray’s provision of advisory services to~~agreements. On June 22, 2023, the Company completed the HEXO Acquisition as described in ~~exchange for an $18 million annual advisory fee payable to Tilray; (ii) a co-manufacturing agreement providing for~~Note ~~third~~7~~-party manufacturing services between~~ (Business acquisitions), and thus these commercial arrangements were terminated and HEXO's financial results were consolidated in the parties and setting forth the terms of Tilray’s international bulk supply to HEXO; and (iii) a procurement and cost savings agreement for shared savings related to specified optimization activities, procurement, and other similar cost savings realized by the parties as a result of the foregoing commercial arrangements.current period results.

Included in revenue from Canadian adult-use cannabis is ~~$8,667~~$nil and ~~$24,302~~$1,500 of advisory services revenue for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023,from the aforementioned HEXO commercial transaction ~~agreements.~~agreements, compared to $7,882 and $15,635 of advisory services revenue in the prior comparative period.

	*For the three months*				*For the nine months*				*For the three months*				*For the six months*
	*ended February 28,*				*ended February 28,*				*ended November 30,*				*ended November 30,*
	*2023*		*2022*		*2023*		*2022*		*2023*		*2022*		*2023*		*2022*
North America	$	70,463	$	73,234	$	228,866	$	236,220	$	114,619	$	76,211	$	208,140	$	158,403
EMEA		71,111		74,671		199,867		225,596		75,292		62,715		154,996		128,756
Rest of World		4,015		3,966		14,203		13,231		3,860		5,210		7,584		10,188
Total	$	145,589	$	151,871	$	442,936	$	475,047	$	193,771	$	144,136	$	370,720	$	297,347

	*February 28,*		*May 31,*		*November 30,*		*May 31,*
	*2023*		*2022*		*2023*		*2023*
North America	$	313,233	$	464,370	$	506,151	$	319,173
EMEA		108,944		119,409		105,325		107,131
Rest of World		3,086		3,720		3,611		3,363
Total	$	425,263	$	587,499	$	615,087	$	429,667

Major customers are defined as customers that ~~each individually account for greater than~~ ~~10%~~ ofare materially significant to the Company’s annual revenues. For the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 and 2022, there were no major customers representing ~~greater than~~ ~~10%~~ ofa material contribution to our quarterly revenues.

~~Charter Amendments~~On December 15, 2023 and December 21, 2023, the Company exchanged $18,500 aggregate principal of its APHA 24 Notes for cancellation by issuing 9,601,538 shares.

On ~~March 16, 2023,~~January 5, 2024, the ~~Company's stockholders formally approved~~Company obtained a Waiver from its lender as 420 was not in compliance with the ~~Company's proposal to amend its certificate of incorporation (the "Charter Amendments"). The Charter Amendments modified~~leverage ratio covenant under the ~~Company's existing certificate of incorporation by canceling the Class~~ 1420 ~~Common Stock and re-allocating such authorized shares to Class~~Secured Credit Agreement. See 2“420 ~~Common Stock. In addition, the Charter Amendments reclassified each issued and outstanding share of Class~~Credit Agreement” discussed in Part II, Item 25. ~~Common Stock as~~ ~~one~~ ~~share of Common Stock, par value $0.0001, of the Company (“Common Stock”). The cumulative effect of the Charter Amendments is that the Company currently has~~ ~~two~~ classes of authorized stock — Common Stock and preferred stock. All of the issued and outstanding Series A Preferred Stock automatically converted into the Company’s common stock following the approval of the Charter Amendments by the vote of the Company’s stockholders. There are no outstanding Series A Preferred Stock following such automatic conversion.

On ~~April 10, 2023,~~January 5, 2024, weAphria Inc. (“Aphria”), a wholly-owned subsidiary of the Company, entered into an ~~Arrangement~~Amended and Restated Wholesale Cannabis Supply Agreement (the ~~“Arrangement~~“Supply Agreement”) with ~~HEXO Corp.~~1974568 Ontario Limited (“~~HEXO”~~Aphria Diamond”), ~~pursuant~~Aphria’s joint venture with Double Diamond Holdings Ltd. The Supply Agreement amends and restates the existing supply agreement, effective as of September 1, 2023, and amends certain terms relating to ~~which Tilray agreed to acquire all of the issued~~pricing and outstanding common shares of HEXO pursuant to a plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”). Under the terms of the Arrangement Agreement, each outstanding common share of HEXO outstanding immediately prior to the effective time of the Arrangement is expected to be transferred to Tilrayproduct classes. See “Aphria Diamond Amended Supply Agreement” discussed in ~~exchange for 0.4352 of a share of Tilray Common Stock.~~ Part II, Item 5. Other Information.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the Condensed Interim Consolidated Financial Statements and the related Notes thereto for the period ended ~~February 28,~~November 30, 2023 contained in this Quarterly Report on Form 10-Q and the Audited Consolidated Financial Statements and the related Notes thereto contained in our Annual Report on Form 10-K ~~as amended~~ for the fiscal year ended May 31, ~~2022.~~ 2023, as well as in conjunction with the sections entitled “Item 1A. Risk Factors” and “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-Kfor the fiscal year ended May 31, 2023. Forward looking statements in this Form 10-Q are qualified by the cautionary statement included in this Form 10-Q under the sub-heading “Cautionary Note Regarding Forward-Looking Statements” in the introduction of this Form 10-Q.

We are a leading global cannabis-lifestyle and consumer packaged goods company headquartered in Leamington and New York, with operations in Canada, the United States, Europe, Australia, and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering a worldwide community to live their very best life, enhanced by moments of connection and wellbeing. Tilray’s mission is to be the most responsible, trusted and market leading cannabis consumer products company in the world with a portfolio of innovative, high-quality and beloved brands that address the needs of the consumers, customers and patients we serve.

Our overall strategy is to leverage our ~~scale,~~brands, infrastructure, expertise and capabilities to drive market share in ~~Canada and internationally,~~the industries in which we compete, achieve industry-leading, profitable growth and build sustainable, long-term shareholder value. In order to ensure the long-term sustainable growth of our Company, we continue to focus on developing strong capabilities in consumer insights, drive category management leadership and assess growth opportunities with the introduction of new ~~products.~~products and entries into new geographies. In addition, we are relentlessly focused on managing our cost of goods and expenses in order to maintain our strong financial position.

The cannabis industry in Canada continues to evolve at a rapid pace during the early periods following the federal legalization of adult-use cannabis. Through analysis of the current market conditions, the following key trends have emerged and are anticipated to influence the near-term future in the industry:

These identified trends have had impacts on the current period results of operations and are discussed in greater detail in the respective ~~section.~~sections.

The cannabis industry in Europe is in its early stages of development whereby countries within Europe are at different stages of legalization of medical and adult-use cannabis as some countries have expressed a clear political ambition to legalize adult-use cannabis (Germany, Portugal, Luxembourg and Czech Republic), some are engaging in an experiment for adult-use ~~(Netherlands,~~(Germany, Netherlands and Switzerland) and some are debating regulations for cannabinoid-based medicine (France ~~Spain, Italy,~~ and ~~the United Kingdom)~~Spain). In Europe, we believe that, despite continuing ~~COVID-19 pressure~~recessionary economic conditions and the Russian conflict with Ukraine, cannabis legalization (both medicinal and adult-use) will continue to gain traction albeit more slowly than originally expected. We also continue to believe that Tilray remains uniquely positioned to maintain and gain significant market share in these markets with its infrastructure and its investments, which is comprised of two EU-GMP cultivation facilities within Europe located in Portugal and Germany, our distribution network and our demonstrated commitment to the availability, quality and safety of our cannabinoid-based medical products. Today, Germany remains the largest medical cannabis market in Europe.

Germany. The new coalition government led by chancellor Olaf Schulz declared its intention to legalize adult-use cannabis use, which aims to regulate the controlled dispensing of cannabis for adult-use consumption. In late October 2022, the German government published key details of its plan to legalize and regulate adult-use cannabis, including what Health Minister Karl Lauterbach described as “complete” cultivation within the country. Subsequently, Lauterbach announced that a first draft of the proposed regulations shall be issued in the first quarter of calendar year 2023, which will be evaluated by the European Union Commission in a formal notification procedure. To date, a draft of the proposed regulations has not yet been issued.

Recently, Mr. Lauterbach advised that the proposal had been revised and that the new plan is a two-part model, which appears to be designed in order to legalize cannabis as broadly as possibly without running afoul of European Union rules. On July 6, 2023, it was announced that the draft regulations pertaining to decriminalization, home cultivation and non-commercial “cultivation associations” (i.e., social clubs) (the "Pillar One Regulations") had been finalized by the health ministry and was ready to be delivered to the German parliament. Due to lack of internal alignment by the SPD party, the Pillar One Regulations, which were initially expected to be introduced to the German parliament in the fourth quarter of calendar year 2023, now will not be brought until early in the calendar year of 2024. It is expected that the Pillar One Regulations will be passed in January 2024, with the new law coming into effect in the first quarter of calendar year 2024.

In addition to the Pillar One Regulations addressing decriminalization, home cultivation and non-commercial “cultivation associations”, it also contains provisions which provide for broad medical cannabis reform, to which there appears to be broad consensus. These provisions include the reclassification of medical cannabis as a non-narcotic, thereby increasing the accessibility of medical cannabis to patients and the abolishment of the tender procedure for in-country cultivation in favor of a permit procedure.

We expect to see the cornerstone framework for the Pillar Two Regulations governing the model projects in January 2024.

We continue to believe that Tilray is well-positioned in Germany to provide consistent and sustainable cannabis products for the adult-use market whether only in-country cultivation is permitted or whether imports are also allowed given our Aphria RX facility located in Germany and our EU-GMP-certified production facility in ~~Portugal.~~Portugal, as well as our distribution platform, which provides us with access to 13,000 pharmacies in Germany. Tilray is also well-positioned to continue to service the medical cannabis market and we believe that the reclassification of medical cannabis as a non-narcotic and the adoption of a permit procedure for in-country cultivation provides Tilray with a larger market opportunity.

Switzerland.In October 2021, Switzerland announced its intention to legalize cannabis by allowing production, cultivation, trade, and ~~consumption. In~~consumption, and in the meantime, ~~a three-year~~it is commencing pilot ~~project commenced on January 30, 2023,~~projects in various cities, which permits selected participants to purchase cannabis for adult-use in various pharmacies in ~~Basel, and more recently in Zurich,~~order to conduct studies on the cannabis market and its impact on Swiss society. It is the first trial for the legal distribution of adult-use cannabis containing THC in Europe. To date, Switzerland has granted several cities, including Basel, Bern, Biel/Bienne, Lucerne, Geneva, and Zurich, the opportunity to start their cannabis pilot projects. Zurich, which has recently been reported to lack cannabis consumers, is currently seeking 400 eligible individuals to participate.

Spain. The Spanish Congress' Health Committee has recently approved a Medical Cannabis Report that paves the way for a government-sponsored bill on medical cannabis. The Report explicitly opens the door to standardized preparations other than the drugs already approved, highlighting their advantages in relation to safety, security and stability; as well as the possibility to prescribe medical cannabis in community pharmacies and not only in hospitals, favoring the access to the patients that may need it.

France. France launched a two-year pilot experiment to supply approximately 3,000 patients with medical cannabis. To date, 2,300 patients are enrolled in the experiment, which has been extended for another year and is now ending March 2024 in order to collect more data and to adopt a legal framework. The first results of the experimentation are positive. Several independent agencies have produced reports that show the effectiveness of medical cannabis, especially in situations of chronic pain.

Czech Republic. The Czech Republic has discussed plans to launch a fully regulated adult-use cannabis market and is reviewing in ~~first half~~the context of ~~calendar year 2023.~~the European regulations.

Malta. In 2021, became the first country in the European Union to legalize personal possession of the drug and permit private “cannabis clubs,” where members can grow and share the drug.

Netherlands. The Netherlands launched a pilot program involving the cultivation of cannabis for adult-use. The purpose of the experiment is to determine whether and how controlled cannabis can be legally supplied to coffeeshops and what the effects of this would be. During the experiment, legally produced cannabis will be sold in coffeeshops in 10 municipalities. Coffeeshops in these municipalities may only sell legally produced cannabis. The term of the experiment is set for four years.

The beverage alcohol category, while more established, continues to shift with changes in consumer trends for the craft industry. Specifically, based on IRI data, for the ~~last~~ 13 weeks ended ~~February 26,~~November 30, 2023, the US beer trends softened slightly as the industry ~~grew 3.3%~~increased 1.6%, ~~with~~while craft beer ~~down 2.9%~~decreased 1.6%, a slight decline from the immediately preceding quarter, which is consistent with the historical seasonality of craft beer. Craft beer still maintains the 4^th largest segment within total beer, generating over $1.1B in retail sales. Sweetwater revenues in the quarter ending August 31, 2023, and November 30, 2023, were both 1% higher than the comparable quarters of the prior year. SweetWater is expected to maintain growth nationally during the same period Sweetwater however, outperformed both the US craft beer market and the US beer industry in the same period in its core market increasing increased sales 4.8% across the Southeast region, where approximately 70%remainder of the 2024 fiscal year through programming and product innovation launches. Early results from the launch of SweetWater’s ~~national beer sales~~latest innovation, Gummies, are ~~currently derived.~~encouraging, with the brand quickly becoming a top 3 offering in activated markets. Additionally, Montauk, which was acquired on November 7, 2022, finished the period with a 5.9% growth based on IRI data for the aforementioned period, through sustained success in home markets and new market expansion. The Company anticipates ~~continuing to grow its beer sales by expanding~~continued growth through focused innovation, targeted marketing efforts, and gains in distribution ~~points~~across the portfolio of ~~its SweetWater, Green Flash, Alpine and Montauk~~brands. The Company has also seen positive trends across the newly acquired brands ~~as well as launching innovative products such as hard seltzers, rose beer, lager, hazy IPAs and pale ales to continue to be a market leader~~portfolio from the Acquisition of the Beverage Alcohol Business Portfolio, which are included in ~~the craft beer industry.~~our results from October 1, 2023.

Breckenridge Distillery is a leader in the ~~Colorado~~ bourbon industry and continues to gain market share in both the vodka and gin markets. A primary growth objective is to continue expansion of market share across the United States, ~~as well as~~including expanding the national ~~chains~~chain's footprint, to maintain a double-digit annual top-line growth. To ensure continued growth in the future, the company is focused on expanding the marketing strategy, highlighting its quality products. ~~Breckenridge Distillery’s commitment to quality has been recognized in recent awards by Whisky Magazine as~~Recent media coverage includes coverage of newly released products, the ~~World's Best Blended, Best American Blended Malt, Best American Blended Limited Release,~~expanded Denver Broncos Sponsorship, and ~~Best American Blended.~~recognition of the world class restaurant located at the distillery. The overall ~~bourbon~~whiskey market ~~continues~~remains positive, but the growing tequila and RTD cocktail markets have slowed. The Company expects its spirits business to continue to grow ~~although competition from tequila~~with innovative new product offerings and ~~RTD’s remains a challenge. The integration of~~continued expansion in the ~~national distributer agreement signed with RNDC in Fall 2022 has been slow, but will also be a growth driver for the business.~~US market.

Manitoba ~~harvest’s~~Harvest’s branded hemp business ~~continues~~continued to expand its U.S. and Canadian leading market share ~~position. These market share gains were offset by many~~position this quarter with consumption up in both the Natural and Conventional Channels, with the brands top five customers ~~reducing inventory levels amidst~~all seeing growth. For the ~~current economic climate to conserve cash. During~~remainder of the ~~quarter, we launched a new CBD wellness beverage, Happy Flower, during “Dry January” via a direct-to-consumer e-commerce platform. We~~year, the Company will look to expand the Happy Flower™ brand with retail distribution into key markets, ~~throughout the remainder of 2023,~~ focusing on U.S. states with established CBD permissibility and ~~established CBD sales.~~sales momentum in future periods.

We strive to continue to expand our business on a consolidated basis, through a combination of organic growth and acquisition. While we continue to execute against our strategic initiatives that we believe will result in the long-term, sustainable growth and value to our stockholders, we continue to evaluate potential acquisitions and other strategic transactions of businesses that we believe complement our existing portfolio, infrastructure and capabilities or provide us with the opportunity to enter attractive new geographic markets and product categories as well as expand our existing capabilities. In addition, we have exited certain businesses and continue to evaluate certain businesses within our portfolio that are dilutive to profitability and cash flow. As a result, we incur transaction costs in connection with identifying and completing acquisitions and strategic transactions, as well as ongoing integration costs as we combine acquired companies and continue to achieve synergies, which is offset by income generated in connection with the execution of these transactions. For the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, we incurred ~~$5.4~~$1.1 million and $9.6 million of transaction expenses, ~~and earned ($3.9) million of transaction income,~~ discussed further below.

Our acquisition ~~and wind down~~ strategy has had a material impact on the Company’s results in the current quarter and we expect will continue ~~to persist~~ into future periods, generating accretive impacts for our stockholders. ~~There~~A summary of their impacts are ~~currently three primary cost saving initiatives~~ as follows:

On ~~July 12, 2022,~~June 22, 2023, Tilray acquired ~~the HEXO Convertible Note from HTI and entered into a strategic alliance with~~ HEXO Corp. (“HEXO”) as discussed in Note ~~6 (Convertible notes receivable) and Note 11 (Convertible debentures payable)~~7 (Business acquisitions). ~~In addition,~~With the HEXO Acquisition, Tilray ~~and HEXO entered into various commercial transaction agreements, including (i) an advisory services agreement regarding Tilray’s provision of advisory services~~initially expected to HEXO in exchange for an $18 million annual advisory fee payable to Tilray; (ii) a co-manufacturing agreement providing for third-party manufacturing services between the parties and setting forth the terms of Tilray’s international bulk supply to HEXO; and (iii) a procurement andachieve additional cost savings ~~agreement for shared~~of $27 million on an annualized pre-tax basis and has subsequently increased this target to between $30 to $ 35 million. These synergies will be realized across production, sales, marketing, distribution, and corporate savings, ~~related to specified optimization activities,~~with incremental upside resulting from consolidating packaging, procurement, freight, and ~~other similar cost savings realized by the parties as a result of the foregoing commercial arrangements.~~

~~Through this strategic alliance, Tilray expects to achieve~~logistics. This builds on Tilray’s substantial ~~cash savings and production efficiencies. In~~progress optimizing its Canadian cannabis operations discussed below. During the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, we have achieved $22.0 million of our synergy plan on an annualized run-rate basis, of which $14.0 million represented actual cost savings during the period. As discussed in our trends section, these cost savings initiatives take time to implement, resulting in related benefits being realized over time.

On September 29, 2023, Tilray acquired a portfolio of craft beer brands, assets and businesses comprising eight beer and beverage brands from Anheuser-Busch Companies, LLC, including breweries and brewpubs associated with them (the “Craft Acquisition”). The acquired businesses include Shock Top, Breckenridge Brewery, Blue Point Brewing Company, 10 Barrel Brewing Company, Redhook Brewery, Widmer Brothers Brewing, Square Mile Cider Company, and HiBall Energy. The details of the acquisition are as described in Note 7 (Business acquisitions). The Craft Acquisition, is expected to be transformational to our beverage alcohol strategy elevating the Company recognized $8.7 million and $24.3 million of advisory services revenue included in Canadian adult-use cannabis revenue. Included in interest expense, net is $2.2 and $5.6 million of interest income for three and nine months ended February 28, 2023. to the 5th largest U.S. Craft Beer market share position from our previous 9th place market share position.

The Company ~~expects~~further believes the Craft transaction will be accretive to ~~earn approximately $40 million during the first 12 month period in connection with the HEXO Convertible Note, to be reported as $31 million~~our Adjusted EBITDA, driven by a range of ~~adult-use cannabis revenue and $9 million of interest income.~~strategic benefits, including:

In addition to acquisitions completed above, the Company has also completed the following cost saving strategies during the quarter:

During ~~our~~the fourth quarter of our fiscal year ended May 31, 2022, the Company launched a $30 million cost optimization plan of our existing cannabis business to solidify our position as an industry leading low-cost producer. The Company took decisive action to manage cash flow amid an evolving retail environment by identifying opportunities to leverage technology, supply chain, procurement, and packaging efficiencies while driving labor savings. In the current period ended February 28,To date as of November 30, 2023, we have achieved ~~$22.0~~$22.3 million ofagainst the plan. The Company now considers this plan fulfilled, owing to a strategic shift in our ~~cost optimization plan on an annualized run-rate basis of~~Cannabis beverage strategy. The Company's original targets involved repurposing our beverage facility; however, this initiative was altered following the Truss acquisition, which ~~$12.0 million represented actual cost savings during the period. The amount achieved is comprised of the following items:~~

In connection with the Tilray-Aphria Arrangement Agreement, we committed to achieving $80 million, subsequently increased to $100 million, of synergies in connection with the integration of Tilray and Aphria and developed a robust plan and timeline to achieve such synergies. In executingrequired additional capacity from our integration plan, we evaluated and optimized the organizational structure, evaluated and retained the talent and capabilities we identified as necessary to achieve our longer-term growth plan and vision, reviewed contracts and arrangements, and analyzed our supply chain and our strategic partnerships. Due to the Company’s actions in connection with the integration of Tilray and Aphria, we exceeded the identified $80 million of cost synergies and achieved such synergies ahead of our plan.

As disclosed in the preceding quarter, the Company achieved the remainder of the targeted $100 million in cost-saving synergies on an annualized run-rate basis. While this milestone marks the completion of the Tilray and Aphria Arrangement Agreement synergy plan, the Company intends to continue to prioritize cost saving initiatives in the future while remaining committed to our growth plan and vision.

~~In addition to our cost saving strategies, the Company has also executed the following strategic transactions during the quarter:~~existing infrastructure.

~~On November 7, 2022, Tilray acquired Montauk Brewing Company, Inc. (“Montauk”), a leading craft brewer company based in Montauk, New York. As consideration for the acquisition of Montauk,~~During our fiscal year ended May 31 2023, the Company ~~paid~~launched an ~~initial purchase price of $35.1~~$8.0 million ~~which was paid with $28.7 million~~cost optimization plan for our international cannabis business to adapt to changing market dynamics and slower than anticipated legalization in ~~cash and $6.4 million from the issuance of 1,708,521 shares of Tilray's Class 2 common stock.~~Europe. In the ~~event that Montauk achieves certain volume and/or EBITDA targets on or before December 31, 2025,~~current period ended November 30, 2023, the ~~stockholders~~Company achieved an annualized run-rate basis of ~~Montauk shall be eligible to receive as additional contingent cash consideration~~$7.6 million of ~~up to $18 million.~~cost savings. The Company ~~determined~~concluded this savings plan as of November 30, 2023. The Company concluded this savings plan as of November 30, 2023. The remaining portion of the savings target was tied to an assumed temporary decrease in demand. However, the assumed temporary reduction did not occur rather demand for our European cannabis products increased, rendering the cost savings associated with that the closing date fair value of this contingent consideration was $10.2 million. In connection with this transaction, the Company intends to leverage SweetWater’s existing nationwide infrastructure and Montauk’s northeast influence to significantly expand our distribution network and drive profitable growth in our beverage-alcohol segment. This distribution network is part of ~~Tilray’s strategy to leverage our growing portfolio of CPG brands and ultimately to launch THC-based product adjacencies upon federal legalization in~~ the ~~U.S.~~plan unnecessary.

In connection with evaluating the profitability of our CC Pharma distribution business, Tilray decided to discontinue its partnership in a medical device reprocessing business given it was not core to CC Pharma's business and was both dilutive from a profitability and cash flow perspective. In connection with evaluating the profitability of our international cannabis business, Tilray also discontinued transactions with one of its customers in Israel as we focus on markets which we believe are more accretive to our profitability and cash flow. In addition, Tilray terminated its relationship with a supplier in Uruguay due to a breach of the underlying contract. During the quarter ended February 28, 2023, the Company sold its interest in ASG Pharma Ltd., a wholly-owned subsidiary incorporated in Malta.

As a result of these strategic business decisions, there were the following impacts on the results for the three and nine months ended February 28, 2023 through the aggregate increase of net loss by $9.3 million, summarized as follows:

~~The impacts of the items discussed in this section are assessed further in our analysis of the results of operations below.~~

Our results of operations can also be affected by economic, political, legislative, regulatory, legal actions, the global volatility and general market disruption resulting from ~~the global COVID-19 pandemic and~~ geopolitical tensions, such as Russia's incursion into Ukraine. Economic conditions, such as recessionary trends, inflation, supply chain disruptions, interest and monetary exchange rates, and government fiscal policies, and the recent banking credit crises, can have a significant effect on operations. Accordingly, we could be affected by civil, criminal, environmental, regulatory or administrative actions, claims or proceedings.

Our consolidated results, in thousands except for per share data, are as follows:

	For the three months												For the nine months												For the three months												For the six months
	ended February 28,						Change			% Change			ended February 28,						Change			% Change			ended November 30,						Change			% Change			ended November 30,						Change			% Change
(in thousands of U.S. dollars)	2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022
Net revenue	$	145,589		$	151,871		$	(6,282	)		(4	)%	$	442,936		$	475,047		$	(32,111	)		(7	)%	$	193,771		$	144,136		$	49,635			34	%	$	370,720		$	297,347		$	73,373			25	%
Cost of goods sold		157,288			112,042			45,246			40	%		363,139			351,497			11,642			3	%		146,362			101,254			45,108			45	%		279,115			205,851			73,264			36	%
Gross profit (loss)		(11,699	)		39,829			(51,528	)		(129	)%		79,797			123,550			(43,753	)		(35	)%
Gross profit																										47,409			42,882			4,527			11	%		91,605			91,496			109			0	%
Operating expenses:
General and administrative		38,999			38,445			554			1	%		117,385			121,401			(4,016	)		(3	)%		43,313			37,878			5,435			14	%		83,829			78,386			5,443			7	%
Selling		6,452			8,641			(2,189	)		(25	)%		25,792			25,283			509			2	%		7,583			9,669			(2,086	)		(22	)%		14,442			19,340			(4,898	)		(25	)%
Amortization		23,518			24,590			(1,072	)		(4	)%		71,872			84,345			(12,473	)		(15	)%		21,917			23,995			(2,078	)		(9	)%		44,142			48,354			(4,212	)		(9	)%
Marketing and promotion		7,354			7,578			(224	)		(3	)%		23,137			20,163			2,974			15	%		9,208			8,535			673			8	%		17,743			15,783			1,960			12	%
Research and development		171			164			7			4	%		502			1,464			(962	)		(66	)%		56			165			(109	)		(66	)%		135			331			(196	)		(59	)%
Change in fair value of contingent consideration		352			(30,747	)		31,099			(101	)%		563			(29,065	)		29,628			(102	)%		300			—			300			0	%		(10,807	)		211			(11,018	)		(5,222	)%
Impairments		1,115,376			—			1,115,376			NM			1,115,376			—			1,115,376			NM
Litigation (recovery) costs		(5,230	)		4,215			(9,445	)		(224	)%		(1,970	)		6,489			(8,459	)		(130	)%
Litigation costs, net of recoveries																										3,042			2,815			227			8	%		5,076			3,260			1,816			56	%
Restructuring costs		2,663			—			2,663			0	%		10,727			795			9,932			1,249	%		2,655			8,064			(5,409	)		(67	)%		3,570			8,064			(4,494	)		(0,056	)%
Transaction (income) costs		5,382			5,023			359			7	%		(3,882	)		35,653			(39,535	)		(111	)%		1,094			3,552			(2,458	)		(69	)%		9,596			(9,264	)		18,860			(204	)%
Total operating expenses		1,195,037			57,909			1,137,128			1,964	%		1,359,502			266,528			1,092,974			410	%		89,168			94,673			(5,505	)		(6	)%		167,726			164,465			3,261			2	%
Operating loss		(1,206,736	)		(18,080	)		(1,188,656	)		6,574	%		(1,279,705	)		(142,978	)		(1,136,727	)		795	%		(41,759	)		(51,791	)		10,032			(19	)%		(76,121	)		(72,969	)		(3,152	)		4	%
Interest expense, net		(1,040	)		(2,312	)		1,272			(55	)%		(8,560	)		(22,422	)		13,862			(62	)%		(8,625	)		(3,107	)		(5,518	)		178	%		(18,460	)		(7,520	)		(10,940	)		145	%
Non-operating (expense) income, net		1,213			71,037			(69,824	)		(98	)%		(50,229	)		186,329			(236,558	)		(127	)%		821			(18,450	)		19,271			(104	)%		(3,581	)		(51,442	)		47,861			(93	)%
Income (loss) before income taxes		(1,206,563	)		50,645			(1,257,208	)		(2,482	)%		(1,338,494	)		20,929			(1,359,423	)		(6,495	)%
Income taxes (recovery)		(10,811	)		(1,830	)		(8,981	)		491	%		(15,313	)		(2,739	)		(12,574	)		459	%
Net income (loss)	$	(1,195,752	)	$	52,475		$	(1,248,227	)		(2,379	)%	$	(1,323,181	)	$	23,668		$	(1,346,849	)		(5,691	)%
Loss before income taxes																										(49,563	)		(73,348	)		23,785			(32	)%		(98,162	)		(131,931	)		33,769			(26	)%
Income tax expense																										(3,380	)		(11,713	)		8,333			(71	)%		3,884			(4,502	)		8,386			(186	)%
Net loss																									$	(46,183	)	$	(61,635	)	$	15,452			(25	)%	$	(102,046	)	$	(127,429	)	$	25,383			(20	)%

Throughout this Management's Discussion and Analysis of Financial Condition and Results of Operations in this Quarterly Report on Form 10-Q, we discuss non-GAAP financial measures, including reference to:

All these non-GAAP financial measures should be considered in addition to, and not in lieu of, the financial measures calculated and presented in accordance with accounting principles generally accepted in the United States of America, ("GAAP"). These measures, which may be different than similarly titled measures used by other companies, are presented to help investors' overall understanding of our financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. Please see "Reconciliation of Non-GAAP Financial Measures to GAAP Measures" below for reconciliation of such non-GAAP Measures to the most directly comparable GAAP financial measures, as well as a discussion of our adjusted gross margin, adjusted gross profit and adjusted EBITDA measures and the calculation of such measures.

We believe that this measure provides useful information to investors because it provides transparency to underlying performance in our consolidated net sales by excluding the effect that foreign currency exchange rate fluctuations have on period-to-period comparability given the volatility in foreign currency exchange markets. To present this information for historical periods, current period net sales for entities reporting in currencies other than the U.S. Dollar are translated into U.S. Dollars at the average monthly exchange rates in effect during the corresponding period of the prior fiscal year rather than at the actual average monthly exchange rate in effect during the current period of the current fiscal year. As a result, the foreign currency impact is equal to the current year results in local currencies multiplied by the change in average foreign currency exchange rate between the current fiscal period and the corresponding period of the prior fiscal year.

The Company combines the Cash and cash equivalent financial statement line item and the Marketable securities financial statement line item as an aggregate total as reconciled in the liquidity and capital resource section below. The Company’s management believes that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to its short-term liquidity position by combining these three GAAP metrics.

We use the following operating metrics and non-GAAP measures to evaluate our business and operations, measure our performance, identify trends affecting our business, project our future performance, and make strategic decisions. Other companies, including companies in our industry, may calculate operating metrics and non-GAAP measures with similar names differently which may reduce their usefulness as comparative measures. Certain variances are labeled as not meaningful ("NM") throughout management's discussion and analysis.

	For the three months						For the nine months						For the three months						For the six months
	ended February 28,						ended February 28,						ended November 30,						ended November 30,
(in thousands of U.S. dollars)	2023			2022			2023			2022			2023			2022			2023			2022
Net cannabis revenue	$	47,549		$	55,045		$	156,017		$	184,269		$	67,114		$	49,898		$	137,447		$	108,468
Distribution revenue		65,385			62,532			186,158			198,587			67,223			60,188			136,380			120,773
Net beverage alcohol revenue		20,640			19,597			62,689			48,765			46,505			21,395			70,667			42,049
Wellness revenue		12,015			14,697			38,072			43,426			12,929			12,655			26,226			26,057
Cannabis costs		77,604			37,042			137,800			122,492			46,472			28,577			96,989			57,438
Beverage alcohol costs		10,663			8,091			32,932			20,674			30,513			11,420			41,779			22,269
Distribution costs		57,964			57,566			165,443			178,093			60,147			52,495			121,615			107,479
Wellness costs		8,299			9,343			26,964			30,238			9,230			8,762			18,732			18,665
Adjusted gross profit (excluding PPA step-up and inventory valuation adjustments) ⁽¹⁾		44,310			39,829			138,020			135,550
Cannabis adjusted gross margin (excluding inventory valuation adjustments) ⁽¹⁾		47	%		33	%		47	%		40	%
Adjusted gross profit (excluding PPA step-up) ⁽¹⁾														52,110			43,989			101,412			93,710
Cannabis adjusted gross margin (excluding PPA step-up) ⁽¹⁾														35	%		43	%		35	%		47	%
Beverage alcohol adjusted gross margin (excluding PPA step-up) ⁽¹⁾		53	%		59	%		53	%		58	%		38	%		52	%		44	%		52	%
Distribution gross margin		11	%		8	%		11	%		10	%		11	%		13	%		11	%		11	%
Wellness gross margin		31	%		36	%		29	%		30	%		29	%		31	%		29	%		28	%
Adjusted EBITDA ⁽¹⁾	$	14,015		$	10,086			39,254		$	36,543		$	10,086		$	11,008			20,820		$	23,839
Cash and cash equivalents and marketable securities		408,283			279,214			408,283			279,214
Working capital		288,830			413,358			288,830			413,358
Cash and marketable securities ⁽¹⁾ as at the period ended:														259,791			433,504			259,791			433,504
Working capital as at the period ended:													$	247,041		$	388,200			247,041			388,200

⁽¹⁾Adjusted EBITDA, adjusted gross profit (excluding PPA step-up) and adjusted gross margin (excluding PPA step-up) for each of our segments, and cash and marketable securities are non-GAAP financial measures. See “Use of Non-GAAP Measures” ~~below~~above for a reconciliation of these Non-GAAP Measures to our most comparable GAAP measure.

Our reporting segments revenue is comprised of revenues from our cannabis, distribution, beverage alcohol, and wellness operations, as follows:

	For the three months										For the nine months										For the three months									For the six months
	ended February 28,				Change			% Change			ended February 28,				Change			% Change			ended November 30,				Change		% Change			ended November 30,				Change		% Change
(in thousands of U.S. dollars)	2023		2022		2023 vs. 2022						2023		2022		2023 vs. 2022						2023		2022		2023 vs. 2022					2023		2022		2023 vs. 2022
Cannabis business	$	47,549	$	55,045	$	(7,496	)		(14	)%	$	156,017	$	184,269	$	(28,252	)		(15	)%	$	67,114	$	49,898	$	17,216		35	%	$	137,447	$	108,468	$	28,979		27	%
Distribution business		65,385		62,532		2,853			5	%		186,158		198,587		(12,429	)		(6	)%		67,223		60,188		7,035		12	%		136,380		120,773		15,607		13	%
Beverage alcohol business		20,640		19,597		1,043			5	%		62,689		48,765		13,924			29	%		46,505		21,395		25,110		117	%		70,667		42,049		28,618		68	%
Wellness business		12,015		14,697		(2,682	)		(18	)%		38,072		43,426		(5,354	)		(12	)%		12,929		12,655		274		2	%		26,226		26,057		169		1	%
Total net revenue	$	145,589	$	151,871	$	(6,282	)		(4	)%	$	442,936	$	475,047	$	(32,111	)		(7	)%	$	193,771	$	144,136	$	49,635		34	%	$	370,720	$	297,347	$	73,373		25	%

Our reporting segments revenue using a constant currency⁽¹⁾ are as follows:

	For the three months										For the nine months										For the three months									For the six months
	ended February 28,										ended February 28,										ended November 30,									ended November 30,
	as reported in constant currency				Change			% Change			as reported in constant currency				Change			% Change			as reported in constant currency				Change		% Change			as reported in constant currency				Change		% Change
(in thousands of U.S. dollars)	2023		2022		2023 vs. 2022						2023		2022		2023 vs. 2022						2023		2022		2023 vs. 2022					2023		2022		2023 vs. 2022
Cannabis business	$	51,007	$	55,045	$	(4,038	)		(7	)%	$	164,746	$	184,269	$	(19,523	)		(11	)%	$	67,361	$	49,898	$	17,463		35	%	$	138,750	$	108,468	$	30,282		28	%
Distribution business		70,144		62,532		7,612			12	%		211,676		198,587		13,089			7	%		64,502		60,188		4,314		7	%		131,454		120,773		10,681		9	%
Beverage alcohol business		20,640		19,597		1,043			5	%		62,689		48,765		13,924			29	%		46,505		21,395		25,110		117	%		70,667		42,049		28,618		68	%
Wellness business		12,385		14,697		(2,312	)		(16	)%		39,144		43,426		(4,282	)		(10	)%		13,004		12,655		349		3	%		26,463		26,057		406		2	%
Total net revenue	$	154,176	$	151,871	$	2,305			2	%	$	478,255	$	475,047	$	3,208			1	%	$	191,372	$	144,136	$	47,236		33	%	$	367,334	$	297,347	$	69,987		24	%

	For the three months										For the nine months										For the three months										For the six months
	ended February 28,				Change			% Change			ended February 28,				Change			% Change			ended November 30,				Change			% Change			ended November 30,				Change			% Change
(in thousands of U.S. dollars)	2023		2022		2023 vs. 2022						2023		2022		2023 vs. 2022						2023		2022		2023 vs. 2022						2023		2022		2023 vs. 2022
North America	$	70,463	$	73,234	$	(2,771	)		(4	)%	$	228,866	$	236,220	$	(7,354	)		(3	)%	$	114,619	$	76,211	$	38,408			50	%	$	208,140	$	158,403	$	49,737			31	%
EMEA		71,111		74,671		(3,560	)		(5	)%		199,867		225,596		(25,729	)		(11	)%		75,292		62,715		12,577			20	%		154,996		128,756		26,240			20	%
Rest of World		4,015		3,966		49			1	%		14,203		13,231		972			7	%		3,860		5,210		(1,350	)		(26	)%		7,584		10,188		(2,604	)		(26	)%
Total net revenue	$	145,589	$	151,871	$	(6,282	)		(4	)%	$	442,936	$	475,047	$	(32,111	)		(7	)%	$	193,771	$	144,136	$	49,635			34	%	$	370,720	$	297,347	$	73,373			25	%

	For the three months									For the nine months										For the three months									For the six months
	ended February 28,									ended February 28,										ended November 30,									ended November 30,
	as reported in constant currency				Change		% Change			as reported in constant currency				Change			% Change			as reported in constant currency				Change		% Change			as reported in constant currency				Change		% Change
(in thousands of U.S. dollars)	2023		2022		2023 vs. 2022					2023		2022		2023 vs. 2022						2023		2022		2023 vs. 2022					2023		2022		2023 vs. 2022
North America	$	73,728	$	73,234	$	494		1	%	$	234,951	$	236,220	$	(1,269	)		(1	)%	$	115,429	$	76,211	$	39,218		51	%	$	210,643	$	158,403	$	52,240		33	%
EMEA		75,091		74,671		420		1	%		225,075		225,596		(521	)		(0	)%		70,129		62,715		7,414		12	%		145,245		128,756		16,489		13	%
Rest of World		5,357		3,966		1,391		35	%		18,229		13,231		4,998			38	%		5,814		5,210		604		12	%		11,446		10,188		1,258		12	%
Total net revenue	$	154,176	$	151,871	$	2,305		2	%	$	478,255	$	475,047	$	3,208			1	%	$	191,372	$	144,136	$	47,236		33	%	$	367,334	$	297,347	$	69,987		24	%

	February 28,		May 31,		Change			% Change			November 30,		May 31,		Change			% Change
(in thousands of U.S. dollars)	2023		2022		2023 vs. 2022						2023		2023		2023 vs. 2022
North America	$	313,233	$	464,370	$	(151,137	)		(33	)%	$	506,151	$	319,173	$	186,978			59	%
EMEA		108,944		119,409		(10,465	)		(9	)%		105,325		107,131		(1,806	)		(2	)%
Rest of World		3,086		3,720		(634	)		(17	)%		3,611		3,363		248			7	%
Total capital assets	$	425,263	$	587,499	$	(162,236	)		(28	)%	$	615,087	$	429,667	$	185,420			43	%

	For the three months												For the nine months												For the three months												For the six months
	ended February 28,						Change			% Change			ended February 28,						Change			% Change			ended November 30,						Change			% Change			ended November 30,						Change			% Change
(in thousands of US dollars)	2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022
Revenue from Canadian medical cannabis products	$	6,035		$	7,050		$	(1,015	)		(14	)%	$	18,920		$	23,353		$	(4,433	)		(19	)%
Revenue from Canadian adult-use cannabis products		45,318			43,504			1,814			4	%		156,063			162,632			(6,569	)		(4	)%
Revenue from wholesale cannabis products		58			2,804			(2,746	)		(98	)%		686			6,763			(6,077	)		(90	)%
Revenue from international cannabis products		9,707			15,820			(6,113	)		(39	)%		27,834			39,792			(11,958	)		(30	)%
Revenue from Canadian medical cannabis																									$	6,288		$	6,365		$	(77	)		(1	)%	$	12,430		$	12,885		$	(455	)		(4	)%
Revenue from Canadian adult-use cannabis																										72,048			52,390			19,658			38	%		143,243			110,745			32,498			29	%
Revenue from wholesale cannabis																										4,289			236			4,053			1,717	%		9,584			628			8,956			1,426	%
Revenue from international cannabis																										11,931			7,705			4,226			55	%		26,183			18,127			8,056			44	%
Total cannabis revenue		61,118			69,178			(8,060	)		(12	)%		203,503			232,540			(29,037	)		(12	)%		94,556			66,696			27,860			42	%		191,440			142,385			49,055			34	%
Excise taxes		(13,569	)		(14,133	)		564			(4	)%		(47,486	)		(48,271	)		785			(2	)%		(27,442	)		(16,798	)		(10,644	)		63	%		(53,993	)		(33,917	)		(20,076	)		59	%
Total cannabis net revenue	$	47,549		$	55,045		$	(7,496	)		(14	)%	$	156,017		$	184,269		$	(28,252	)		(15	)%	$	67,114		$	49,898		$	17,216			35	%	$	137,447		$	108,468		$	28,979			27	%

Cannabis revenue based on market channel using a constant currency⁽¹⁾ is as follows:

	For the three months												For the nine months												For the three months												For the six months
	ended February 28,												ended February 28,												ended November 30,												ended November 30,
	as reported in constant currency						Change			% Change			as reported in constant currency						Change			% Change			as reported in constant currency						Change			% Change			as reported in constant currency						Change			% Change
(in thousands of US dollars)	2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022
Revenue from Canadian medical cannabis products	$	6,442		$	7,050		$	(608	)		(9	)%	$	20,093		$	23,353		$	(3,260	)		(14	)%
Revenue from Canadian adult-use cannabis products		48,721			43,504			5,217			12	%		162,777			162,632			145			0	%
Revenue from wholesale cannabis products		62			2,804			(2,742	)		(98	)%		726			6,763			(6,037	)		(89	)%
Revenue from international cannabis products		10,269			15,820			(5,551	)		(35	)%		31,627			39,792			(8,165	)		(21	)%
Revenue from Canadian medical cannabis																									$	6,377		$	6,365		$	12			0	%	$	12,687		$	12,885		$	(198	)		(2	)%
Revenue from Canadian adult-use cannabis																										73,021			52,390			20,631			39	%		146,132			110,745			35,387			32	%
Revenue from wholesale cannabis																										4,338			236			4,102			1,738	%		9,796			628			9,168			1,460	%
Revenue from international cannabis																										11,442			7,705			3,737			49	%		25,219			18,127			7,092			39	%
Total cannabis revenue		65,494			69,178			(3,684	)		(5	)%		215,223			232,540			(17,317	)		(7	)%		95,178			66,696			28,482			43	%		193,834			142,385			51,449			36	%
Excise taxes		(14,487	)		(14,133	)		(354	)		3	%		(50,477	)		(48,271	)		(2,206	)		5	%		(27,817	)		(16,798	)		(11,019	)		66	%		(55,084	)		(33,917	)		(21,167	)		62	%
Total cannabis net revenue	$	51,007		$	55,045		$	(4,038	)		(7	)%	$	164,746		$	184,269		$	(19,523	)		(11	)%	$	67,361		$	49,898		$	17,463			35	%	$	138,750		$	108,468		$	30,282			28	%

Revenue from Canadian medical ~~cannabis products:~~cannabis: Revenue from Canadian medical cannabis ~~products~~ decreased to ~~$6.0~~$6.3 million and ~~$18.9~~$12.4 million for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, compared to revenue of ~~$7.1~~$6.4 million and ~~$23.4~~$12.9 million for the prior year same ~~periods.~~period. On a constant currency basis revenue from Canadian medical cannabis ~~products decreased to~~was $6.4 million and ~~$20.1~~$12.7 million for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, compared to revenue of ~~$7.1~~$6.4 million and ~~$23.4~~$12.9 million for the prior year same periods. ~~This~~While revenue was relatively consistent period over period and on a constant currency basis for the three month period, the six month slight decrease in revenue from medical cannabis ~~products is primarily~~continues to be driven by increased competition from the adult-use recreational market and its related price compression impacting the medical cannabis market.

Revenue from Canadian adult-use ~~cannabis products:~~cannabis: During the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, our revenue from Canadian adult-use cannabis ~~products~~ increased to ~~$45.3~~$72.0 million and ~~decreased to $156.1~~$143.2 million, compared to revenue of ~~$43.5~~$52.4 million and ~~$162.6~~$110.7 million and for the prior year same ~~periods. Due~~period. Further, the prior year revenue includes advisory fees in the amount of $7.9 million and $15.6 million for the three and six months ended November 30, 2022, compared to $nil and $1.5 million for the three and six months ended November 30, 2023. Excluding these advisory service fees, revenue increased by $27.4 million and $46.6 million for the three and six months ended November 30, 2023. The increase in adult-use revenue was driven by continuous launches of new product innovations from our existing brand portfolios as well as the increased revenue from the acquisition of HEXO on June 22, 2023, and Truss on August 3, 2023. Additionally, excluding the decline in the Canadian dollar, on a constant currency basis, our revenue from Canadian adult-use cannabis ~~products~~ increased to ~~$48.7~~$73.0 million and ~~increased to $162.8~~$146.1 million for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023. Included in the current period results was the favorable impact of the HEXO arrangement which resulted in $8.7 million and $24.3 million of advisory services revenue for the three and nine months ended February 28, 2023 that did not occur in the prior period comparative. This increase was offset by the negative impacts of price compression, challenges in the province of Quebec and change in potency preferences for both the three and nine months ended.

Wholesale cannabis revenue: Revenue from wholesale cannabis ~~products decreased~~increased to ~~$0.1~~$4.3 million and ~~$0.7~~$9.6 million for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, compared to revenue of ~~$2.8~~$0.2 million and ~~$6.8~~$0.6 million for the prior year same ~~periods which is consistent on~~period. On a constant currency ~~basis.~~basis, revenue from wholesale cannabis increased to $$4.3 million and $9.8 million for the three and six months ended November 30, 2023 compared to revenue of $0.2 million and $0.6 million. The Company continues to believe that wholesale cannabis revenue will remain subject to quarter-to-quarter variability and is based on opportunistic sales. The wholesale transactions that occurred in the current year periods aided with our liquidity initiatives to increase our cash flow from operations despite having unfavorable impacts on our gross margin and EBITDA of $(0.2) million and $(2.9) million for the three and six months ended November 30, 2023.

International cannabis revenue: Revenue from international cannabis ~~products decreased~~increased to ~~$9.7~~$11.9 million and ~~$27.8~~$26.2 million for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, compared to revenue of ~~$15.8~~$7.7 million and ~~$39.8~~$18.1 million for the prior year same ~~periods.~~period. Given the ~~deterioration~~increase of the Euro against the U.S. Dollar inwhen compared to the prior year quarter, on a constant currency basis, revenue from international cannabis ~~products decreased to $10.3~~was $11.4 million and ~~$31.6~~$25.2 million ~~from $15.8~~compared to $7.7 million and ~~$39.8~~$18.1 million in the prior year same ~~periods~~period for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023. ~~During~~The increase in the ~~nine month~~period is largely driven by expansion into emerging international medical markets. Additionally, in the prior period the Company recognized a one-time return adjustment of $3.1 million related to a former customer in ~~Israel. In addition, the Company had $5.1 million and $9.7 million of revenue in the three and nine months ended February 28, 2022, to~~ Israel ~~which did not repeat in the current period results given the challenging and severe deterioration of market conditions in Israel.~~that commenced bankruptcy proceedings.

Revenue from Distribution operations increased to ~~$65.4~~$67.2 million and ~~decreased to $186.2~~$136.4 million for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, compared to revenue of ~~$62.5~~$60.2 million and ~~$198.6~~$120.8 million for the prior year same ~~periods.~~period. Revenue was ~~negatively~~positively impacted during ~~both~~ the three ~~and nine~~ month ~~periods~~period from the ~~deterioration~~increase of the Euro against the U.S. Dollar in the quarter, which when the impacts are eliminated on a constant currency basis, revenue ~~increased to $70.1~~was $64.5 million and ~~$211.7~~$131.5 million for the three and ~~nine~~six months ended ~~February 28, 2023 when compared to prior year same periods. However, this impact is offset~~November 30, 2023. The increase in the ~~nine month~~ period ~~increase~~was driven by increased production capacity achieved through out-sourcing to third party production facilities as ~~there was a flood that occurred in the comparative prior period~~well as leveraging our own internal production and ~~forced a business closure for approximately five days leading~~improved procurement processes, which has allowed CC Pharma to a decrease in net revenue in the prior period of almost $5.0 million, which did not recur in the current nine-month period. Additionally, the Company is continuing to prioritize higher margin sales, and as a result of our focus on higher margin sales and capacity constraints, management believes in future periods we can continue to drive larger profit margins despite not increasing revenue in our distribution business as we approach full utilization of our facility.improve its product mix.

Revenue from our Beverage alcohol operations increased to ~~$20.6~~$46.5 million and ~~$62.7~~$70.7 million for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, compared to revenue of ~~$19.6~~$21.4 million and ~~$48.8~~$42.0 million for the prior year same ~~periods.~~period. The increase in the three and six month ~~and nine month period relates~~periods relate primarily to our ~~acquisition~~acquisitions of the newly acquired Craft Acquisition brands and Montauk which occurred on September 29, 2023 and November 7, ~~2022.~~2022, respectively, and is not reflected in the full prior year comparative periods.

Our Wellness revenue from Manitoba Harvest ~~decreased to $12.0~~was relatively consistent at $12.9 million and ~~$38.1~~$26.2 million for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 compared to ~~$14.7~~$12.7 million and ~~$43.4~~$26.1 million from the prior year same ~~periods.~~period. On a constant currency basis for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, ~~same periods,~~ Wellness revenue ~~decreased~~increased to ~~$12.4~~$13.0 million and ~~$39.1~~$26.5 million from ~~$14.7 million~~$12.7 and ~~$43.4~~$26.1 million. ~~The decrease in revenue for~~Overall, sales remained relatively consistent period over period with the ~~three months ended related to continual changes of inventory management~~increase being driven by ~~one of our customers based on~~ a ~~warehousing strategy as well as~~promotional sale at a decline in sales velocity from a recent price increase required to protect our margin given the inflation on our ingredient costs. The nine month decrease is impacted by the aforementioned items as well as the prior year comparison including a one-off private label sale that did not recur in the current quarter.large bulk retailer.

Gross profit, gross margin and adjusted gross margin⁽¹⁾ for our reporting segments

Our gross profit and gross margin for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 and 2022, is as follows:

	For the three months												For the nine months												For the three months												For the six months
(in thousands of U.S. dollars)	ended February 28,						Change			% Change			ended February 28,						Change			% Change			ended November 30,						Change			% Change			ended November 30,						Change			% Change
Cannabis	2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022
Net revenue		47,549			55,045			(7,496	)		(14	)%		156,017			184,269			(28,252	)		(15	)%		67,114			49,898			17,216			35	%		137,447			108,468			28,979			27	%
Cost of goods sold		80,362			37,042			43,320			117	%		137,800			122,492			15,308			12	%		46,472			28,577			17,895			63	%		96,989			57,438			39,551			69	%
Gross profit (loss)		(32,813	)		18,003			(50,816	)		(282	)%		18,217			61,777			(43,560	)		(71	)%
Gross profit																										20,642			21,321			(679	)		(3	)%		40,458			51,030			(10,572	)		(21	)%
Gross margin		(69	)%		33	%		(102	)%		(309	)%		12	%		34	%		(22	)%		(65	)%		31	%		43	%		(12	)%		(28	)%		29	%		47	%		(18	)%		(38	)%
Inventory valuation adjustments		55,000			—			55,000			NM			55,000			12,000			43,000			358	%
Purchase price accounting step-up																										2,938			—			2,938			—			7,454			—			7,454			0	%
Adjusted gross profit ⁽¹⁾		22,187			18,003			4,184			23	%		73,217			73,777			(560	)		(1	)%		23,580			21,321			2,259			11	%		47,912			51,030			(3,118	)		(6	)%
Adjusted gross margin ⁽¹⁾		47	%		33	%		14	%		42	%		47	%		40	%		7	%		18	%		35	%		43	%		(8	)%		(19	)%		35	%		47	%		(12	)%		(26	)%
Distribution
Net revenue		65,385			62,532			2,853			5	%		186,158			198,587			(12,429	)		(6	)%		67,223			60,188			7,035			12	%		136,380			120,773			15,607			13	%
Cost of goods sold		57,964			57,566			398			1	%		165,443			178,093			(12,650	)		(7	)%		60,147			52,495			7,652			15	%		121,615			107,479			14,136			13	%
Gross profit		7,421			4,966			2,455			49	%		20,715			20,494			221			1	%		7,076			7,693			(617	)		(8	)%		14,765			13,294			1,471			11	%
Gross margin		11	%		8	%		3	%		38	%		11	%		10	%		1	%		10	%		11	%		13	%		(2	)%		(15	)%		11	%		11	%		0	%		0	%
Beverage alcohol
Net revenue		20,640			19,597			1,043			5	%		62,689			48,765			13,924			29	%		46,505			21,395			25,110			117	%		70,667			42,049			28,618			68	%
Cost of goods sold		10,663			8,091			2,572			32	%		32,932			20,674			12,258			59	%		30,513			11,420			19,093			167	%		41,779			22,269			19,510			88	%
Gross profit		9,977			11,506			(1,529	)		(13	)%		29,757			28,091			1,666			6	%		15,992			9,975			6,017			60	%		28,888			19,780			9,108			46	%
Gross margin		48	%		59	%		(11	)%		(19	)%		47	%		58	%		(11	)%		(19	)%		34	%		47	%		(13	)%		(28	)%		41	%		47	%		(6	)%		(13	)%
Purchase price accounting step-up		1,009			—			1,009			NM			3,223			—			3,223			NM			1,763			1,107			656			59	%		2,353			2,214			139			6	%
Adjusted gross profit ⁽¹⁾		10,986			11,506			(520	)		(5	)%		32,980			28,091			4,889			17	%		17,755			11,082			6,673			60	%		31,241			21,994			9,247			42	%
Adjusted gross margin ⁽¹⁾		53	%		59	%		(6	%)		(10	%)		53	%		58	%		(5	%)		(9	%)		38	%		52	%		(14	%)		(27	%)		44	%		52	%		(8	%)		(15	%)
Wellness
Net revenue		12,015			14,697			(2,682	)		(18	)%		38,072			43,426			(5,354	)		(12	)%		12,929			12,655			274			2	%		26,226			26,057			169			1	%
Cost of goods sold		8,299			9,343			(1,044	)		(11	)%		26,964			30,238			(3,274	)		(11	)%		9,230			8,762			468			5	%		18,732			18,665			67			0	%
Gross profit		3,716			5,354			(1,638	)		(31	)%		11,108			13,188			(2,080	)		(16	)%		3,699			3,893			(194	)		(5	)%		7,494			7,392			102			1	%
Gross margin		31	%		36	%		(5	)%		(14	)%		29	%		30	%		(1	)%		(3	)%		29	%		31	%		(2	)%		(6	)%		29	%		28	%		1	%		4	%
Total
Net revenue		145,589			151,871			(6,282	)		(4	)%		442,936			475,047			(32,111	)		(7	)%		193,771			144,136			49,635			34	%		370,720			297,347			73,373			25	%
Cost of goods sold		157,288			112,042			45,246			40	%		363,139			351,497			11,642			3	%		146,362			101,254			45,108			45	%		279,115			205,851			73,264			36	%
Gross profit (loss)		(11,699	)		39,829			(51,528	)		(129	)%		79,797			123,550			(43,753	)		(35	)%
Gross profit																										47,409			42,882			4,527			11	%		91,605			91,496			109			0	%
Gross margin		(8	)%		26	%		(34	)%		(131	)%		18	%		26	%		(8	)%		(31	)%		24	%		30	%		(6	)%		(20	)%		25	%		31	%		(6	)%		(19	)%
Inventory valuation adjustments		55,000			—			55,000			NM			55,000			12,000			43,000			358	%
Purchase price accounting step-up		1,009			—			1,009			NM			3,223			—			3,223			NM			4,701			1,107			3,594			325	%		9,807			2,214			7,593			343	%
Adjusted gross profit ⁽¹⁾		44,310			39,829			4,481			11	%		138,020			135,550			2,470			2	%		52,110			43,989			8,121			18	%		101,412			93,710			7,702			8	%
Adjusted gross margin ⁽¹⁾		30	%		26	%		4	%		15	%		31	%		29	%		2	%		7	%		27	%		31	%		(4	)%		(13	)%		27	%		32	%		(5	)%		(16	)%

Cannabis gross margin: Gross margin decreased during the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 to ~~-69%~~31% and ~~12%~~29% from ~~33%~~43% and ~~34%~~47% for the prior year same ~~periods. The three and nine month decrease in cannabis gross margin is primarily related to~~period. Excluding the impact of the non-cash ~~inventory valuation allowance that occurred in the current year which was lower in the prior year. Excluding this valuation allowance,~~fair value purchase price accounting step-up, adjusted gross margin during the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 ~~increased~~decreased to ~~47%~~35% and 35% from ~~33%~~43% and ~~increased to~~ 47% ~~from 40%~~ when comparing the same prior year ~~periods. The largest impact on~~period. A portion of the decrease is a result of the termination of the HEXO advisory services agreement which contributed $nil and $1.5 million of gross profit in the current ~~period~~year compared to $7.9 and $15.6 million in the prior year, which if excluded would decrease adjusted gross margin ~~is the inclusion of the $8.7 million~~to 32% and ~~$24.3 million of HEXO advisory fee revenue included in cannabis revenue~~38% for the three and ~~nine month periods. When this revenue is excluded from this computation, our adjusted cannabis gross margin would have been 35% and 37% for the three and nine month periods. The reason for the decline~~six months ended November 30, 2022. Further, in the ~~three month period when excluding~~prior year second quarter the ~~impacts from HEXO is attributed to the impacts of price compression as well as a decrease in utilization of our~~Company's international cannabis ~~facilities to manage demand requirements. Additionally during the nine month period, the Company~~revenue section recognized a one-time return ~~as discussed in the international cannabis revenue section~~ that reduced our top line revenue as well as a one-time inventory disposals incurred as exit costs from Israel for a combined impact of reducing gross profit by $1.4 million. ~~Additionally, in~~Lastly, significant wholesale transactions with negative gross profit of $(0.2) and $(2.9) million, were entered into to optimize our inventory levels and prioritize the ~~immediately preceding quarter~~generation of positive operating cash flow. Combining the ~~inventory adjustment of $2.8 million related to Uruguay was reclassified to restructuring costs in the current period. Further impacting the decrease in the~~aforementioned factors, adjusted gross cannabis margin ~~is a shift~~would have been 37% and 38% compared 33% and 38% in ~~strategic priorities to focus on pursuing cash flow generating activities. The Company has made~~ the business decision to lower production in our cannabis facilities as a result of slower than anticipated legalization globally. We will continue to prioritize reductions in operational costs as we continue to assess additional potential cost saving initiatives.prior period comparative period.

Distribution gross margin: Gross margin of 11% and 11% for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 ~~increased~~decreased from 8%13% and ~~10%~~11% for the same periods in the prior year. ~~The increase~~While consistent for the six month period comparison, the decrease in the gross margin for the three ~~and nine~~ month period is attributed to ~~a change in~~ product ~~mix as the Company continues to focus on higher margin sales.~~mix.

Beverage alcohol gross margin: Gross margin of ~~48%~~34% and ~~47%~~41% for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 decreased from ~~59%~~47% and ~~58%~~47% from the same ~~periods~~period in the prior year. Adjusted gross margin of ~~53%~~38% and ~~53%~~44% for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 decreased from ~~59%~~52% and ~~58%~~52% from the same periods in the prior year. The decrease in the adjusted beverage alcohol gross margin ~~for the current three month period is~~was a result of the ~~Montauk acquisition that was not completed in~~newly acquired Craft Acquisition brands, which currently have lower margins than our historical business, primarily due to the ~~prior period comparison. The decrease in beverage alcohol gross margin for the nine month period is a result~~current under utilization of the Breckenridge and Montauk acquisitions that were not completed in the prior period comparison. Both acquired companies operate at a slightly lower margin than Sweetwater, which contributed to the decrease. Additionally, Sweetwater has expanded operations in Colorado in the current period which has had negative impacts on the margin as it is still in the start-up phase.breweries we acquired.

Wellness gross margin: Gross margin of ~~31%~~29% and 29% for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 decreased from ~~36%~~31% and ~~30%~~28% from the same ~~periods~~period in the prior year. The decrease in the three ~~and nine~~ month ~~decrease is related to the impacts of higher input costs of seed ingredients as~~period was a result of ~~inflation. The Company increased prices~~a change in ~~the second quarter to combat the impacts of this inflation and as~~sales mix towards more bulk retail sales which have a ~~result the~~lower margin. Wellness gross margin ~~has remained~~stayed consistent ~~from~~during the ~~immediately preceding quarter.~~six month period.

	For the three months												For the nine months												For the three months										For the six months
	ended February 28,						Change			% Change			ended February 28,						Change			% Change			ended November 30,				Change			% Change			ended November 30,						Change			% Change
(in thousands of US dollars)	2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022						2023		2022		2023 vs. 2022						2023			2022			2023 vs. 2022
General and administrative	$	38,999		$	38,445		$	554			1	%	$	117,385		$	121,401		$	(4,016	)		(3	)%	$	43,313	$	37,878	$	5,435			14	%	$	83,829		$	78,386		$	5,443			7	%
Selling		6,452			8,641			(2,189	)		(25	)%		25,792			25,283			509			2	%		7,583		9,669		(2,086	)		(22	)%		14,442			19,340			(4,898	)		(25	)%
Amortization		23,518			24,590			(1,072	)		(4	)%		71,872			84,345			(12,473	)		(15	)%		21,917		23,995		(2,078	)		(9	)%		44,142			48,354			(4,212	)		(9	)%
Marketing and promotion		7,354			7,578			(224	)		(3	)%		23,137			20,163			2,974			15	%		9,208		8,535		673			8	%		17,743			15,783			1,960			12	%
Research and development		171			164			7			4	%		502			1,464			(962	)		(66	)%		56		165		(109	)		(66	)%		135			331			(196	)		(59	)%
Change in fair value of contingent consideration		352			(30,747	)		31,099			(101	)%		563			(29,065	)		29,628			(102	)%		300		—		300			0	%		(10,807	)		211			(11,018	)		(5,222	)%
Impairments		1,115,376			—			1,115,376			0	%		1,115,376			—			1,115,376			NM
Litigation (recovery) costs		(5,230	)		4,215			(9,445	)		(224	)%		(1,970	)		6,489			(8,459	)		(130	)%
Litigation costs, net of recoveries																										3,042		2,815		227			8	%		5,076			3,260			1,816			56	%
Restructuring costs		2,663			—			2,663			0	%		10,727			795			9,932			1,249	%		2,655		8,064		(5,409	)		(67	)%		3,570			8,064			(4,494	)		(56	)%
Transaction (income) costs		5,382			5,023			359			7	%		(3,882	)		35,653			(39,535	)		(111	)%		1,094		3,552		(2,458	)		(69	)%		9,596			(9,264	)		18,860			(204	)%
Total operating expenses	$	1,195,037		$	57,909		$	1,137,128			1,964	%	$	1,359,502		$	266,528		$	1,092,974			410	%	$	89,168	$	94,673	$	(5,505	)		(6	)%	$	167,726		$	164,465		$	3,261			2	%

Operating expenses are comprised of general and administrative, share-based compensation, selling, amortization, marketing and promotion, research and development, change in fair value of contingent consideration, impairments, litigation ~~(recovery)~~ costs, net of recoveries, restructuring costs and transaction (income) costs. These costs ~~increased~~decreased by ~~$1,137.1 million to $1,195.0 million~~($5.5) and increased by ~~$1,093.0~~$3.2 million to ~~$1,359.5~~$89.2 and $167.7 million for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 as compared to ~~$57.9 million~~$94.7 and ~~$266.5~~$164.5 million for the same ~~periods~~period of the prior year. ~~This nine month increase was primarily a result of the non-cash impairments recorded in the~~These changes period over period are described ~~in detail~~ below.

During the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, the changes in general and administrative costs ~~increased by 1% and decreased by 3% as~~when compared to the prior year same ~~periods.~~periods are described as follows:

	For the three months												For the nine months												For the three months												For the six months
	ended February 28,						Change			% Change			ended February 28,						Change			% Change			ended November 30,						Change			% Change			ended November 30,					Change			% Change
(in thousands of US dollars)	2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022						2023			2022		2023 vs. 2022
Executive compensation	$	2,754		$	4,238		$	(1,484	)		(35	)%	$	9,359		$	9,565		$	(206	)		(2	)%	$	3,324		$	3,050		$	274			9	%	$	6,985		$	6,605	$	380			6	%
Office and general		6,799			4,012			2,787			69	%		20,011			21,755			(1,744	)		(8	)%		8,065			7,383			682			9	%		16,233			13,212		3,021			23	%
Salaries and wages		13,621			14,076			(455	)		(3	)%		38,407			37,536			871			2	%		15,795			10,151			5,644			56	%		28,909			24,786		4,123			17	%
Stock-based compensation		9,630			9,355			275			3	%		29,766			27,025			2,741			10	%		8,201			10,943			(2,742	)		(25	)%		16,458			20,136		(3,678	)		(18	)%
Insurance		3,159			4,835			(1,676	)		(35	)%		8,588			14,461			(5,873	)		(41	)%		2,499			2,726			(227	)		(8	)%		6,348			5,429		919			17	%
Professional fees		1,165			3,601			(2,436	)		(68	)%		5,385			9,669			(4,284	)		(44	)%		2,503			1,730			773			45	%		4,002			4,220		(218	)		(5	)%
Gain on sale of capital assets		(15	)		(861	)		846			(98	)%		(2	)		(631	)		629			(100	)%
Insurance proceeds		—			(4,032	)		4,032			(100	)%		—			(4,032	)		4,032			(100	)%
(Gain) loss on sale of capital assets																										(23	)		(64	)		41			(64	)%		(20	)		13		(33	)		(254	)%
Travel and accommodation		1,104			1,102			2			0	%		3,484			2,876			608			21	%		1,374			1,219			155			13	%		2,481			2,380		101			4	%
Rent		782			2,119			(1,337	)		(63	)%		2,387			3,177			(790	)		(25	)%		1,575			740			835			113	%		2,433			1,605		828			52	%
Total general and administrative costs	$	38,999		$	38,445		$	554			1	%	$	117,385		$	121,401		$	(4,016	)		(3	)%	$	43,313		$	37,878		$	5,435			14	%	$	83,829		$	78,386	$	5,443			7	%

Executive compensation ~~decreased~~increased by ~~35%~~9% and 2%6% in the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023. ~~The three month decrease is due to a change in the executive team structure during the quarter, while the nine month period~~Executive compensation has remained ~~consistent.~~generally consistent period over period.

Office and general increased by ~~69%~~9% and ~~decreased by 8%~~23% during the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023. The increase for the three ~~months~~month period is a result of the acquisition of the newly acquired beverage alcohol business portfolio, Montauk ~~increased operations~~ and ~~some reclassification of other expenses during the period. The offset to this was that~~HEXO, which did not occur in the nine month period, there was a necessary one-time exit costs incurred in our international cannabis business to terminate operations that were no longer accretive to our focus of being free cash flow positive. Specifically, $1.6 million of bad debt expenses were incurred in the period from the discontinuance of business with our aforementioned Israel customer. The Company took this necessary step in order to continue pursuing sustainable growth by focusing on areas of the business that generate positive cash flows. Additionally, $1.6 million of exit costs recognized in the immediately proceeding quarter from our producer partnership in Uruguay were reclassified to restructuring costs in the currentprior period.

Salaries and wages ~~decreased by 3% and~~ increased by 2%56% and 17% during the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023. The ~~decrease~~increase is primarily due to ~~our focus on optimizing our cost structure and is offset by~~ the inclusion of ~~Breckenridge~~newly acquired beverage alcohol business portfolio, Montauk and HEXO employees, ~~who~~which were ~~partially included~~not in the prior period comparison and Montauk employees, who were not included in the prior period comparatives. The Company’s headcount remained consistent with approximately 1,700 employees compared to 1,800 employees as of February 28, 2022.period.

The Company recognized stock-based compensation expense of ~~$9.6 million~~$8.2 and ~~$29.8~~$16.5 million for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 compared to ~~$9.4~~$10.9 and $20.1 million ~~and $27.0~~ for the same ~~periods~~period in the prior year. The balance ~~has remained relatively consistent period over period as this~~ is based on the ~~time~~time-based vesting schedules and varies according to the assumptions used in the vesting model. During the quarter, as a result of a change in the probability of achievement of stock price targets for certain grants issued in 2021, as well as an increased forfeiture rate, stock based ~~vesting schedules.~~compensation decreased period over period.

Insurance expenses decreased by ~~35%~~8% and ~~41%~~increased by 17% for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 to ~~$3.2 million~~$2.5 and ~~$8.6~~$6.3 million from ~~$4.8~~$2.7 and $5.4 million for the same period in the prior year. The decrease for the three months ended November 30, 2023, was driven by the Company's decision to self-insure certain of its property risks. The increase for the six months ended November 30, 2023, was driven by the expanded polices required for our newly acquired beverage alcohol business portfolio, HEXO and ~~$14.5~~Montauk entities.

Rent expenses increased by 113% and 52% for the three and six months ended November 30, 2023 to $1.6 and $2.4 million from $0.7 and $1.6 million for the same ~~periods~~period in the prior year. This ~~item~~increase was ~~a target of~~driven by the ~~Tilray-Aphria Arrangement Agreement synergies.~~

~~Gain on sale of capital assets decreased to ($0.0) million~~expanded polices required for our newly acquired beverage alcohol business portfolio, HEXO and ($0.0) million for the three and nine months ended February 28, 2023 compared to ($0.6) million and ($0.9) million for the prior year same periods. There were minimal disposals in the three and nine month periods in the current year, which did not recur from the comparative prior period. Additionally, the capital asset disposal of $2.2 million recorded in the immediately preceding quarter has been reclassified in the current period to restructuring costs.Montauk entities.

For the three and six months ended ~~February 28,~~November 30, 2023, the Company incurred selling costs of ~~$6.5 million~~$7.6 and ~~$25.8~~$14.4 million or ~~4.4%~~3.9% and ~~5.8%~~3.9% of net revenue as compared to ~~$8.6~~$9.7 and $19.3 million and ~~$25.3 million~~6.7% and ~~5.7% and 5.3%~~6.5% of net revenue in the prior year ~~periods.~~period. These costs relate to third-party distributor commissions, shipping costs, Health Canada cannabis fees, and patient acquisition and maintenance costs. Patient acquisition and ongoing patient maintenance costs include funding to individual clinics to assist with additional costs incurred by clinics resulting from the education of patients using the Company’s products. The decrease in the three month period was related to the renegotiation of terms in one of our distributor relationships resulting in ~~a one-time credit during the period.~~reduced variable fees. This impact was ~~offset~~also emphasized in the three ~~and nine~~ month period as a portion of our selling fees related to our Canadian adult-use cannabis with fixed components and did not ~~decrease~~increase with the ~~decline~~increase in our revenue during the quarter. ~~Additionally, there are no selling fees associated with our advisory fee revenue and thus there is no correlation between selling fees and this stream of revenue.~~

The Company incurred non-production related amortization charges of ~~$23.5 million~~$21.9 and ~~$71.9~~$44.1 million for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 compared to ~~$24.6 million~~$24.0 and ~~$84.4~~$48.4 million in the prior year period. The decreased amortization in ~~both~~ the ~~three and nine month periods,~~period is a result of the reduced intangible asset ~~levels.~~levels, as a result of prior year impairments.

For the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, the Company incurred marketing and promotion costs of ~~$7.4 million~~$9.2 and ~~$23.1~~$17.7 million as compared to ~~$7.6 million~~$8.5 and ~~$20.2~~$15.8 million for the prior year ~~periods.~~period. The increase inis due to the ~~nine month period is a result~~acquisition of the continued focus of investing in our Canadian cannabis brands by prioritizing our retail partnerships through the education of budtenders. Additionally, the prior year comparative did not include the marketing spend related to Breckenridge for a portion of the prior quarternewly acquired beverage alcohol business portfolio, HEXO and ~~Montauk for the full quarter.~~Montauk.

Research and development costs were ~~$0.2 million~~$0.1 and ~~$0.5~~$0.1 million during the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 compared to $0.2 ~~million~~ and ~~$1.5~~$0.3 million in the prior year period. These relate to external costs associated with the development of new products.

The Company measures contingent consideration at fair value classified as Level 3, as discussed in Note 25 (Fair value measurements). The Company currently has three contingent consideration liabilities of $3.0 million, $13.3 million and $4.4 million for the Sweetwater, Montauk, and Truss acquisitions, respectively, as of November 30, 2023 compared to $16.2 million, $10.9 million and $nil respectively as of May 31, 2023. The decrease in fair value of $10.8 million was driven by the lowered probability of achieving the incentive targets, primarily relating to Sweetwater, which was offset by an increase related to the increased probability of achieving the contingent consideration from the Montauk acquisition as well as the newly acquired contingent consideration from the Truss acquisition.

~~This non-cash impairment expense has no impact on the Company’s compliance with debt covenants, its cash flows or available liquidity.~~

For the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, the Company recorded ~~($5.2)~~$3.0 and $5.1 million ~~net and ($2.0) million,~~of litigation settlements costs, net of ~~litigation recovery~~favorable recoveries, and the third party fees associated with defending these claims, compared to an expense of ~~$4.2 million~~$2.8 and ~~$6.5~~$3.3 million for the ~~three and nine months ended February 28, 2022.~~prior period comparative. The ~~recovery~~increase is ~~a result of the proceeds received and accrued for the SLC~~related to period to period variability as litigation ~~of $39.9 million, which was received subsequent to quarter-end. These SLC litigation proceeds were offset by judgements, probable and estimated losses as well as ongoing litigation fees.~~is non-recurring in nature.

In connection with ~~executing~~the execution of our acquisition strategy and strategic transactions, the Company has incurred non-recurring restructuring and exit costs associated with the integration efforts of these transactions. For the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, the Company incurred $2.7 ~~million~~ and ~~$10.7~~$3.6 million of restructuring costs compared to ~~$nil~~$8.1 and ~~$0.8~~$8.1 million for the prior period comparative.

The Company approves detailed restructuring initiative plans at the executive level and recognizes these expenses in the period in which the plan has been committed to. The detailed breakdown of the restructuring plans in place, inclusive of their expected timeline for completion, for the three and ~~nine~~six months ended ~~February 28, 2022. The breakdown of the restructuring charges for the three and nine months ended February 28,~~November 30, 2023, ~~are~~is as follows:

HEXO Acquisition: Pursuant to our announced synergy program of $27 million in relation to the HEXO acquisition, we expect our HEXO restructuring plan to span the first 24 months following the acquisition. In the ~~three month~~current six-month period, we recognized $1.2 million related to employee termination benefits in relation to the conversion of our Masson facility from cannabis to produce and the optimization of our Redecan facilities.

Truss Acquisition: In relation to the acquisition of Truss, the Company ~~incurred $2.7~~has decided to repurpose the facility for the production of non-cannabis beverages. The Company expects the timeline of completion of this program to be 18 months from date of acquisition. In the current six-month period, we recognized $1.6 million of ~~expenses~~restructuring charges related to ~~severance~~the costs ~~required to right size~~of exiting the ~~Company's production to better align with current demand requirements.~~ facility until the new business has resumed.

Canadian Business Cost Reduction Plan: As referenced in our Canadian cannabis cost optimization plan for $30 million, the Company has committed to reducing costs, which was completed during the three months ended November 30, 2023. In the current six-month period, we recognized $0.3 million of restructuring charges related to the relocation of our Broken Coast facility from Duncan to Nanaimo, BC, and the employee termination benefits associated with the transition of packaging finished goods to the Aphria One location.

Distribution Cost Optimization: The Company executed a cost optimization plan during the quarter to reduce costs within the distribution segment by $1.5 million annually. It is expected that this plan will be completed within the fiscal year, however the Company continues to evaluate this segment for further cost optimizations and production efficiencies. In the ~~nine month~~current six-month period, we recognized $0.5 million related to employee termination benefits in association with executing this plan.

For the prior period three and six months ended November 30, 2022, the Company ~~incurred~~recognized $8.1 and $8.1 million of restructuring charges. This was comprised of $1.6 million of exit cost and $2.8 million for inventory adjustments from the termination of our producer partnership in Uruguay due to a breach of the underlying contract in our International cannabis business. Additionally, amounts related to the Tilray-Aphria ~~arrangement agreement~~Arrangement Agreement for the closure of our Canadian cannabis facility in Enniskillen of $1.5 million were reclassified from transaction costs to restructuring costs during the quarter in the amount of $1.4 million. It is anticipated that there will continue to be additional costs associated with this transaction until the resolution of our lease termination for our Enniskillen facility and the restructuring of Nanaimo facility are completed.incurred. The Company also incurred $2.2 million of write-offs from the exit of our medical device reprocessing business in our distribution reporting segment. These ~~one-time non-cash charges~~exit costs were ~~a required exit cost as we determined this business venture was no longer accretive to our focus of being free cash flow positive~~non-recurring in nature and isdid not ~~anticipated to~~ have ~~ongoing expenses.~~on going impacts in the current year.

~~Items classified as transaction~~Transaction (income) costs, ~~are non-recurring in nature~~which includes acquisition related income and ~~correspond largely to our acquisition,~~expenses, related legal, financial advisor and ~~synergy strategy.~~due diligence cost and expenses and transaction related compensation. The three and ~~nine~~six months ended November 30, 2023 decrease of 7%69% and ~~111%~~204% from the prior year period is related to the following items:

	For the three months												For the nine months												For the three months												For the six months
	ended February 28,						Change			% Change			ended February 28,						Change			% Change			ended November 30,						Change			% Change			ended November 30,						Change			% Change
(in thousands of US dollars)	2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022
Change in fair value of convertible debenture payable	$	207		$	56,128		$	(55,921	)		(100	)%	$	(20,375	)	$	151,851		$	(172,226	)		(113	)%	$	(3,894	)	$	(12,698	)	$	8,804			(69	)%	$	(6,041	)	$	(20,582	)	$	14,541			(71	)%
Change in fair value of warrant liability		5,256			21,089			(15,833	)		(75	)%		6,841			58,802			(51,961	)		(88	)%		6,247			37			6,210			16,784	%		(1,951	)		1,585			(3,536	)		(223	)%
Foreign exchange loss		(1,955	)		(2,548	)		593			(23	)%		(26,621	)		(18,452	)		(8,169	)		44	%
Foreign exchange (loss) gain																										(1,024	)		907			(1,931	)		(213	)%		5,243			(24,666	)		29,909			(121	)%
Loss on long-term investments		(925	)		(3,326	)		2,401			(72	)%		(2,529	)		(6,834	)		4,305			(63	)%		459			(596	)		1,055			(177	)%		350			(1,604	)		1,954			(122	)%
Other non-operating (losses) gains, net		(1,370	)		(306	)		(1,064	)		348	%		(7,545	)		962			(8,507	)		(884	)%		(967	)		(6,100	)		5,133			(84	)%		(1,182	)		(6,175	)		4,993			(81	)%
Total non-operating income (expense)	$	1,213		$	71,037		$	(69,824	)		(98	)%	$	(50,229	)	$	186,329		$	(236,558	)		(127	)%	$	821		$	(18,450	)	$	19,271			(104	)%	$	(3,581	)	$	(51,442	)	$	47,861			(93	)%

For the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, the Company recognized a change in fair value of its convertible debentures payable of ~~$0.2~~($3.9) million and ($~~20.4)~~6.0) million compared to ~~$56.1~~($12.7) million and ~~$151.9~~($20.6) million in the prior year same periods. The change is driven primarily by the changes in the Company’s share price, ~~and~~ the change in the trading price of the convertible debentures payable. Additionally, for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, the Company recognized a change in fair value of its warrants, resulting in a gain of ~~$5.3~~$6.2 million and ~~$6.8~~a loss ($2.0) million compared to ~~$21.1~~gains of $0.0 million and ~~$58.8~~$1.6 million also as a result of the change in our share ~~price.~~price and the exercise price of the instrument. For the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, the Company recognized a loss of ($~~2.0)~~1.0) million and ~~($26.6)~~a gain of $5.2 million, resulting from the changes in foreign exchange rates during the period, compared to ~~losses~~a gain of ~~($2.5)~~$0.9 million and a loss of ($~~18.5)~~24.7) million for the prior year same periods, largely associated with the ~~weakening~~recovery of the Euro. Lastly, included in other non-operating (losses) gains, net for the three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 was ~~($1.2)~~the downside protection share issuance relating to the HTI Note settlement, as described in Note 15 (Stockholders' equity) offset by a $1.1 million ~~and ($7.4) million related to a change in fair value on a derivative liability recognized in~~gain from the ~~three month period that did not occur in~~repurchase of the ~~comparative periods.~~ TLRY 23 convertible note.

Adjusted EBITDA is a non-GAAP financial measure that does not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company calculates adjusted EBITDA as net ~~loss~~loss/net income before income taxes, net interest expense, depreciation and amortization, equity in net loss of equity-method investees, purchase price accounting step-up on inventory, ~~write downs,~~ stock-based compensation, ~~integration activities,~~restructuring costs, transaction (income) costs, litigation costs net of recoveries, change in fair value of contingent consideration, unrealized currency gains and losses and other adjustments.

~~The Company’s management believes~~We believe that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to its results of operations and financial condition. In addition, management uses this measure for reviewing the financial results of the Company and as a component of performance-based executive compensation.

Historically, we have included lease expenses for leases that were treated differently under IFRS 16 and ASC 842 in the calculation of adjusted EBITDA, aiming to align our definition with industry peers reporting under IFRS. The decision to include these lease expenses in the Company's definition of adjusted EBITDA was based on our efforts to maintain comparability with peers. However, as the Company has continued to diversify, particularly with strategic acquisitions such as the newly acquired beverage alcohol business portfolio, this comparison is no longer relevant, accordingly, we are no longer including this adjustment.

Had the Company continued to include lease expenses that were treated differently under IFRS 16 and ASC 842 , the impact to adjusted EBITDA would have been $1.1 million and $1.8 million for the three and six months ended November 30, 2023. In comparison, under the previous reconciliation, the impact to adjusted EBITDA would have been $0.7 million and $1.4 million for the three and six months ended November 30, 2022.

We do not consider Adjusted EBITDA in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA is that it excludes certain expenses and income that are required by U.S. GAAP to be recorded in our consolidated financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as this metric reflects the exercise of judgment by management about which expenses and income are excluded or included in determining Adjusted EBITDA. In order to compensate for these limitations, management presents Adjusted EBITDA in connection with GAAP results.

For three and ~~nine~~six months ended ~~February 28,~~November 30, 2023, adjusted EBITDA ~~increased to $14.0 and $39.3 million compared~~decreased to $10.1 million and ~~$36.5~~$20.8 million compared to $11.0 and $23.8 million from the prior year same ~~periods.~~ period. The decrease was primarily driven by the aforementioned negative impacts to our cannabis gross margin.

Adjusted EBITDA should not be considered in isolation from, or as a substitute for, net loss. There are a number of limitations related to the use of Adjusted EBITDA as compared to net loss, the closest comparable GAAP measure. Adjusted EBITDA adjusts for the following:

Adjusted gross profit and adjusted gross margin are non-GAAP financial measures and may not be comparable to similar measures presented by other companies. Adjusted gross profit is our Gross profit (adjusted to exclude ~~inventory valuation adjustment and~~ purchase price accounting valuation step-up) and adjusted gross margin is our Gross margin (adjusted to exclude ~~inventory valuation adjustment and~~ purchase price accounting valuation step-up) and are non-GAAP financial measures. The Company’s management believes that adjusted gross profit and adjusted gross margin are useful to our management to evaluate our business and operations, measure our performance, identify trends affecting our business, project our future performance, and make strategic decisions. We do not consider adjusted gross profit and adjusted gross margin percentage in isolation or as an alternative to financial measures determined in accordance with GAAP.

We actively manage our cash and investments in order to internally fund operating needs, make scheduled interest and principal payments on our borrowings, and ~~make~~complete acquisitions. On March 3, 2022, we entered into an at the market offering arrangement (the "ATM Program") pursuant to which we offered and sold our common stock having an aggregate offering price of up to $400 million. The ATM Program was intended to strengthen our balance sheet and improve our liquidity position and was utilized to offer and sell common stock having a total of $400 million for the period through February 28, 2023. The Company fully completed its sales of shares under the ATM Program. In addition, the Company may from time to time use excess cash to repurchase its outstanding convertible debentures payable in open market transactions. We believe that existing cash, cash equivalents, ~~short-term investments~~marketable securities and cash generated by operations, together with ~~received proceeds from the ATM Program and~~ access to external sources of funds, will be sufficient to meet our domestic and foreign capital needs for a short and long term outlook.

For the Company's short-term liquidity requirements, we are focused on generating positive cash flows from operations and being free cash flow positive. As a result of delays in legalization across multiple markets, management continues to ~~reduce operations,~~optimize our operating structure, headcount, as well as the elimination of other discretionary operational costs. Some of these actions may be less accretive to our adjusted EBITDA in the short term, however we believe that they will be required for our liquidity aspirations in the near term future. Additionally, the Company continues to invest our excess cash in the short-term in marketable securities which are comprised of U.S. treasury bills and term deposits with major Canadian banks.

Subsequent to the period ended November 30, 2023, the Company exchanged $18.5 million principal of APHA 24 Notes prior to their maturity, demonstrating our commitment to optimizing our capital structure and enhancing financial flexibility. We intend to continue to opportunistically purchase or exchange additional APHA 24 Notes prior to their underlying maturity date in June 2024. We believe this demonstrates and reinforces our commitment to optimizing our capital structure and enhancing financial flexibility.

For the Company's long-term liquidity requirements, we will be focused on funding operations through profitable organic and inorganic growth through acquisitions. We may need to take on additional debt or equity financing arrangements in order to achieve these ambitions on a long-term basis.

The following table sets forth the major components of our statements of cash flows for the periods presented:

	For the three months						For the nine months						For the three months												For the six months
	ended February 28,						ended February 28,						ended November 30,						Change			% Change			ended November 30,						Change			% Change
	2023			2022			2023			2022			2023			2022			2023 vs. 2022						2023			2022			2023 vs. 2022
Net cash provided by (used in) operating activities	$	(18,632	)	$	(46,390	)	$	(35,692	)	$	(156,738	)	$	(30,409	)	$	29,209		$	(59,618	)		(204	)%	$	(46,251	)	$	(17,060	)	$	(29,191	)		171	%
Net cash (used in) investing activities		(4,592	)		(1,026	)		(277,527	)		(16,618	)
Net cash provided by (used in) investing activities														81,497			(271,398	)		352,895			(130	)%		55,207			(272,935	)		328,142			(120	)%
Net cash (used in) provided by financing activities		(2,442	)		(5,565	)		63,922			(33,612	)		(85,366	)		(57,256	)		(28,110	)		49	%		(71,348	)		66,364			(137,712	)		(208	)%
Effect on cash of foreign currency translation		445			412			(1,615	)		(2,284	)		95			(980	)		1,075			(110	)%		709			(2,060	)		2,769			(134	)%
Cash and cash equivalents, beginning of period		190,218			331,783			415,909			488,466			179,132			490,643			(311,511	)		(63	)%		206,632			415,909			(209,277	)		(50	)%
Cash and cash equivalents, end of period		164,997			279,214			164,997			279,214		$	144,949		$	190,218		$	(45,269	)		(24	)%	$	144,949		$	190,218		$	(45,269	)		(24	)%
Increase (decrease) in cash and cash equivalents	$	(25,221	)	$	(52,569	)	$	(250,912	)	$	(209,252	)
Marketable securities														116,418			243,286			(126,868	)		(52	)%		116,418			243,286			(126,868	)		(52	)%
Less: restricted cash														(1,576	)		-			(1,576	)		0	%		(1,576	)		-			(1,576	)		0	%
Cash and marketable securities(1)													$	259,791		$	433,504		$	(173,713	)		(40	)%	$	259,791		$	433,504		$	(173,713	)		(40	)%

The change in net cash ~~used in~~provided by (used in) operating activities was ($~~18.6)~~30.4) million and ~~was~~ ($~~35.7)~~46.3) million for three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 compared to ~~($63.5)~~$29.2 million and ($~~156.7)~~17.1) million for the prior year same ~~periods.~~period. This ~~decrease~~increase in cash used in the three ~~and nine~~ month ~~periods~~period was primarily related to ~~improved operating efficiencies realized through our synergy programs, increased management~~the settlement of ~~our working capital requirements and for~~pre-acquisition liabilities assumed from the ~~nine months ended February 28, 2023,~~HEXO acquisition. Additionally, the prior period included the cash collection of the $18.3 million ~~of the cash collected from the HTI Share Consideration's~~ purchase price ~~derivative.~~derivative from HTI as noted in the transaction cost section above, which did not recur in the current year.

The change in net cash ~~used in~~provided by (used in) investing activities was ~~($4.6)~~$81.5 million and ~~($277.5)~~$55.2 million for three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 compared to ($~~8.0)~~271.4) million and ($~~16.6)~~272.9) million for the prior year same ~~periods,~~period, and is a result of ~~our purchase of $243.1 million~~the sale of marketable securities ~~and our~~in the current periods compared to investing in marketable securities in the prior periods as well as the cash used in the acquisition of ~~Montauk Brewing Company~~various businesses, Note ~~5 (Goodwill) which did not occur in the comparative periods~~7 (Business acquisitions).

The change in cash ~~used in financing activities was ($2.4) million and the change in cash~~(used in) provided by financing activities was ~~$63.9~~($85.4) million and ($71.3) million for three and ~~nine~~six months ended ~~February 28,~~November 30, 2023 compared to ($~~25.6)~~57.3) million and ~~($33.6)~~$66.4 million for the prior year same ~~periods. The nine month net~~period. In the current period, cash was provided by ~~financing activities was primarily due to~~funds from the ~~funds received in the current quarter from our ATM program that was not in place for the prior year period. The three month change in cash used in financing activities was from~~overallotment of TLRY 27 Notes and other long term debt offset by the repurchase of ~~our outstanding~~ convertible ~~debentures payable.~~notes and long-term debt, while in the comparative period a larger amount of cash was provided by the ATM capital raise and smaller amounts of repurchased debt.

In addition to the litigation described in the Part II, Item 1 - Legal Proceedings, the Company is and may be a defendant in lawsuits from time to time in the normal course of business. While the results of litigation and claims cannot be predicted with certainty, the Company believes the reasonably possible losses of such matters, individually and in the aggregate, are not material. Additionally, the Company believes the probable final outcome of such matters will not have a material adverse effect on the Company’s consolidated results of operations, financial position, cash flows or liquidity.

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States. The accounting principles we use require us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and amounts of income and expenses during the reporting periods presented. We believe in the quality and reasonableness of our critical accounting policies; however, materially different amounts may be reported under different conditions or using assumptions different from those that we have applied. The accounting estimates that have been identified as critical to our business operations and to understanding the results of our operations pertain to revenue recognition, valuation of inventory, valuation of long-lived assets, goodwill and intangible assets, stock-based compensation and valuation allowances for deferred tax assets. The application of each of these critical accounting policies and estimates is discussed in Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K ~~as amended~~ for the fiscal year ended May 31, ~~2022.~~2023.

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in “Part I, Item 1. Note 1 – Basis of presentation and summary of significant accounting policies” to our financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

There have been no ~~significant~~material changes in market risk from those addressed in the Company’s Annual Report on Form 10-K ~~as amended~~ for the fiscal year ended May 31, ~~2022~~2023 during the ~~nine~~six months ended ~~February 28,~~November 30, 2023. See the information set forth in Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk, of the Company’s Annual Report on Form 10-K ~~as amended~~ for the fiscal year ended May 31, ~~2022.~~2023.

We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, and summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report was made under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of ~~February 28,~~November 30, 2023, our disclosure controls and procedures (a) are effective to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is timely recorded, processed, summarized and reported and (b) include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Consistent with guidance issued by the SEC, the scope of management’s assessment of the effectiveness of our disclosure controls and procedures did not include the internal controls over financial reporting of ~~Montauk Brewing Company, Inc.~~our recently acquired businesses including: (i) HEXO Corp., ~~which we~~acquired June 22, 2023;, (ii) Truss Beverage Co. acquired August 3, 2023; and (iii) the portfolio of craft beer brands, assets and businesses comprising eight beer and beverage brands, acquired on ~~November 7, 2022. Montauk Brewing Company, Inc.~~September 29, 2023. These acquired businesses represented ~~1.1%~~2.3%, 0.6% and 3.2% of our consolidated assets and ~~0.6%~~5.9%, 1.3%, and 3.2% of our consolidated net revenues respectively as of and for the ~~nine~~six months ended ~~February 28,~~November 30, 2023.

There have been no changes in our “internal control over financial reporting” (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. As mentioned above, the Company acquired ~~Breckenridge Distillery~~HEXO Corp. on ~~December 7, 2021~~June 22, 2023, Truss Beverage Co., on August 3, 2023 and ~~Montauk Brewing Company, Inc.~~the eight beer and beverage brands on ~~November 7, 2022.~~September 29, 2023. The Company is in the process of reviewing the internal control structure of ~~Breckenridge Distillery~~HEXO Corp., Truss Beverage Co., and ~~Montauk Brewing Company, Inc.,~~the eight beer and beverage brands and if necessary, will make appropriate changes as it integrates them into the Company’s overall internal control over financial reporting process.

In the ordinary course of business, we are at times subject to various legal proceedings and disputes, including the proceedings specifically discussed below. We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in our consolidated financial statements. These legal reserves may be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is not probable or the amount of loss is not estimable, we do not accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available, our management believes that it has established appropriate legal reserves. Any liabilities arising from pending legal proceedings are not expected to have a material adverse effect on our consolidated financial position, consolidated results of operations, or consolidated cash flows. However, it is possible that the ultimate resolution of these matters, if unfavorable, may be material to our consolidated financial position, consolidated results of operations, or consolidated cash flows.

“Item 3. Legal Proceedings” of our Annual Report on Form 10-K ~~as amended~~ for the fiscal year ended May 31, ~~2022~~2023 includes a discussion of our legal proceedings. There have been no material changes from the legal proceedings described in our Form 10-K, except with respect to the matters disclosed and incorporated herein by reference to Note ~~17,~~ ~~Commitments~~19 (Commitments and ~~contingencies~~contingencies), in the Notes to the Consolidated Financial Statements included in Part I, Item 1 of this Form 10-Q.

“Item 1A. Risk Factors” of our Annual Report on Form 10-K ~~as amended~~ for the fiscal year ended May 31, ~~2022~~2023 includes a discussion of our known material risk factors, other than risks that could apply to any issuer or offering. A summary of our risk factors is included below. Except ~~as noted~~for the below ~~in the summary of our~~ risk factors, there have been no material changes from the risk factors described in our Form ~~10-K as amended.~~10-K.

Additional impairments of our goodwill, impairments of our intangible and other long-lived assets, and changes in the estimated useful lives of intangible assets could have a material adverse impact on our financial results.

Goodwill, intangible and other long-lived assets comprise a significant portion of our total assets. As of February 28, 2023, our goodwill and intangible assets totaled $2.01 billion and $994.3 million, respectively. We assess or test goodwill for impairment in accordance with Generally Accepted Accounting Principles in the U.S. (“GAAP”), while our other long-lived assets, including our finite-lived intangible assets, are tested for impairment when circumstances indicate that the carrying amount may not be recoverable. A decrease in our market capitalization or profitability, or unfavorable changes in market, economic or industry conditions could increase the risk of additional impairment. Any resulting additional impairments could have a negative impact on our stock price.

For the three and nine months ended February 28, 2023, the Company recognized non-cash impairment charges of $603.5 million in cannabis goodwill and $15 million in wellness goodwill, $205 million in intangible assets and $104 million in capital assets. These non-cash impairment charges were a result of a decline in the Company's market value which was determined to be other than temporary, as well as increased borrowing rates which forced the Company to adjust the company specific risk premium.

We will continue to monitor key assumptions and other factors utilized in our goodwill, intangible and other long-lived assets impairment analysis, and if business or other market conditions develop that are materially different than we currently anticipate, we will conduct an additional impairment evaluation. Any reduction in or impairment of the value of goodwill, intangible assets and long-lived assets will result in a charge against earnings, which could have a material adverse impact on our reported financial results.

We may experience difficulties ~~closing~~achieving the ~~Arrangement~~expected benefits, including revenue and ~~integrating Tilray and HEXO~~’ssales growth, of acquiring certain craft beer operations ~~and realizing the~~(the “Craft Acquisition”).

 The Craft Acquisitions were completed on September 29, 2023. Efforts to achieve expected benefits of the ~~Arrangement.~~

The success of the Arrangement will depend in part on our ability to realize the expected operational efficiencies and associated cost synergies and anticipated business opportunities and growth prospects from combining Tilray and HEXO in an efficient and effective manner. We may not be able to fully realize the operational efficiencies and associated cost synergies or leverage the potential business opportunities and growth prospects to the extent anticipated or at all. Additionally, closing of the Arrangement transactions remains subject to the satisfaction of various closing conditions set forth in the Arrangement Agreement.

The Arrangement Agreement was entered into on April 10, 2023, and we are in the early stages of preparing for our anticipated integration efforts assuming the Arrangement is successfully completed. If so, the integration of operations and corporate and administrative infrastructuresCraft Acquisitions may require substantial resources and divert management attention. Challenges associated with ~~the integration~~achieving such benefits may include those related to ~~retaining~~sales and ~~motivating executives~~marketing efforts across our expanded product portfolio, operational efficiency and ~~other key employees, blending corporate cultures, eliminating duplicative operations,~~production optimization, and making necessary modifications to internal control over financial reporting and other policies and procedures in accordance with applicable laws. Some of these factors are outside our control, and any of them could delay or increaseeffectively integrating the ~~cost of our integration efforts.~~

The integration process could take longer than anticipated and could result in the loss of key employees, the disruption of each company’s ongoing businesses, increased tax costs, inefficiencies, and inconsistencies in standards, controls, information technology systems, policies and procedures, any of which could adversely affect our ability to maintain relationships with employees, customers or other third parties, or our ability to achieve the anticipated benefits of the transaction, and could harm our financial performance.Craft Acquisitions into Tilray. If we are unable to successfully integrate certain aspects of the operations of ~~Tilray and HEXO~~the Craft Acquisitions or experience delays, we may incur unanticipated liabilities and be unable to fully realize the potential benefit of the revenue growth, synergies and other anticipated benefits resulting from the arrangement, and our business, results of operations and financial condition could be adversely affected. ~~Even if we~~Some of these factors are ~~able to successfully close~~outside our control, and any of them could delay or increase the ~~Arrangement transactions, the foregoing risks for the Company would still exist.~~cost of our efforts.

On ~~December 5, 2022,~~September 12, 2023, Tilray repurchased $20,000 of its TLRY 23 Notes for cancellation by issuing 7,000,000 shares and paying $610 of cash to settle both principal and accrued interest. After cancellation, the ~~Company~~outstanding principal balance of the TLRY 23 Notes was $107,331.

On September 29, 2023, Tilray issued ~~1,979,541~~1,032,616 shares of ~~Tilray's Class 2~~its common stock to ~~Double Diamond Holdings Ltd. ("Double Diamond") in connection with the assignment from Double Diamond~~HTI Investments MA LLC pursuant to the ~~Company~~terms of a $50.0 million convertible promissory note ~~payable~~originally issued by ~~1974568 Ontario Limited.~~Tilray to HTI on July 12, 2022 and which was settled at maturity on August 31, 2023 as previously disclosed.

On ~~February 21,~~October 4, 2023, ~~the Company~~Tilray entered into an arrangement with MediPharm Labs Inc. (“MediPharm”) to acquire 100% ownership of 1000652011 Ontario Inc.. As consideration for such acquisition, Tilray issued ~~(i) 2,208,739~~1,371,157 shares of ~~Tilray's Class 2~~its common stock ~~and (ii) 120,000~~to Medipharm. On October 13, 2023, Tilray issued an additional 201,995 shares of ~~Tilray Series A preferred~~its common stock to ~~Double Diamond in connection with~~MediPharm to satisfy certain obligations under the ~~assignment from Double Diamond to the Company of a promissory note payable by 1974568 Ontario Limited.~~acquisition arrangement.

Each of the foregoing issuances of Tilray’s ~~Class 2~~ common stock was made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended, for the offer and sale of securities not involving a public offering. No underwriter participated in the offer and sale of the shares issued pursuant to the foregoing issuances, and no commission or other remuneration was paid or given directly or indirectly in connection therewith. Additionally, each of the foregoing issuance of Tilray's ~~Class 2~~ common stock was reported on a Form 8-K filed by the Company with the U.S. Securities and Exchange Commission.

On January 5, 2024, the Company’s wholly-owned subsidiary, Four Twenty Corporation (the “Borrower”), entered into a Waiver (the “Waiver”) to that certain Credit Agreement dated as of June 30, 2023 (the “420 Credit Agreement”) by and among the Borrower, Bank of America, N.A., in its capacity as Administrative Agent (in such capacity, the “Administrative Agent”), and certain other guarantors and lenders thereto. The Waiver provides for a waiver of a potential event of default relating to the “Consolidated Leverage Ratio” financial covenant contained in the 420 Credit Agreement. The foregoing description of the Waiver does not purport to be complete and is qualified in its entirety by the full text of the Waiver, which is being filed as Exhibit 10.2 to this quarterly report on Form 10-Q for the quarter ended November 30, 2023.

The Supply Agreement amends and restates the existing supply agreement, effective as of September 1, 2023, and amends certain terms relating to pricing and product classes. Pursuant to the Supply Agreement, Aphria will purchase cannabis products on a non-exclusive basis from Aphria Diamond grown at Aphria Diamond’s Leamington, Ontario cannabis cultivation facility (the “Aphria Diamond Facility”) and will supply Aphria Diamond with rooted cuttings to be used for cultivation of cannabis products at the Aphria Diamond Facility. Aphria Diamond agrees to exclusively supply cannabis products to Aphria, subject to limited exceptions to allocate un-utilized cultivation capacity at the Aphria Diamond Facility. The foregoing summary of the Supply Agreement does not purport to be complete and is qualified in its entirety by reference to the Supply Agreement, a copy of which is attached hereto as Exhibit 10.1 and incorporated herein by reference.

		Page
PART I.	FINANCIAL INFORMATION	1
Item 1.	Financial Statements (Unaudited)	1
	Consolidated Statements of Financial Position (Unaudited)	1
	Consolidated Statements of Loss and Comprehensive Loss (Unaudited)	2
	Consolidated Statements of Stockholders' Equity (Unaudited)	3
	Consolidated Statements of Cash Flows (Unaudited)	4
	Notes to Condensed Interim Consolidated Financial Statements (Unaudited)	5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3229
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	5752
Item 4.	Controls and Procedures	5752
PART II.	OTHER INFORMATION	5853
Item 1.	Legal Proceedings	5853
Item 1A.	Risk Factors	5954
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	6255
Item 3.	Defaults Upon Senior Securities	6255
Item 4.	Mine Safety Disclosures	6255
Item 5.	Other Information	6255
Item 6.	Exhibits	6356
Signatures		6558

	*February 28,*			*May 31,*
	*2023*			*2022*
Land	$	29,056		$	31,882
Production facility		353,630			453,412
Equipment		199,453			254,486
Leasehold improvement		7,764			7,455
Construction in progress		8,909			7,505
	$	598,812		$	754,740
Less: accumulated amortization		(173,549	)		(167,241	)
Total	$	425,263		$	587,499

	*November 30,*			*May 31,*
	*2023*			*2023*
Land	$	46,385		$	30,635
Production facility		344,593			344,627
Equipment		319,749			185,422
Leasehold improvement		8,147			7,753
Finance lease, right-of-use assets		57,056			—
Construction in progress		12,794			8,048
	$	788,724		$	576,485
Less: accumulated amortization		(173,637	)		(146,818	)
Total	$	615,087		$	429,667

		*November 30,*		*May 31,*
	*Classification on Balance Sheet*	*2023*		*2023*
Assets
Finance lease, right-of-use assets	Capital assets	$	57,056	$	—
Operating lease, right-of-use assets	Right of use assets		13,551		5,941
Total right-of-use asset		$	70,607	$	5,941
Liabilities
Current:
Current portion of finance lease liabilities	Accrued lease obligations - current	$	1,336	$	—
Current portion of operating lease liabilities	Accrued lease obligations - current		3,707		2,423
Non-current:
Finance lease liabilities	Accrued lease obligations - non-current		56,010		—
Operating lease liabilities	Accrued lease obligations - non-current		13,964		7,936
Total lease liabilities		$	75,017	$	10,359

	*Operating*			*Finance*
	*leases*			*leases*
2024	$	4,106		$	4,622
2025		3,295			4,699
2026		3,486			4,782
2027		3,412			4,542
Thereafter		4,012			87,903
Total minimum lease payments	$	18,311		$	106,548
Imputed interest		(640	)		(49,202	)
Obligations recognized	$	17,671		$	57,346

	*February 28,*			*May 31,*
Reporting Unit	*2023*			*2022*
Cannabis	$	2,640,669		$	2,640,669
Distribution		4,458			4,458
Beverage alcohol		123,325			102,999
Wellness		77,470			77,470
Effect of foreign exchange		2,210			39,640
Impairments		(842,431	)		(223,931	)
Total	$	2,005,701		$	2,641,305

	b)	~~33,314,412 shares to purchase the HEXO convertible notes receivable.~~
	c)	~~15,994,406~~865,426 shares to settle ~~amounts owed~~a contractual change of control severance obligations in the aggregate amount of $1,500 incurred in connection with the HEXO Acquisition.

	*Total*		*2024*		*2025*		*2026*		*2027*		*Thereafter*
Long-term debt repayment	$	168,539	$	77,892	$	11,157	$	40,435	$	4,743	$	34,312
Convertible notes		449,070		189,830		259,240		—		—		—
Material purchase obligations		26,878		19,946		5,515		840		239		338
Construction commitments		5,433		5,433		—		—		—		—
Total	$	649,920	$	293,101	$	275,912	$	41,275	$	4,982	$	34,650

										*APHA 24*
	*Convertible*			*Warrant*			*Contingent*			*Convertible*
	*notes receivable*			*Liability*			*Consideration*			*Debt*			*Total*
Balance, May 31, 2022	$	111,200		$	(14,255	)	$	(16,007	)	$	(216,753	)	$	(135,815	)
Additions		167,752			—			(10,245	)		—			157,507
Unrealized gain (loss) on fair value		70,779			6,841			(563	)		(6,334	)		70,723
Impairments		(181,375	)		—			—			—			(181,375	)
Balance, February 28, 2023	$	168,356		$	(7,414	)	$	(26,815	)	$	(223,087	)	$	(88,960	)

													*APHA 24*
	*Convertible*			*Equity*			*Warrant*			*Contingent*			*Convertible*
	*notes receivable*			*Investments*			*Liability*			*Consideration*			*Debt*
Balance, May 31, 2023	$	103,401		$	5,651		$	(1,817	)	$	(27,107	)	$	(120,568	)
Additions		—			—			—			(4,181	)		—
Disposals		(28,720	)		—			—			—			—
Unrealized gain (loss) on fair value		—			(151	)		(1,951	)		10,584			(7,831	)
Impairments		—						—			—			—
Balance, November 30, 2023	$	74,681		$	5,500		$	(3,768	)	$	(20,704	)	$	(128,399	)

		*Significant*
	*Valuation*	*unobservable*
Financial asset / financial liability	*technique*	*input*	*Inputs*
		~~Volatility,~~	~~70%~~
APHA Convertible debentures	Black-Scholes	~~forfeiture rate,~~Volatility,	~~30%~~50%
		expected life (in years)	0.5
Warrant liability	Black-Scholes	Volatility,	50%
		expected life (in years)	1.3
~~Warrant liability~~	~~Black-Scholes~~	~~Volatility,~~	~~70%~~
		~~expected life (in years)~~	~~2.0~~
Contingent consideration	Discounted cash flows	Discount rate,	5% - 11%
		achievement	25% - ~~80%~~
~~Convertible notes receivable~~	~~Black-Scholes~~	~~Effective interest rate,~~	~~17% - 22%~~
		~~conversion~~	~~0% - 60%~~90%

	-	An established brand portfolio with a devoted consumer base, coupled with growth potential through integration and expanded capabilities in both alcoholic and non-alcoholic beverages.
	-	The acquisition encompasses four production facilities and eight brewpub locations, further solidifying our operational presence.
	-	A reinforced nationwide distribution footprint, propelling Tilray's beer sales volume from four million cases to twelve million, thereby tripling its market reach on a pro forma basis.

	●	~~partially offsetting~~refunds from outstanding government rebates of $(1.1) million claims not previously recognized as assets associated with the decrease in the period were the fees incurred for the Montauk acquisition in the current quarter which differed from the fees incurred for the Breckenridge acquisitions which occurred in the prior period comparative;Aphria and Tilray Arrangement Agreement;

Exhibit Number		Description

3.1*		~~Third~~Fourth Amended and Restated Certificate of Incorporation of Tilray Brands, Inc., dated as of ~~March 16,~~November 30, 2023.

~~3.2~~10.1*†		~~Certificate~~Fourth Amended and Restated Wholesale Cannabis Supply Agreement, dated as of ~~Designation of Series A Preferred Stock, dated February 21, 2023 (incorporated~~January 5, 2024, by ~~reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 21, 2023).~~

10.1*		~~Promissory note in the amount of $9,264,249.68 payable by~~and between 1974568 Ontario ~~Limited.~~Limited and Aphria Inc.

10.2*†		~~Promissory note in the amount of $6,648,304 payable by 1974568 Ontario Limited.~~

~~10.3~~		~~Voting~~Waiver to Credit Agreement, dated as of ~~February 21, 2023,~~January 5, 2024, by and between Four Twenty Corporation, Bank of America, N.A., and the ~~Company~~Guarantors and ~~Double Diamond Holdings Ltd. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on February 21, 2023).~~Lenders party thereto.

31.1*		Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*		Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1**		Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit Number		Description

32.2**		Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101*		The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended ~~February 28,~~November 30, 2023, formatted in Inline XBRL: (i) Consolidated Statements of Financial Position, (ii) Consolidated Statements of Loss and Comprehensive Loss , (iii) Consolidated Statements of Stockholders' Equity, (iv) Consolidated Statements of Cash Flows, and (v) Notes to Condensed Interim Consolidated Financial Statements, tagged as blocks of text and including detailed tags.

104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

	Tilray Brands, Inc.

Date: ~~April 10, 2023~~January 9, 2024	By:	/s/ Irwin D. Simon
		Irwin D. Simon
		Chairman and Chief Executive Officer

Date: ~~April 10, 2023~~January 9, 2024	By:	/s/ Carl Merton
		Carl Merton
		Chief Financial Officer